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ABSTRACT
DIVERGENT EVOLUTION OF DI-LYSINE ER RETENTION VS.
FARNESYLATION MOTIF-MEDIATED ANCHORING OF THE ANKB
VIRULENCE EFFECTOR
John Perpich
April 12, 2018
Legionella pneumophila is an aquatic organism capable of intracellular
replication within a wide range of protozoan hosts and within human
macrophages where it causes Legionnaires’ Disease. L. pneumophila
manipulates a variety of host cell processes by translocating, into the host cell
cytosol, more than 300 effector proteins via the type IVB secretion system
(T4SS). The AnkB effector from the AA100/130b strain (AnkB-AA100) contains a
C-terminal CaaX motif that rapidly becomes farnesylated upon translocation into
the host cell and anchored to the cytosolic face of the Legionella-containing
vacuole (LCV) membrane, which is essential for intracellular replication. We
show that a homolog of AnkB from the Paris strain (AnkB-Paris) has a frameshift
mutation that truncates the C-terminus eliminating the CaaX motif, but creating a
unique KNKYAP sequence that resembles a eukaryotic di-lysine ER retention
motif (KxKxx). AnkB-Paris localizes to the cytosolic face of the LCV membrane
most likely through the ER retention motif. Phylogenetic analyses indicate that
the AnkB-Paris allele is common among environmental isolates and is positively
v

selected specifically for the di-lysine motif. Ectopic expression of AnkB-Paris
results in a perinuclear distribution and trans-rescues the ankB mutant of the
AA100/130b strain for intravacuolar replication. The trans-rescue is dependent
on an intact di-lysine ER-retention motif, which most likely enables anchoring of
AnkB to the ER-derived LCV membrane. AnkB contains a N-terminal eukaryotic
F-box domain that recruits the cellular ubiquitylation machinery by interacting
with the host Skp1 protein resulting in decoration of the LCV with
polyubiquitylated proteins. Proteins targeted for ubiquitylation during infection
are likely bound by ankyrin domains in the C-terminus of AnkB. Based on the
crystal structure, we identified four residues within the ankyrin domains likely
involved in binding specific substrate proteins. Mutation of these residues did not
affect protein folding but resulted in loss of accumulation of ubiquitylated proteins
around the LCV and a severe defect in intracellular replication, similar to the
ankB null mutant. Overall, we identified a di-lysine ER retention motif in the Cterminus of AnkB-Paris and 4 substrate binding residues within the 3 ankyrin
domains of AnkB-AA100 both of which are essential for biological function.
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INTRODUCTION

1. History and Etiology of Legionnaires’ Disease
Legionnaires’ disease was first described in the aftermath of an outbreak
of a severe pneumonia in 221 people at a convention of the American Legion in
Philadelphia that ultimately claimed 34 lives [1, 2]. Many of the people who
became ill had visited the Bellevue Stratford Hotel in Philadelphia, however,
some affected individuals had merely walked passed the hotel [3]. Nevertheless,
there was a strong association between staying at the hotel and development of
the pneumonia. It is apropos that the epidemic occurred on the centennial of
Koch’s discovery of the bacterium responsible for anthrax, since the identification
of the causative agent of Legionnaires’ disease closely followed Koch’s
postulates. The postulates state that to establish the cause of an infectious
disease, the organism must be present in diseased but not healthy hosts [4]. It
must be isolated in pure culture from diseased individuals and reproduce the
disease when inoculated into a healthy host [4]. Finally, it must be re-isolated in
pure culture from the diseased experimental host [4]. After an extensive
epidemiological investigation, a small filamentous gram-negative rod was
isolated from infected patients. The causative agent was later identified and
classified into the new family Legionellaceae as Legionella pneumophila [5].
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L. pneumophila is a gram-negative, motile, non-spore-forming bacillus.
Although the bacterium is found free-living and biofilm-associated, it primarily
persists in freshwater environments by infecting and replicating within several
protozoans including members of Acanthamoeba, Hartmannella, Naegleria, and
Tetrahymena [6]. L. pneumophila has a biphasic lifecycle that alternates
between a nonmotile replicative phase and a flagellated transmissive phase [7,
8].
More than 50 species and 70 serogroups in the genus have been
described with almost 50% of the species causing disease in humans [9].
Among the various isolates of L. pneumophila, serogroup 1 accounts for 85% of
cases in the USA. In Australia and New Zealand, 30% of cases of Legionnaires’
disease are caused by L. longbeachae, which is found mostly in soil [5].
2. Epidemiology and Clinical Manifestations
The worldwide incidence of Legionnaires’ disease is difficult to determine
due to differences in awareness levels, diagnosis, and reporting throughout the
world [10]. The data are better in countries where it is a reportable disease such
as the USA, New Zealand, Australia, Japan, Canada, and Europe where the
incidence ranges from 2-14 per million people [11]. L. pneumophila is thought to
account for 2-9% of community-acquired pneumonia with most cases occurring
during the warmer and wetter months of the year [10]. In the USA, the reported
incidence has increased from 3.9 to 11.5 cases per million people during the
period from 2000-2009 [12]. Still, the disease is thought to be largely
underreported even in countries with surveillance programs. For example, a
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German study of community-acquired pneumonia that utilized a standard
protocol to rigorously diagnose Legionella pneumonia found a prevalence of 180360 cases per million people [10].
Risk factors for Legionnaires’ disease include age >50 years, male
gender, smoking, chronic lung disease, diabetes, and end-stage renal disease
[10, 13]. Additional risk factors include immunosuppression, hematologic
malignancies, lung cancer, and treatment with chemotherapy. Persons infected
with human immunodeficiency virus (HIV) may be at greater risk according to
CDC surveillance data, however, clinical studies in HIV cohorts have failed to
verify this [14-16].
Clinically, L. pneumophila causes two distinct illnesses. Pontiac fever is a
self-limiting flu-like illness with symptoms of fever, headache, malaise, and
myalgia [17]. This manifestation of L. pneumophila infection was first described
in 1968 as an epidemic that occurred in a county health department building in
Pontiac, Michigan [17]. At the time, the causative agent was not identified.
However, after the description of Legionnaires’ disease in 1976, the cause of
Pontiac fever was retrospectively identified as L. pneumophila. The other clinical
syndrome caused by L. pneumophila is the multisystem disease involving
pneumonia known as Legionnaires’ disease, which mimics other types of
pneumonia with fever, cough, dyspnea, headache, myalgia, and delirium [13, 18].
The similarity to other types of pneumonia and the empiric nature of treatment for
community-acquired pneumonia likely contribute to under-reporting of cases of
Legionnaires’ disease. However, gastrointestinal or neurological symptoms
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suggest Legionella as the cause of the pneumonia [10]. Nevertheless,
Legionnaires’ disease is difficult to distinguish clinically from other pneumonias.
Diagnosis of Legionnaires’ disease can be achieved using several
modalities, including culture of the organism, immunofluorescence microscopy,
urine antigen testing, and nucleic acid based assays. Diagnosis by culture
remains the gold standard for diagnosis, but can suffer from low sensitivity due to
inadequate sample collection and, potentially, poor survival of the bacteria within
respiratory secretions [13]. Urine antigen testing is a commonly used test due to
its ease of sample collection and fast turnaround time. This test employs
monoclonal antibodies to detect lipopolysaccharide (LPS) antigens shed by the
organism [9]. The diagnostic utility of this test is limited by its ability to detect
only serogroup 1 and by the fact that about 8% of patients do not shed LPS in
their urine [10]. In addition, the results cannot be used in epidemiologic
investigations that endeavor to trace the source of the contagion. The
community acquired pneumonia guidelines published by the Infectious Disease
Society of America (IDSA) recommend blood and sputum cultures as well as
urinary antigen testing for L. pneumophila and S. pneumoniae in patients with
severe community acquired pneumonia (CAP) [19]. Ultimately, this would seem
a prudent approach in most cases.
The mortality rate of Legionnaires’ disease is estimated to be 10-40% with
the number of fatalities likely decreasing. One study found that mortality rates
dropped from 34% to 12% between 1980-1998 [20]. This may be due to newer
antibiotic therapies, which are the mainstay of treatment for Legionnaires’
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disease, or more aggressive treatment of community acquired pneumonia.
Prompt treatment is important since delayed initiation of antibiotics may increase
mortality associated with Legionella pneumonia [21]. The empiric antibiotic
therapy for CAP recommended by the IDSA will be effective in patients infected
with Legionella. The bacteria are susceptible to macrolides including
erythromycin and azithromycin as well as fluoroquinolones such as levofloxacin
[13]. Legionella are naturally resistant to beta-lactam antibiotics, which is an
important consideration, since clinicians do not always follow IDSA guidelines
particularly in an outpatient setting.
3. Microbial Ecology and Transmission
Freshwater is the major habitat for L. pneumophila and the bacteria have
been isolated from these environments throughout the world [22]. The organism
is relatively sensitive to drying, pH extremes, and temperatures much above or
below the preferred 25-42°C [23]. Within these aquatic environments, Legionella
bacteria invade into, and persist within, free living protozoan hosts, including at
least 14 species of amoebae, two species of ciliated protozoa, and a slime mold
[13]. The intracellular environment of these hosts provides a nutrient-rich and
sheltered environment for replication [24]. In addition to their persistence in
natural bodies of water, Legionella bacteria can also survive and replicate in
man-made bodies of water.
L. pneumophila has been isolated from air conditioning systems, cooling
towers, hot tubs, showers, and dental water lines [25-28]. Legionnaires’ disease
outbreaks are strongly associated with these man-made aquatic environments.

5

The increased presence of man-made water systems in the latter half of the 20th
century is what led to the initial outbreak and description of Legionnaires’ disease
[29]. These man-made aquatic environments may provide a habitat more
favorable to Legionella proliferation, as bacterial counts within these
environments can exceed those found in rivers, lakes, and ponds. Yamamoto
and colleagues found that bacterial counts within cooling tower water samples
correlated positively with increases in water temperature, pH, and levels of
protozoans [30]. Several methods for disinfection of these reservoirs have been
utilized including physical, thermal, and chemical treatments [31]. It is generally
recommended that treatment and maintenance plans be in place for these water
systems, however, the are no definitive recommendations [31]. When water from
these man-made reservoirs is aerosolized, it can be inhaled by people in close
association and cause the disease.
4. Metabolism
Early work using chemically defined media revealed L. pneumophila could
only grow on amino acids and did not utilize glucose or starch [32, 33]. Pyruvate
and α-ketoglutarate both stimulated growth, however, addition of glucose or
starch did not impact growth rate. George et al., found that L. pneumophila is
auxotrophic for arginine, cysteine, isoleucine, leucine, threonine, valine,
methionine, and phenylalanine or tyrosine [32, 34-36]. The sole sources of
carbon and energy were serine and, to a lesser degree, threonine. Later, it was
determined that L. pneumophila can utilize glucose as well as glycerol for
synthesis of histidine and mannose at certain times [37]. The bacteria have two
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growth phases within cells, a replicative and a transmissive phase. From the
perspective of gene expression, these phases correspond closely with in vitro
grown bacteria in exponential (E) and post-exponential (PE) states, respectively
[38]. It is now appreciated that L. pneumophila alters its basic metabolism in each
of these phases [13].
During its replicative phase, L. pneumophila uses serine as its major
carbon source for amino acid and protein synthesis and also as its major energy
source [37]. Serine is converted to pyruvate, which is then converted to acetylCoA. The acetyl-CoA can drive energy production via the tricarboxylic acid
(TCA) cycle and also serves as a substrate for synthesis of the energy storage
compound poly-3-hydroxybutyrate (PHB) [38, 39]. The replicative form is
nonmotile, contains little to no PHB, and is minimally infectious [13]. As nutrients
within the host cell are depleted, the alarmone, 3’,5’-bispyrophosphate (ppGpp),
accumulates within the bacterial cell and causes an increase in the stationaryphase σ factor RpoS [40]. During stationary phase, the PHB is broken down and
used as the major source of carbon and energy [41, 42]. RpoS expression
causes the bacteria to transition into the transmissive phase, which is
characterized by osmotic resistance, sodium sensitivity, motility, accumulation of
PHB granules, and high infectivity [13, 41]. These infectivity traits include egress
from the spent host cell, extracellular survival, invasion of a new host, and
lysosome evasion [38]. Thus, L. pneumophila is an asaccharolytic organism that
subsists on amino acids via the TCA cycle and oxidative phosphorylation.
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5. Intracellular Life Cycle
The life cycle of L. pneumophila has been described in multiple host cell
types ranging from protozoans, including Acanthameoba castellanii,
Hartmannella vermiformis, and Dictyostelium discoideum, to various mammalian
cells, including mouse bone marrow-derived macrophages, human mononuclearderived macrophages (hMDM), HeLa, A549, and CHO-K1 cells [29]. While some
host cell specific differences exist, most of the fundamental life cycle is the same
in all of these eukaryotic cells [29]. Preliminary studies on entry indicated that
the bacteria enter the host cell by coiling phagocytosis, however, they can also
enter by traditional phagocytosis [43]. Unlike most bacteria whose phagosomes
fuse with lysosomes, phagosomes containing Legionella do not become acidic or
fuse with lysosomes [44]. Instead, they remodel the phagosome into a
replicative niche called the Legionella containing vesicle (LCV) [18]. During the
first hour, the LCV becomes surrounded by rough ER-derived vesicles and
mitochondria [45-48]. The vacuoles acquire ER markers such as BiP, but do not
accumulate endocytic or lysosomal markers such as LAMP-1, cathepsin D, and
Rab5 [46, 47, 49]. Since amoebae feed on bacteria, it is likely that L.
pneumophila evolved to become an intracellular pathogen due to selective
pressure to avoid the lysosomal pathway.
6. T4SS and Manipulation of Host Cell Processes
Control over host cell processes is achieved by virtue of the type IVB
secretion system (T4SS), which is a protein translocation machine designed to
inject bacterial effector proteins into the host cell that modulate host cell functions
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and promote formation of a replicative niche [29]. This virulence system was codiscovered by two groups and is now known as the dot/icm system for defect in
organelle trafficking or intracellular multiplication, respectively [50, 51]. This
system is essential for L. pneumophila survival and proliferation within phagocytic
cells as mutations that impair translocation of all T4SS effector proteins render
the bacteria unable to replicate [52]. In addition, the system is also involved in
bacterial entry into host cells, establishing the LCV, manipulation of various
cellular processes, and exit from the host cell [29, 53, 54]. Host cell processes
that are affected during an infection include vesicle trafficking, protein translation,
apoptosis, and ubiquitination pathways [29].
L. pneumophila encodes at least 330 effector proteins, which is nearly 5
times more than other intracellular pathogens including Salmonella enterica. In
fact, the bacterium dedicates nearly 10% of its proteome to effectors [52].
Knocking out any single effector protein rarely results in a bacterial strain
defective for intracellular replication. Functional redundancy is the widely
accepted explanation for the large number of effectors and the absence of a
growth defect in strains lacking any one effector [55]. Evidence for this, in part,
comes from work in the Isberg laboratory [56]. A strain lacking 5 large regions of
the genome including 31% of the known effectors of the T4SS was not defective
for in vitro growth and only minimally defective for growth in mouse
macrophages. However, deletion of just one of the regions caused reduced
growth in amoebae. In addition, the importance of each of the 5 regions differed
depending on the species of amoebae that was infected. Interestingly, deletion
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of a region five, which contained ankB, resulted in a growth defect in vitro. The
strain variations observed in L. pneumophila reflect its highly plastic genome that
has evolved to adapt to multiple host cells. Many effectors contain eukaryotic
protein domains and Legionella has evolved by acquiring genetic material
through horizontal gene transfer from its host cells [57]. Therefore, the functional
redundancy exists to expand Legionella’s host range to be a generalist pathogen
to ensure survival in diverse hosts in the aquatic environment.
Many effector proteins contain eukaryotic domains to facilitate
manipulation of host cell processes [58]. These domains are mixed and matched
in different combinations to make new effectors. One comprehensive study of
effectors in 38 Legionella species found 608 Legionella effector ortholog groups,
but only seven effectors were conserved as “core effectors” and found in all
species [59]. The authors identified numerous new effector domains as well as
novel domain combinations.
7. Genome Plasticity
Members of the Legionella genus are capable of infecting protozoans in
many freshwater environments throughout the world and they have a very broad
host range [29]. Protozoans that serve as hosts are diverse and include
amoeba, slime molds, and ciliates. In response to the need to parasitize many
different protozoa, the genome of Legionella, and L. pneumophila in particular, is
highly plastic [60].
An analysis of the genomes of 6 L. pneumophila strains (Paris, Lens,
Philadelphia, Corby, Alcoy, and AA100/130b) revealed that, although the GC
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content was consistent at 38% for all strains, there was significant heterogeneity
among them [60]. The total size of the genomes ranged from 3.345 mega bases
(Mb) in Lens to 3.576 Mb in Corby, while the number of genes ranged from 2980
in Lens to 3288 in AA100/130b [60]. The number of genes specific to a given
strain varied from 144 in Corby to 386 in AA100/130b, which translates to
between 6 and 11% of the genes as strain specific [60]. Intriguingly, a large
percentage of genes are dispensable for growth of the Philadelphia strain in
bacterial culture. Deleting 27% of all protein encoding genes from various places
in the chromosome did not result in a growth defect in vitro [56]. Together, these
regions represent 49% of the known Dot/Icm translocated effectors [56]. In
addition, they had a lower GC content than the rest of the genome suggesting
acquisition by horizontal gene transfer [56]. These data indicate that the genome
of L. pneumophila is highly adaptable and that genome plasticity, particularly of
the effectors, has played a major role in shaping the different strains [60].
In support of the idea of genome plasticity, the effector repertoires also
differ between strains within the same species. Cazalet et al., compared the
genome sequences of L. pneumophila from strains Paris and Lens [61]. They
identified 10% of Lens genes and 14% of Paris genes as strain-specific. The
Paris strain contains 10 eukaryotic-like genes, including several with ankyrin
domains, that are not found in the Lens strain [61]. Likewise, the Lens strain
contains 3 eukaryotic-like genes not found in the Paris strain [61]. This diversity
is remarkable especially when one considers that these differences occur
between members of the same serotype and species [61]. It is possible that this
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plasticity exists to allow L. pneumophila to parasitize the multitude of protozoan
hosts it may encounter and, thereby, to adapt to virtually any aquatic
environment.
Burstein et al., analyzed the genome sequence of 38 Legionella species,
including L. pneumophila, and compared the repertoire of effectors contained
within each [59]. The genome size varied significantly from 2.37 Mb in L.
adelaidensis up to 4.82 Mb in L. santicrucis [59]. The percentage of guanine and
cytosine nucleotides in the genome (GC content) was also highly variable and
ranged from 36.7% to 51.1% [59]. The number of putative effector genes varied
greatly from 52 in L. adelaidensis to 247 in L. waltersii [59]. Interestingly, the
genome size is not necessarily predictive of the number of effectors, since
species with very different size genomes can have similar numbers of effectors
[59]. Their analysis identified a total of 5,885 predicted effectors among all the
species with very little overlap and only 7 core effectors common to all [59].
These core effectors seemed to evolve over a long period of time suggesting
they are fundamental to Legionella pathogenesis. The effectors unique to a
given species also had low GC content suggestive of recent acquisition by
horizontal gene transfer from ameobal or protozoal hosts which have a lower GC
content than L. pneumophila [59]. L. pneumophila had the most species-specific
effectors and the most dynamic complement of effectors [59]. This suggests that
L. pneumophila is particularly prone to horizontal gene transfer and may explain
why most infections in humans are due to L. pneumophila. Overall, the genomes
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of Legionella spp. are highly variable in relation to size and GC content, as well
as the number of effectors and their predicted function.
Identification of the function of individual L. pneumophila effectors using a
genetic approach has been challenging because most single gene knock-outs do
not result in a growth defect due to the high degree of functional redundancy
among the effectors [62, 63]. Ghosh and colleagues describe five types of
redundancy [62]. In molecular redundancy, two or more effectors target the
same host protein using the same mechanism. Target redundancy occurs when
multiple effectors target the same host protein but by distinct molecular
mechanisms. In pathway redundancy, effectors alter a single host pathway but
each target different components. Cellular process redundancy occurs when
multiple effectors target analogous or complementary host pathways that control
the same host cell process. Finally, system redundancy is where effectors target
multiple host cell processes to accomplish a single goal. Modulating cell death is
an example of this type of redundancy, since L. pneumophila can alter apoptosis,
necrosis, pyroptosis, or autophagy. The presence of so many types of
redundancies suggests that L. pneumophila has evolved over a long period of
time and become highly sophisticated as an intracellular pathogen. L.
pneumophila has the highest rate of gain and loss of effectors among Legionella
spp., making it particularly malleable [59]. By frequently shifting its effector
repertoire, L. pneumophila may have had the best chance at making the jump
from infecting protozoans to infecting human macrophages.
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8. Ankyrin Domain-Containing Proteins in L. pneumophila
The majority of ankyrin domain-containing proteins are found in eukaryotic
organisms where they are some of the most common protein domains. The
domain was first described in yeast and Drosophila but is named after the human
protein responsible for attachment of the cytoskeleton to the plasma membrane
[64]. Ankyrin domain proteins are involved in numerous cellular processes
including cell-cell signaling, development, cytoskeleton anchoring, transcription,
and cell cycle regulation [65].
The ankyrin repeat (ANK) is a 33-residue motif that forms a helix-loophelix conformation and is involved in protein-protein interactions [66]. The
helices are arranged anti-parallel with the loop projecting out to make interactions
with adjacent loops forming a β-sheet structure [65]. This basic structure can be
repeated from 1 to 33 domains, although most proteins contain six or fewer
repeats [65]. Key residues that define the motif and stabilize the first α-helix
include the TPLH sequence at positions 4 through 7. The V/I-V-X-L/V-L-L motif
(X is any hydrophilic amino acid) contributes to the second α-helix and stabilizes
adjacent ANK repeats [65, 67]. The substrate binding surface of the ankyrin
domain is composed of the β-hairpin/loop region as well as the inner short
helices [67]. These interaction surfaces were determined from co-crystal
structures of six ankyrin repeat proteins and determine the specificity of the
protein-protein interaction.
Proteins containing ANK domains are also found among bacteria,
archaea, and many viral genomes [65]. Fifteen ank genes have been identified
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in four sequenced L. pneumophila genomes with 11 shared among all four
(ankB, ankC, ankD, ankF, ankG, ankh, ankl, ankJ, ankK, ankN, ankQ) [64].
Ankyrin repeat genes in L. pneumophila were likely acquired through horizontal
gene transfer from amoebal or protozoal hosts and appear to be novel without
significant homology to known ank genes [57, 68]. L. pneumophila effectors
containing ANK domains are diverse in that they can be combined with F-box
domains, leucine-rich repeats, cysteine peptidase domains, and
glycosyltransferase domains to name a few [59]. Eight of the 11 ANK effectors
are translocated through the T4SS based on adenylate cyclase fusion assays
[69]. Three of the 11 effectors, ankB, ankH, and ankJ, are essential for
intracellular growth in human macrophages and amoebae [70, 71]. While the
functions of AnkH and AnkJ are unknown, AnkB is responsible for recruiting
polyubiquitylated proteins to the LCV during infection in macrophages and
amoebae.
9. Protein Ubiquitylation
Ubiquitylation is a post-translational modification of proteins that involves
the covalent attachment of the 76-amino acid ubiquitin protein. The process
occurs only in eukaryotic cells and is highly conserved from amoebae to
mammals [72, 73]. Lysine residues on the target protein are the most common
site of attachment, however, ubiquitin can also be conjugated on other residues
including cysteine or the free α-amino group of an N-terminal residue [72].
Additional ubiquitin molecules can be added to other residues in the substrate
protein resulting in multi-monoubiquitylation [74-77]. In polyubiquitylation,
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additional ubiquitin molecules are added onto the first ubiquitin molecule via one
of seven lysines (K6, K11, K27, K29, K33, K48, and K63) creating a polymeric
ubiquitin chain [74, 77]. Homogenous ubiquitin chains are named based on
which K residue within ubiquitin contains the additional ubiquitin molecules [74,
77]. The nature of the polyubiquitin linkage determines the fate of the
ubiquitylated protein. Typically, linkage of a single ubiquitin moiety alters protein
localization or activity, whereas addition of multiple moieties, particularly on K 48,
targets the protein for degradation by the 26S proteasome [72, 78, 79]. In
contrast to targeting K48-linked proteins for degradation via the proteasome, K63linked proteins can promote lysosomal degradation of plasma membrane
proteins [74]. In addition, K63-linkages can promote protein-protein interactions.
In canonical NF-κB activation, K63-linked ubiquitin chains are generated on the
IL-1β receptor and recruit the TAK1-TAB1-TAB2/3 complex and the IKK complex,
which allows TAK1 to phosphorylate IKK2 [80]. Ubiquitination of ribosomal
proteins, for example, can stabilize interactions and promote translation [81]. In
addition, K63-linked proteins can serve as a scaffold to recruit DNA repair
enzymes and cell cycle checkpoint proteins to sites of DNA damage [82].
Ubiquitylation is a three-step process that begins with an E1 activating
enzyme that covalently attaches ubiquitin to itself via a high energy thioester
linkage [72]. The activated ubiquitin is then transferred to the active site of an E2
ubiquitin conjugating enzyme. Finally, the E2-ubiquitin interacts with an E3
ubiquitin ligase complex that transfers ubiquitin to a specific substrate. E3
ubiquitin ligases can be either HECT, RING, or RING-IBR-RING (RBR) type [83,
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84]. RING-type E3 ligases consist of either a single U-box domain protein or as
part of a complex, such as the SKP1-CUL1-F-box (SCF) complex [78, 83]. The
SCF complex is composed of a RING-box 1 protein (RBX1), cullin 1 (CUL1), Sphase kinase associated protein 1 (SKP1), and an F-box domain containing
protein [85, 86]. The F-box domain protein also contains a protein-protein
interaction domain such as WD40 or leucine-rich repeat (LRR) domain, which
directs the E3 ubiquitin ligase complex to specific substrates [87]. This makes Fbox proteins modular in nature, and they contain a domain for interacting with the
cellular ubiquitylation machinery and a domain for interacting with substrate
proteins.
E3 ligases of the SCF family recognize substrates by multiple
mechanisms including by binding specific degron motifs within the targeted
proteins, by altered protein localization, and by domain-based recognition [88,
89]. Canonical degrons are short defined motifs in target proteins that are
recognized by the F-box protein only after they have been phosphorylated by
specific kinases. For example, the FBXW1 protein binds the degron Asp-SerGly-X-X-Ser (where X is any amino acid and both Ser are phosphorylated) [88,
90]. This provides specificity to the E3 and restricts degradation to cellular
conditions under which the protein kinase is active. Recognition of substrates by
F-box proteins can be restricted to certain subcellular compartments [91]. The
FBXL20 protein contains a CaaX motif, which undergoes isoprenylation directing
it to membranes [92]. FBXL20 can only target its substrate protein for
degradation when it is localized to membranes, which provides control of
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recognition by restricting access of the E3 to its substrate [92]. Finally, F-box
proteins can recognize substrates by binding specific domains [93]. The FBXO4
protein binds TRF1 via an intermolecular beta sheet as opposed to a short
degron [94]. L. pneumophila encodes multiple F-box proteins which have the
potential to interface with host cell processes and drastically alter the
ubiquitylation state of the cell.
10. Manipulation of Host Ubiquitylation Pathways
During infection of macrophages and amoebae, the LCV acquires an
aggregate of polyubiquitinated proteins. L. pneumophila strain Philadelphia-1
encodes five F-box proteins including LegU1, LicA, AnkB, PpgA, and Lpg2525.
Ensminger and Isberg characterized the E3 ubiquitin ligase activity of these
proteins [95]. All 5 of the effectors are delivered by the T4SS during infection.
Three of these F-box proteins (LegU1, AnkB, and LicA) associate with
components of the host ubiquitylation machinery [95]. LegU1 and AnkB were
shown to interact with host SKP1 and CUL1 in a manner dependent upon an
intact F-box domain [95]. LegU1 can bind to the host protein BAT3 when
ectopically expressed in HEK-293T cells and can direct its ubiquitylation in vitro.
The fact that Legionella encodes multiple F-box proteins and that these proteins
interface with the host ubiquitylation machinery, and target host proteins for
ubiquitylation, suggests that this process should be critical for intracellular
growth. However, legU1, ankB, and lpg2160 were all shown to be dispensable
for intracellular growth of the Philadelphia strain in both murine macrophages and
amoebae [95]. In addition, a triple F-box mutant (legU1, ankB, and licA) in the
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Philadelphia-1 strain background still accumulated polyubiquitinated proteins
around its LCV [96]. Although this may seem to argue against the importance of
manipulating the ubiquitylation machinery, it may simply be explained by
functional redundancy and highlight the importance of this process for
intracellular growth in various hosts. If manipulating the ubiquitylation machinery
is crucial for infection, one might expect L. pneumophila to have acquired
multiple F-box proteins from the many hosts it has encountered over time.
The importance of each of the F-box proteins in Legionella depends on
the strain. Different strains encode different compliments of F-box proteins. For
example, the Paris and Lens strains have three genes that encode F-box
proteins, whereas the Philadelphia strain encodes five [97]. The F-box effector,
AnkB, is essential for accumulation of polyubiquitinated proteins around the LCV
during infection in some strains. In the Paris strain, the percentage of LCVs
associated with ubiquitin is reduced by about half in ankB mutant infected cells
compared with WT infected cells in the macrophage-like THP-1 cell line [98]. In
the AA100/130b strain, the percentage of LCVs surrounded by ubiquitin dropped
from 88% in WT infected hMDMs to 30% in ankB mutant infected cells [99]. In
both the AA100/130b and Paris strains, AnkB is essential for intracellular growth
in macrophages (hMDMs and U937 for AA100/130b and THP-1 for Paris) and
amoebae [71, 98]. However, AnkB is not essential in the Philadelphia strain for
robust intracellular growth within mouse macrophages [95]. These results
indicate that among F-box proteins, there is a high degree of functional
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redundancy and that AnkB may make the largest contribution to manipulation of
host ubiquitin pathways in certain strains.
In addition to F-box proteins, L. pneumophila also utilizes several other
means to promote ubiquitylation of proteins. First, the LubX effector contains an
eukaryotic U-box domain and has E3 ubiquitin ligase activity [100]. Interestingly,
it ubiquitylates another L. pneumophila effector, SidH, and is designated as a
metaeffector or an effector that regulates other effectors [100]. Second, the SidC
and SdcA effectors also possess E3 ligase activity and use a mechanism that
involves the CHD catalytic triad [101]. The targets of these proteins are
unknown, however, they are involved in recruiting ER vesicles and
polyubiquitylated proteins to the LCV [73]. Finally, L. pneumophila also employs
a novel ubiquitylation strategy that uses NAD as an energy source and is
independent of E1 and E2 enzymes [102]. An ADP-ribosyl group from NAD is
added to a ubiquitin molecule resulting in an activated intermediate. This
intermediate is attacked by a Ser residue in a substrate protein resulting in the
covalent addition of ubiquitin to the substrate through a phosophor-ribosyl
linkage. The SidE family of effectors contains a mono-ADP-ribosyltransferase
(mART) motif that catalyzes the ubiquitylation of host Rab33b and Rab1 by this
mechanism [103]. Thus, L. pneumophila utilizes diverse strategies to manipulate
the host ubiquitylation machinery to promote its replication within eukaryotic cells.
11. Manipulation of Host Prenylation
Protein prenylation is a eukaryotic post-translational modification of
proteins that facilitates anchoring to membranes [104-106]. The process
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involves covalent attachment of either a 15 carbon farnesyl or 20 carbon
geranylgeranyl moiety onto a conserved cysteine residue within the CaaX motif,
where “a” is an aliphatic amino acid and “X” is any amino acid [104, 106-108].
The first step is attachment of the farnesyl group by farnesyltransferase (FTase)
or geranylgeranyl group by geranylgeranyltransferase (GGTase) to the cysteine
within the CaaX motif [109]. The prenylated protein is further processed by the
activity of the Ras-converting enzyme I (Rce1) which removes the -aaX tripeptide
from the C-terminus [109]. Finally, the isoprenylcysteine carboxyl
methyltransferase (Icmt) enzyme methylates the prenylated cysteine residue
[109]. The modified protein can be anchored to the plasma membrane or other
subcellular membranes including the LCV membrane [104, 109, 110].
In two studies, eleven genes encoding proteins containing a eukaryotic
CaaX motif were identified among four L. pneumophila strains (Philadelphia,
Paris, Lens, and Corby) with five being conserved in all 4 strains [111, 112].
When ectopically expressed in mammalian cells, six of these displayed a plasma
membrane localization indicative of prenylation. When the cysteine residue
within the CaaX motif was mutated to alanine, all the proteins redistributed to the
cytoplasm. In addition, the LCV accumulated prenylated proteins during infection
in a dot/icm-dependent manner. It is likely that these prenylated proteins are
either dot/icm translocated effectors or host proteins recruited to the LCV in a
dot/icm-dependent manner. Therefore, L. pneumophila hijacks the protein
prenylation machinery to lipidate and anchor specific CaaX motif-containing
effectors to the surface of the LCV.
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There is evidence that prenylation of L. pneumophila effectors is critical
for intracellular replication. The AnkB effector from strain AA100/130b is a CaaX
motif containing effector that has been characterized in more detail [110].
Ectopically expressed AnkB localizes to the plasma membrane in a CaaX motifdependent manner [110]. In addition to the CaaX motif, host cell FTase activity
is required for the membrane localization of ectopically expressed AnkB [110].
The CaaX motif and host cell FTase activity are also required for localization of
AnkB to the cytosolic face of the LCV membrane during infection in hMDMs and
amoebae [110]. Importantly, farnesylation of AnkB is essential for intracellular
replication within macrophages and amoebae as well as intrapulmonary
proliferation in a mouse model of Legionnaires’ disease [110]. Even though
farnesylation of AnkB is essential for its biological function, a naturally occurring
variant of AnkB in the Paris strain (AnkB Paris) lacks this motif altogether. This
ankB allele contains a mutation at nucleotide 450 that truncates the C-terminus
eliminating the CaaX motif and creating a new KNKYAP sequence. This
sequence matches the eukaryotic di-lysine motif consensus, KXKXX, found in
the C-terminus of proteins, which is responsible for trafficking proteins from the
Golgi to the ER [113-115]. This will be discussed further in chapter 2.
12. AnkB
AnkB is a 172-amino acid protein that contains a eukaryotic F-box domain,
which interacts with the host E3 SCF ubiquitin ligase complex, thus mimicking
host F-box proteins [71, 99]. AnkB also contains three eukaryotic-like ANK
domains, that likely bind specific substrates, and a C-terminal eukaryotic CaaX

22

motif [110]. AnkB is the only effector known to be required for intracellular
replication in both amoeba and human cells, and in a mouse model of
intrapulmonary proliferation [71, 98, 99, 116]. It’s importance during infection is
strain specific, as knockouts made in the AA100/130b or Paris strain result in a
replication defect, however, a knockout made in the Philadelphia strain does not
[71, 95, 98]. The Philadelphia strain encodes five F-box proteins and the
AA100/130b strain encodes two, while the Paris strain encodes three [95, 98,
117]. Thus, it is possible that the Philadelphia strain does not depend upon AnkB
because it contains F-box proteins that can functionally compensate for the loss
of AnkB, while the Paris and AA100/130b strains do not.
A model for AnkB function is shown in Figure 1. Upon contact with a
suitable host cell, AnkB is translocated through the T4SS into the host cell
cytoplasm where it rapidly becomes farnesylated on its C-terminal CaaX motif
[110, 118]. Farnesylation of AnkB confers hydrophobicity allowing it to insert into
the cytosolic face of the LCV membrane [110]. AnkB recruits the host
ubiquitylation machinery by binding to the Skp1 component of the host SCF E3
ubiquitin ligase complex via its F-box domain [99]. As a result, polyubiquitinated
proteins accumulate around the LCV during infection [119]. These proteins are
polyubiquitylated on K48 which targets them for degradation by the 26S
proteasome generating a high level of cellular amino acids that drives bacterial
replication [120].
Evidence for the role of K48-linked polyubiquitylated proteins in generating
amino acids for intracellular growth comes from data showing that inhibition of

23

the proteasome with MG132 prevents replication of WT bacteria in hMDMs [120].
Importantly, this defect could be completely rescued by supplementation with a
5-fold excess of amino acids, which suggests that the sole purpose of
manipulating the ubiquitylation machinery is to generate a surplus of free amino
acids [120]. It was shown that AnkB has a prominent role in this process.
Replication of the ankB mutant can be rescued by addition of a 5-fold excess of
amino acids or by specific single amino acids such as serine and cysteine, which
are converted by the bacteria to pyruvate that feeds the TCA cycle [120].
Importantly, some non-essential amino acids also rescue the ankB mutant.
Interestingly, addition of pyruvate or citrate can also rescue the ankB mutant for
intracellular replication [120]. The fact that the ankB mutant can be rescued by
addition of pyruvate or citrate indicates that sufficient amino acid levels are
present within the host cell, and that higher levels of amino acids are required
specifically as sources of energy to feed the TCA cycle [120]. RelA, an indicator
of amino acid starvation, is upregulated in the ankB mutant during an infection
[121]. Importantly, induction of RelA was reversed, and intracellular replication of
the ankB mutant was rescued, by addition of a 5-fold excess of amino acids
[120]. Overall, the ankB mutant undergoes a starvation response within
amoebas and hMDMs, which is consistent with a nutritional role for AnkB. These
data indicate that the K48-linked polyubiquitylated proteins surrounding the LCV
are assembled by AnkB and are degraded by the proteasome, which results in a
surplus of free amino acids that are taken up by the bacteria and shunted
through the TCA cycle to generate ATP to drive replication.
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While AnkB seems to be a nutritional virulence factor that recruits
polyubiquitylated proteins to the LCV in order to generate amino acids for
replication, the specific substrates of AnkB are currently unknown and their
identification could reveal novel roles. It seems unlikely that AnkB would
indiscriminately target proteins for degradation, since ankyrin domains typically
mediate specific protein-protein interactions [66]. Identification of AnkB
substrates could reveal that it also has a role in modulating certain host pathways
by targeting specific proteins for degradation. Alternatively, AnkB may target
specific host proteins rich in amino acids for which L. pneumophila is auxotrophic
or those rich in serine or cysteine to drive energy production via the TCA cycle.
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Fig. 1. Model of AnkB Function. AnkB is translocated via the Dot/Icm system
where it rapidly becomes farnesylated by the host enzymes FTα, RCE1, and
ICMT. This allows it to insert into the cytosolic face of the LCV membrane where
it interacts with the host ubiquitylation machinery and directs the K 48-linked
polyubiquitylation of specific host proteins. These proteins are degraded by the
proteasome into peptide fragments which are further processed into free amino
acids. Adapted and modified from reference [78].
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SPECIFIC AIMS

AnkB of the AA100/130b strain (AnkB AA100) is farnesylated and inserts
into the cytoplasmic face of the LCV membrane, a process which is essential for
recruiting polyubiquitylated proteins to the vacuole and for full virulence of L.
pneumophila [110]. Substitution of the farnesylated cysteine to alanine blocks
farnesylation of AnkB and causes a loss of LCV polyubiquitin accumulation and
results in a replication defect identical to the ankB null mutant. Ectopic
expression of AnkB-AA100 in HEK293T cells results in farnesylation of the
effector which directs its localization to the plasma membrane and trans-rescues
the ankB mutant for intracellular replication [110].
Unlike AnkB AA100, a naturally occurring ankB allele found in the Paris
strain (AnkB Paris) localizes to the leading edge of lamellipodium formation along
with α-actinin [98]. The ankB Paris allele contains a mutation at nucleotide 450
that truncates the C-terminal 18 amino acids, deletes half of the last ankyrin
repeat, and eliminates the CaaX motif. This frame shift mutation creates a new
C-terminus, which resembles a eukaryotic di-lysine motif. In eukaryotic cells, this
motif is responsible for trafficking proteins from the Golgi to the ER [115].
Despite lacking the farnesylation motif essential for function of AnkB AA100,
AnkB Paris still mediates recruitment of polyubiquitylated proteins to the LCV and
is essential for intracellular replication and virulence in a mouse model, although
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to a lesser degree compared to strain AA100/130b [71, 98]. Therefore, AnkB
Paris likely contains an alternative anchoring mechanism that allows it to localize
to the ER-derived LCV membrane during infection.
Except for a single target of AnkB Paris, the proteins ubiquitylated by
AnkB have not been identified [98]. The primary role of decorating the LCV with
polyubiquitylated proteins appears to be in the generation of free amino acids to
power replication, since an ankB mutant can be rescued by a 5-fold excess of
amino acids [120]. However, this does not exclude the possibility that AnkB may
target specific host proteins to manipulate specific host pathways. Identification
of the specific proteins targeted by AnkB could provide new insights into the
virulence mechanisms employed by L. pneumophila.
I hypothesize, that AnkB from the Paris strain contains a eukaryotic-like dilysine motif that is critical for directing it to the cytoplasmic face of the ER-derived
LCV during infection and that, once there, it binds and ubiquitylates specific host
proteins.
Specific Aim 1: Determine the mechanism by which AnkB Paris is anchored to
the cytosolic face of the LCV membrane.
Specific Aim 2: Determine the residues within the ankyrin domains of AnkB that
are responsible for binding substrates and promoting their ubiquitylation.
Specific Aim 3: Identify host and/or L. pneumophila substrate proteins that are
ubiquitylated by AnkB during infection.
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MATERIALS AND METHODS

Bacterial strains, cell cultures, and infections
L. pneumophila strain AA100/130b (ATCC BAA-74), its isogenic dotA and
ankB mutants, and complemented mutants were grown on BCYE agar plates for
3-4 days at 37⁰C prior to infection as previously described [71]. When required,
antibiotics were used at a concentration of 50 µg/mL for kanamycin and 5 µg/mL
for chloramphenicol. The E. coli strain DH5α was used for cloning. E. coli was
grown in Luria-Bertani (LB) and antibiotics were used at a concentration of 100
µg/mL for ampicillin and 40 µg/mL for chloramphenicol. HEK293T cell line was
maintained in DMEM (Gibco, Grand Island, NY) supplemented with 10% FBS.
Purification and preparation of human monocyte-derived macrophages
(hMDMs) was performed as previously described. Monocytes were isolated from
whole blood of healthy donors and then allowed to adhere to 6 well low
adherence cell culture plates for 3 days at 37°C and 5% CO2 in RPMI 1640
supplemented with 20% FBS. Monocytes were then counted and re-suspended
RPMI 1640 supplemented with 10% FBS and plated on coverslips at a density of
2 X 105 cells per well of a 24 well cell culture plate and incubated for a further 2
days. The cell culture media was then replaced with RPMI 1640 supplemented
with 5% FBS for one day, and then with RPMI 1640 supplemented with 1% FBS
for one day. The resulting hMDMs were then used for infection.
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All methods were carried out in accordance with relevant guidelines and
regulations. We confirm that all experimental protocols were approved by the
Institutional Review Board (IRB) committee (IRB# 04.0358). We confirm that
informed consent was obtained from all subjects, as required per our approved
IRB protocol.
Infection of hMDMs was performed as previously described. Bacteria
were resuspended in RPMI 1640 with 10% FBS and macrophages were infected
in triplicate for 1 hour at a multiplicity of infection (MOI) of 10. Plates were
centrifuged at 200 g for 5 minutes to synchronize the infection. Infected cells
were treated with 50 µg/mL gentamicin for 1 hour to kill extracellular bacteria.
Following gentamicin treatment, cells were washed three times with Hank’s
buffered saline solution (HBSS) and then RPMI containing 10% FBS was added.
At 10 hours post infection, cells were fixed and processed for confocal
microscopy. Infection of HEK-293 cells was performed at an MOI of 50 for 1
hour followed by treatment with gentamicin 50 µg/mL for 1 hour. At 10 hours
post infection, cells were fixed and processed for confocal microscopy.
HEK293T cell transfection and infection
To create ankB-Paris and ankB-ParisK149, 151R, ankB from strain
AA100/130b cloned into the mammalian vector p3XFlag-CMV-10 (Sigma) was
used as a template for site directed mutagenesis by PCR. HEK293T cells (85%
confluent) were re-plated onto poly-L lysine treated coverslips in 24 well plates at
a density of 5x104 cells/well. After overnight incubation, cells were transfected
with 0.625 µg plasmid DNA per well using 1.5 µg polyethylenimine (PEI) per well.
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After 24 hours, cells were infected with bacteria suspended in DMEM at an MOI
of 100 for 1 hour at 37⁰C and 5% CO2. Plates were centrifuged at 200 g for 10
minutes to synchronize the infection. Extracellular bacteria were eliminated by
treatment with gentamicin 50 µg/mL for 1 hour. At 10 hours post infection, cells
were fixed and processed for confocal microscopy.
LCV AnkB localization
To the determine localization of AnkB on the LCV surface during infection,
post-nuclear supernatants of infected hMDMs were prepared and then
differentially labeled as described previously [110]. Briefly, a total of 1 X 106
hMDMs were infected with L. pneumophila at an MOI of 10 for 2h. Post nuclear
supernatants were prepared as described previously and LCVs were allowed to
adhere to poly-L-lysine coated glass coverslips and fixed using 4%
paraformaldehyde [110]. To differentiate between intact LCVs and extracellular
bacteria, the LCVs were labeled prior to permeabilization with mouse antiLegionella antisera (1/1000 dilution) and rabbit anti-AnkB antisera (1/200 dilution)
for 1h. LCVs were then permeabilized with -20°C methanol and counter-labeled
with goat anti-Legionella antisera (1/1000 dilution) for 1h to detect intact LCVs.
The LCVs were then labeled with Alexa-Fluor conjugated secondary antibodies
(anti-mouse 488, anti-rabbit 555 and anti-goat 647) following the manufacturers
recommendations (Invitrogen).
Confocal microscopy
Processing of infected cells for confocal microscopy was performed as we
described previously [110]. Purification of the LCVs and their labeling prior to
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permeabilization to localize AnkB on the cytosolic side of the LCV membrane
was performed as we described previously [110]. For antibody labeling, goat
polyclonal anti-L. pneumophila was used at a dilution of 1:500 and detected by
Alexa-Fluor 488-conjugated donkey anti-goat IgG (Invitrogen, Carlsbad, CA).
Poly-ubiquitinated proteins were detected using mouse anti-polyubiquitin FK1
antibody at a dilution of 1:50 (BIOMOL International/Affiniti, Exeter, United
Kingdom), followed by Alexa-Fluor 647-conjugated goat anti-mouse IgM
(Invitrogen, Carlsbad, CA). For detection of 3X-Flag tagged proteins during
transfection experiments, mouse monoclonal anti-Flag (Sigma) antibodies were
used followed by detection with Alexa-Fluor 488-conjugated donkey anti-mouse
(Invitrogen, Carlsbad, CA). An Olympus FV1000 laser scanning confocal
microscope was used to examine cells as we described previously. On average,
8-15 0.2 µm serial Z sections of each image were captured and stored for further
analyses, using Adobe Photoshop CS3.
Adenylate cyclase and Western blot analysis
L. pneumophila strain AA100/130b (ATCC BAA-74) or its isogenic dotA
mutant harboring pCya-AnkB-Paris, pCya empty vector, or pCya-AnkB-Paris with
K149R or K151R were grown on BCYE agar plates for 3-4 days at 37⁰C prior to
infection as previously described [71]. U937 macrophages differentiated with
PMA at 50 ng/mL were infected at MOI 50 in triplicate and plates were
centrifuged to synchronize the infection. After 2 hours at 37°C and 5% CO 2, cells
were washed three times with PBS and lysed by adding 250 µl of 0.1 N HCl
containing 0.5% Triton X-100 and incubating at room temperature for 20 minutes.
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Lysates were assayed for cAMP using the Direct Cyclic AMP Enzyme
Immunoassay kit (Enzo Life Sciences, Inc.). Aliquots of bacteria used for
infection (1 x 108 bacteria) were lysed by adding SDS-PAGE loading buffer and
boiling for 5 minutes. Fusion protein expression was assessed by Western blot
using anti-M45 (1:50 dilution) according to standard procedures. Blots were reprobed with anti-CAT (1:2000).
PCR and Sequencing of ankB alleles
The ankB allele was amplified with the following primers: ankB1F: 5’GGATCCCAAGAGATTTTTAG-3’ and ankB1R: 5’ –
CATTTAACAAACAAGGCACT-3’ using standard PCR conditions. PCR primers
were located in genes flanking ankB. Briefly, 25 ng of genomic DNA was used
as template in a 25 µL PCR reaction containing 1U of Taq polymerase (Midsci,
St. Louis MO), 150 µM dNTPs, 20 pmol/µl of each primer with the following
cycling parameters: 94oC-5’ – 1 cycle followed by 30 cycles of 94oC-1’, 55oC-1,
72oC 1’ and a final 5 min extension at 72oC. DNA sequencing was performed on
both strands at the University of Washington Sequencing Core, and the
sequence data was assembled and edited using the DNASTAR suite (DNASTAR
Inc., Madison, WI).
Phylogenetic Analysis
Maximum likelihood (ML) tree was constructed using MEGA version 6
assuming the TN93 + G substitution model [122]. The percentage of trees in
which the associated taxa clustered together was determined by a bootstrap
analysis of 1000 trees. Initial tree for the heuristic search was obtained
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automatically by applying Neighbor-Joining and BioNJ algorithms to a matrix of
pairwise distances estimated using the Maximum Composite Likelihood (MCL)
approach, and then selecting the topology with superior log likelihood value. A
discrete gamma distribution was used to model evolutionary rate differences
among sites (5 categories (+G, parameter = 0.2388)). Nucleotide sequence data
has been submitted to GenBank® and assigned the following accession
numbers: KM276667-KM276681.
Analysis of Selection Pressures
(a) Site Models: To identify the different selective forces, i.e., negative,
neutral or positive selection, that acted upon ankB codons during its evolutionary
history we tested the fit of the sequence data to several codon-based models
implemented in CODEML package of PAML ver 4.7 accessed via its GUI
interface PAMLX1.2 essentially as described before [123-125]. In brief, we used
site models to determine selective pressures on each ankB codon by comparing
the differences in the likelihood score of each model’s fit to the sequence data via
a series of likelihood ratio tests [LRTs) [123]. To verify or supplement CODEML
outcomes, we conducted several other alternate tests including GARD (genetic
algorithms for recombination detection) to detect recombination among ankB
sequences, and SLAC (single-likelihood ancestor counting), FEL (fixed effects
likelihood), IFEL (internal fixed effects likelihood), REL (random effects
likelihood), and MEME (mixed effects models of evolution), which can each
detect positive and negatively selected codon in protein coding genes and can
explicitly account and correct for recombination within sequences. All these

34

methods were accessed and their outcomes analyzed via the
www.datamonkey.org server [126].
(b) Branch Site Models. To determine whether the ankB1 allele branch
experienced positive selection in its evolutionary history we used two versions of
the branch-site models A (M2N2) implemented in CODEML: 1) M2N2A1, which
specifically tested for evidence of positive selection in the clade leading up to
ankB1 and ankB8; and 2) M2N2A2, which specifically sought evidence for
positive selection in the ankB1 branch itself. The fit of each model to the data
was tested via LRTs with 1 degree of freedom and that measured the difference
in the likelihood score of each model (eg., M2N2A1) with a constrained version
whereby ω for the branch suspected to be under positive selection was fixed at 1
(e.g. M2N2A1ωf). It has been suggested that selection of branches of interest to
test for selection, or testing one branch at a time can sometimes lead to
statistical instability or acceptance of poorly supported models [126]. Thus to
confirm the outcomes of our CODEML branch site results, we performed
supplemental analysis for detecting all branches that may have significantly
experienced positive selection in their evolutionary history with the GA (genetic
algorithm) branch method implemented at www.datamonkey.org.
Infection of A549 GFP-BirA Cells and Effector Complex Isolation
To create pBio-ankB and pK/A-ankB, ankB from strain AA100/130b cloned
into the pICC1544 vector described previously and transformed into WT L.
pneumophila strain AA100/130b [127]. Bacteria were grown overnight to OD550
of 1.5-1.7, induced for 1 hour with 1 mM IPTG, and used to infect A549 GFP-BirA

35

cells. A549 GFP-BirA cells were maintained in G418 at a final concentration of
800 µg/mL and plated the day before infection at 5.5-5.75 x 106 cells per plate.
Cells were infected at MOI 50 and centrifuged for 10 minutes at 400 x g at room
temperature before being placed into the incubator at 37°C and 5% CO 2 for 2
hours. Plates were washed three times with 1x PBS and returned to the
incubator for 7 hours. At the end of the infection, plates were washed twice with
1x PBS and cross-linked using 10 mL of 1% formaldehyde (in 1x PBS) per plate
for 30 minutes at room temperature. Cross-linking was quenched by addition of
1 mL of 1.25 M glycine and 50 mM cysteine (in 1x PBS) for 15 minutes at room
temperature. Cells were washed three times in 1x PBS. Plates were scraped at
4°C in 1x PBS, centrifuged for 10 minutes at 500 x g, and stored at -80°C. Cells
were lysed for 30 minutes in 50 mM Na2HPO4, 150 mM NaCl, and 1% CHAPS,
pH 7.3 using 1 mL per plate. Cellular debris was pelleted at 20,000 x g for 20
minutes at 4°C. Sixty µl of equilibrated nickel resin (ThermoFisher 88221) was
added to each sample and incubated for 2 hours at 4°C. Resin was washed 5
times in lysis buffer plus 20 mM imidazole and protease inhibitors. Bound
complexes were eluted in lysis buffer plus 250 mM imidazole three times for 10
minutes each at 4°C with shaking. Elutions were pooled and 50 µL of
equilibrated streptavidin agarose (ThermoFisher 20357) was added and samples
were incubated for 2 hours at 4°C. Resin was washed 4 times with lysis buffer
and 4 times with 50 mM ammonium bicarbonate (AMBIC). Fifty µL AMBIC was
left over beads with the final wash.
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Cloning, Protein Expression and Purification of AnkB and Skp1
The human gene Skp1 (residues 1 to 163) was first cloned into
pRSFDuet-1 between NdeI and AvrII restriction sites. The gene AnkB (lpg2144,
residues 1 to 168) from Legionella pneumophila strain Philadelphia was then
cloned into the same vector between BamHI and NotI as a N-terminal His-tagged
fusion protein. The C-terminal ankyrin domain (residues 54 to 168) was cloned
into pET15b as a N-terminal His-tagged fusion and pET29a as a C-terminal Histagged fusion. Mutagenesis was performed using the QuikChange Multi SiteDirected Mutagenesis Kit (Agilent Technologies). All constructs were verified by
DNA sequencing and transformed into a BL21 E. coli strain. The cells were
grown at 37 ºC in Luria Broth (LB) to an optical density of 0.8, and expression
was induced with 1 mM isopropyl -D-1-thiogalactopyranoside at 30 ºC for 4
hours or 16 ºC overnight. After centrifuging the cells, the pellets were
resuspended in buffer A (50 mM HEPES, 500 mM NaCl, 5% (w/v) glycerol, pH
7.6), containing 1 mM phenylmethylsulfonyl fluoride and 0.1 mg/ml lysozyme,
and lysed by sonication. Cell debris was removed by centrifugation, and the
fusion protein was bound to Ni-NTA Agarose (Qiagen) beads, washed with buffer
A containing 30 mM imidazole and eluted with buffer A containing 250 mM
imidazole. The protein was further purified by size-exclusion chromatography on
a Superdex75 column (GE Healthcare) in buffer B (10 mM HEPES, 100 mM
NaCl, pH 7.0) before crystallization trials. The His-tag in the pET15b constructs
was cleaved with thrombin before injecting the protein into a size-exclusion
column.
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For selenomethionine labeling, the plasmid was transformed into a
methionine auxotroph, E.coli DL41 (DE3), and the cells were grown in LeMaster
medium supplemented with selenomethionine. For
grown in M9 minimal medium supplemented with

15N-labeling,

the cells were

15N-ammonium

chloride as the

sole source of nitrogen. The expression and purification protocols were the same
as for the native protein.
Crystallization and Structure Determination
Crystallization was performed by the hanging drop vapor diffusion method
at 293K using the Classics II commercial screen (Qiagen). Native AnkB (54-168)
concentrated to 7.6 mg/mL crystallized in a 1:1 mixture with the reservoir buffer
(0.2 M lithium sulfate, 0.1 M HEPES pH 7.5, 25% (w/v) PEG 3350). Crystals of
the SeMet-labeled C-terminal domain were obtained at 10 mg/mL with the
mother liquor (0.2 M lithium sulfate, 0.1 M Bis-Tris pH 6.5, 25% (w/v) PEG 3350).
AnkB (1-168) in complex with Skp1 was concentrated to ~ 4.5 mg/mL and
crystals were obtained from a condition containing 0.2 M trimethylamine N-oxide,
0.1 M Tris pH 8.5 and 20% (w/v) PEG 2000 MME.
The ankyrin domain and complex crystals were cryoprotected with 20%
glycerol and 20% sucrose, respectively, and flash-cooled in a N2 cold stream. Xray diffraction data were collected at beamlines A1 and F1 of Cornell HighEnergy Synchrotron Source (CHESS) using an ADSC Quantum 210 CCD
detector. Data processing and scaling were performed with HKL-2000 [128].
The diffraction data of the ankyrin domain were phased using anomalous signal
from selenium atoms by the single-wavelength anomalous dispersion method,
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with the program SHELX [129]. The initial model was built with ARP/wARP and
refined with Refmac5 [130, 131]. Full length AnkB in complex with Skp1 was
determined by molecular replacement using Skp1 and F-box from a deposited
SCF complex structure (PDB code 1LDK) and AnkB (54-168) as the search
model [132]. The model was built by ARP/wARP, completed with Coot and
improved by several cycles of refinement using Refmac5 [130, 131, 133]. Water
molecules were added in the last stage of refinement.
The refinement statistics are shown in Table 3. The final ankyrin domain
and complex structures respectively have 0 and 1 outlier in the Ramachandran
plot computed using MolProbity [134].
In vitro Pull-Down
AnkB (residues 54-168) was used as bait for the Pierce Pull-Down PolyHis
Protein:Protein Interaction Kit (ThermoFisher 21277). Both U937 macrophages
and HEK293T cells were used as a source of cellular lysate in separate
experiments. The protocol was performed per the manufacturer’s instructions.
Elutions were run on an SDS-PAGE gel and stained with Sypro Ruby.
HEK293T Transfections and Co-IP
Cells were grown to 70% confluence and plated into T-175 flasks at 4 x
106 cells per flask and incubated overnight. Cells were transfected using 11 µg
of plasmid DNA per flask with polyethylenimine as the transfection reagent
(Polysciences) for 24 hours. Cells were lysed in 50 mM Tris HCl pH 7.5, 150 mM
NaCl, 1 mM EDTA, and 1% Triton X-100 with protease inhibitors. Flag-tagged or
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HA-tagged proteins were captured using anti-Flag magnetic beads (Sigma) or
anti-HA magnetic beads (ThermoFisher) per the manufacturer’s instructions.
Antibodies and Western Blotting
Protein samples were heated to 95°C for 5 minutes in sample buffer,
separated by SDS-PAGE and transferred to a PVDF membrane. Anti-Flag
(Sigma) was used at 1:1000, anti-HA (Bethyl) was used at 1:1000, and anti-AnkB
was used at 1:30,000 in 6% non-fat milk in PBS+0.05% Tween-20 overnight at
4°C. Secondary anti-mouse-HRP was used at 1:50,000 and anti-rabbit-HRP was
used at 1:100,000. Blots were developed using chemiluminescent substrate
(ThermoFisher) and imaged using a CCD camera.
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CHAPTER 1
IDENTIFICATION OF HOST PROTEIN TARGETS OF ANKB

Results
In vitro Pull Down
Identification of biologically-relevant protein interacting partners can be
challenging, particularly in the context of proteins involved in bacterial
pathogenesis. Approaches include yeast 2-hybrid assays, coimmunoprecipitations, label transfer interaction analyses, far-Western blots, and
in vitro pull downs [135, 136]. In vitro pull downs have been successfully used to
identify novel host interacting partners of bacterial proteins in L. pneumophila and
Coxiella burnetii [137-139]. We chose an in vitro pull down to identify host
proteins targeted by AnkB. Since AnkB is an E3 ubiquitin ligase responsible for
recruiting K48-linked polyubiquitylated proteins to the LCV, and K48-linked
proteins are typically targeted for degradation; it is likely that proteins
ubiquitylated by AnkB will be unstable during a natural infection. Due to solubility
issues, we purified a His6 tagged version of the three ankyrin domains of AnkB
(residues 54-168) from E. coli by nickel affinity chromatography followed by size
exclusion chromatography. This purified version of AnkB was used as bait in an
in vitro pull down with lysates from the U937 macrophage-like cell line or
HEK293T cells serving as prey. Columns were washed and interacting partners
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were eluted. A column without AnkB was used as a negative control. Elutions
were run on an SDS-PAGE gel, stained, and unique bands were excised and
identified by mass spectrometry (MS).
The results for both U937 and HEK293T cell lines are shown (Fig. 2).
Each band indicated was excised from the gel along with the corresponding area
of the control lane and proteins were identified by MS. There were five bands
common to both cell lines of the same apparent molecular weight (MW). A total
of 176 proteins were identified among these five bands (Appendices 1 and 2).
The two to four most abundant proteins in each of the five bands found only in
the AnkB condition were chosen for confirmatory studies using co-IP (Table 1).
To confirm putative AnkB binding partners, HEK293T cells co-expressing
Flag-tagged AnkB or bacterial alkaline phosphatase (BAP) and hemagglutinin
(HA)-tagged versions of each candidate substrate were subjected to co-IP using
anti-Flag magnetic resin followed by Western blot using anti-HA antibodies.
Overall, none of the 13 candidate proteins was found to interact with AnkB. Each
potential interacting partner either non-specifically bound to the anti-Flag resin,
showed no binding to AnkB or the resin, or was poorly expressed.
An example of a protein that expressed well but failed to bind either AnkB
or BAP is also shown in Figure 3. Expression of PYCR was apparent in both
AnkB and BAP co-expressing cells, however to a lesser degree in the BAP
condition. PYCR did not co-IP with either AnkB or BAP indicating that it is not a
true binding partner of AnkB under our experimental conditions. Similar results
were obtained for ANP32A, ANP32B, ANP32E, CSNK2A1, and SET (data not
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shown). Candidate substrates that showed low expression include DBR1,
TACO1, and UGT8 (Fig. 4 and data not shown).
A representative example of non-specific binding to the beads is shown in
Figure 3. HA-PYCRL co-precipitated with AnkB to a greater degree than with
BAP. However, expression of PYCRL in PYCRL/BAP co-expressing cells was
also lower, which likely accounts for the difference in the intensity of the PYCRL
band in the AnkB and BAP lanes. Similar non-specific binding was also
observed for TBL1XR1, FAM98A, and RACK1 (data not shown). PIP4k2b
appeared to specifically bind AnkB as shown in Figure 5a. PIP4k2b was present
in the AnkB but not the BAP immunoprecipitate. However, further investigation
revealed that PIP4k2b bound non-specifically to the anti-Flag resin to a similar
degree when co-transfected with either p3x flag empty vector or p3x-ankB (Fig.
5b compare AnkB/PIP4k2b to p3x/PIP4k2b). Competition of BAP for PIP4k2b
binding to anti-Flag resin is one possible explanation for the conflicting results
observed when empty vector or BAP is used as a negative control. A positive
control co-IP using the known AnkB binding partner, Skp1, showed that Skp1
bound specifically to AnkB under these experimental conditions (Fig. 5b).
Overall, this indicates that PIP4k2b is not a binding partner for AnkB under our
experimental conditions.
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Fig. 2. In vitro Pull Down His-6 tagged AnkB (54-168) was bound to a nickel
column and lysates from either the U937 or HEK293T cell line were passed over
the column. Columns were washed and eluted. Elutions were run on an SDSPAGE gel and stained with SyproRuby. Bands that appear to be common to
both cell lines are labeled with the same number. Control- no AnkB bound to the
column, Exp- AnkB bound, Bait- purified AnkB.

44

Table 1. Candidate AnkB-Interacting Host Proteins
Name

Description

Band

*ANP32B

Acidic leucine-rich nuclear phosphoprotein B

3

RACK1

Receptor of activated protein kinase C

3

ANP32A

Acidic leucine-rich nuclear phosphoprotein A

4

*SET

Protein SET

4

ANP32E

Acidic leucine-rich nuclear phosphoprotein E

5

TACO1

Translational activator of cytochrome c oxidase

5

PYCRL

Pyrroline 5-carboxylate reductase

5

*CSNK2A1 Casein kinase II subunit alpha

5

FAM98A

Protein FAM98A

6

*PIP4K2B

Phosphatidylinositol 5-phosphate 4-kinase type 2beta

6

DBR1

Lariat debranching enzyme

8

UGT8

2-hydroxyacylsphingosine 1-betagalactosyltransferase

8

TBL1XR1

F-box-like/WD repeat-containing protein

8

* Found in both U937 and HEK293T
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IP: anti-Flag

Lysate

Fig. 3. Co-IP of AnkB and either PYCRL or PYCR. HEK293T cells were
transfected with Flag-ankB or Flag-BAP and either HA-PYCR or HA-PYCRL as
indicated. Cell lysates were incubated with anti-Flag magnetic resin, washed,
and eluted. Elutions were run on SDS-PAGE gels and subjected to Western
blotting with anti-HA antibodies.
IP: anti-Flag

Lysate

UGT8

ANP32B

Fig. 4. Co-IP of AnkB and either UGT8 or ANP32B. HEK293T cells were
transfected with flag-ankB or flag-BAP (control) and either ha-ugt8 or ha-anp32b
as indicated. Cell lysates were incubated with anti-Flag magnetic resin and
elutions were run on SDS-PAGE gels and subjected to Western blotting with antiHA antibodies. The expected positions of HA-UGT8 and HA-ANP32B are
indicated.
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a.

IP: anti-Flag

Lysate

b.
IP: anti-AnkB

Lysate

PIP4k2b

Skp1

Fig. 5. Co-IP of AnkB and PIP4k2b. (a) HEK293T cells were transfected with
Flag-ankB or Flag-BAP and HA-PIP4k2b as indicated. Lysates were incubated
with anti-Flag magnetic beads and elutions were run on SDS-PAGE gel and
subjected to Western blotting with anti-HA antibodies. (b) Similar to (a) except
that an additional negative control using empty p3X flag vector and a positive
control using HA-Skp1 were also included. Expected positions of HA-Skp1 and
HA-PIP4k2b are indicated.
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Identification of AnkB Substrates by Two-Step Immunoprecipitation
The failure of the in vitro pull down to identify AnkB substrates may be due
to various potential caveats. E3 ubiquitin ligase substrate identification is
challenging due to the transient and low affinity nature of E3 ligase-substrate
interactions and the instability of the resulting ubiquitylated substrates [135, 140].
Ensminger and colleagues successfully identified a substrate of the L.
pneumophila F-box protein LegU1 using a two-step enrichment approach [95].
They ectopically expressed HA-ubiquitin and 3x-flag legU1 in HEK293T cells and
purified in tandem using anti-Flag resin followed by anti-HA resin. The resulting
two-step immunoprecipitate was resolved on an SDS-PAGE gel and proteins
were identified by MS. We employed a similar approach whereby HEK293T cells
were transfected with 3x-flag ankB (or 3x-flag vector as a control) and HAubiquitin and treated with MG132 to inhibit the proteasome. Treating cells with
MG132 can result in the stabilization of substrate-F-box protein complexes within
the cell, which helps facilitate isolation of ubiquitylated substrates [140].
Ubiquitylated AnkB substrates were purified first using anti-Flag resin followed by
anti-HA resin. The resulting two-step immunoprecipiate was resolved on a SDSPAGE gel and proteins were identified by MS.
Three distinct bands on the gel unique to the AnkB condition were
identified as potential substrates (Fig. 6). The entire list of proteins identified in
all the bands is shown in Appendix 3, while a list of proteins identified in at least 2
of 3 replicates is shown in Table 2 (numbers indicate total spectrum counts).
Bands 1 and 2 contained the E3 ubiquitin ligase HUWE1 as well as ubiquitin
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itself (Table 2 and Appendix 3). Region 3 contained no proteins identified from at
least 2 replicates. Region 4 contained peptides derived from AnkB and ubiquitin
which likely represents ubiquitylated AnkB based on the apparent molecular
weight and the fact that ubiquitylation of AnkB has been described previously
[141]. To confirm HUWE1 as an AnkB substrate, ha-huwe1 and 3x-flag ankB (or
3x-flag vector as a control) were co-transfected into HEK293T cells and
immunoprecipitated with anti-Flag magnetic beads. The resulting
immunoprecipitants were subjected to Western blotting using anti-HA antibodies.
As shown in Figure 7, HA-HUWE1 expressed well but failed to bind AnkB. Since
HUWE1 was never detected in the control sample among any of the three
replicates (Table 2), it is unlikely to non-specifically bind the anti-Flag resin. As
the confirmatory co-IP was done using fewer cells than the initial two-step
enrichment, it is possible that the binding between AnkB and HUWE1 is transient
enough to not be detectable with fewer cells.
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ankB control

Rep. 3

Rep. 2
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1
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Fig. 6. SDS-PAGE Gel of Two-Step Immunoprecipitation. p3x-flag ankB or
p3x vector was co-transfected with ha-ubiquitin into HEK293T cells. AnkB was
purified using anti-Flag resin and elutions were subjected to a second IP with
anti-HA resin. Elutions from anti-HA resin were ran on an SDS-PAGE gel and
stained with Sypro Ruby. Numbers indicate regions that were excised from the
gel and identified by MS. Three replicates were performed.
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IP: AnkB

lysate

Fig. 7. Co-IP of HUWE1 and AnkB. p3x-flag ankB or p3x vector was cotransfected with ha-huwe1 into HEK293T cells. AnkB was immunoprecipitated
with anti-Flag resin. Elutions were subjected to Western blotting with anti-HA
antibodies. SU indicates same µg of DNA used for co-transfection and SM
indicates same number of moles.

51

Table 2. Proteins Appearing in Two or More Replicates from Two-Step
Immunoprecipitation (spectral counts are shown)

Protein

MW
kDa

Band 1

AnkB

Control

Rep 1

Rep 2

Rep 3

Rep 1

Rep 2

Isoform 2 of E3
480
ubiquitin-protein ligase
HUWE1
Polyubiquitin-B
26

2

7

1

2

2

2

Desmoglein-1

114

1

1

2

4

Serum albumin

69

5

2

Immunoglobulin heavy 38
constant alpha 1
Band 2

2

1

Isoform 2 of E3
480
ubiquitin-protein ligase
HUWE1
Ubiquitin-40S
18
ribosomal protein
S27a
Desmoglein-1
114

4

4

12

3

8

3

3

5

1

18

4

6

6

15

3

4

3

27

2

4

114

1

10

52

3

1

Band 3
AnkB Legionella
pneumophila
Ubiquitin-60S
ribosomal protein L40
40S ribosomal protein
S3
Desmoglein-1

Rep 3

1

1

1

3

4

AnkB Substrate Identification by Formaldehyde Cross-linking in vivo
As a final attempt to identify substrates of AnkB during infection, we
modified a method previously described for identification of host protein
substrates of L. pneumophila effectors [127, 142]. This method takes advantage
of formaldehyde cross-linking to stabilize transient protein-protein interactions
and uses a tandem affinity purification of cross-linked effector complexes. The
effector of interest is cloned into the pICC1544 plasmid which contains a tag with
two His-6 epitopes and an E. coli biotinylation site. L. pneumophila strains
expressing this fusion construct are used to infect A549 GFP-BirA cells that
express the E. coli BirA biotin ligase enzyme. When the effector is translocated,
it is recognized and biotinylated by the BirA ligase expressed in the host cell.
Effector-host protein complexes are stabilized via formaldehyde cross-linking and
purified first on nickel and then on streptavidin. The negative control for this
experiment contains a mutation in the biotinylation site such that it no longer
becomes biotinylated during infection. In this way, effector complexes containing
bound host protein targets can be highly purified and the associated host
proteins identified by MS.
AnkB was expressed well from the pICC1544 plasmid (Fig. 8). In the
initial experiment, 1.2 x 108 A549 GFP-BirA cells per condition were infected with
L. pneumophila expressing pBio-ankB or pK/A-ankB (control). A total of 115 and
116 host proteins were identified in the Bio and K/A conditions, respectively.
AnkB was not identified in either condition indicating that the proteins identified
are contaminants rather than true AnkB interactors. Samples from this
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experiment were run on an SDS-PAGE gel and subjected to Western blotting
with antibodies to AnkB. As shown in Figure 9, AnkB was undetectable in
lysates prepared from cells infected with L. pneumophila expressing either pBioankB or pK/A-ankB. However, AnkB was detected after nickel purification in both
conditions. Samples from the unbound fraction after streptavidin purification did
not show the expected depletion of biotinylated AnkB, which indicates either
most of the purified AnkB was bacterially derived or failed to become biotinylated
upon translocation into the host cell. Since it is possible that more infected cells
are required for detection of AnkB by MS, a second experiment was done using
2.3 x 108 A549 GFP-BirA cells. This experiment also failed to detect AnkB.
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Bio-AnkB
IPTG

-

+

K/A-AnkB

- +

Fig. 8. Expression of Bio-AnkB and K/A-AnkB. L. pneumophila harboring
pBio-ankB or pK/A-ankB was grown to an OD550 of 1.5 and induced with 1 mM
IPTG for 1 hour. 1 x 108 bacteria were lysed in SDS-PAGE loading buffer and
ran on an SDS-PAGE gel. AnkB was identified by Western blot using anti-AnkB.

Fig. 9. Purification of Cross-Linked AnkB-Host Protein Complexes. AnkB
complexes were purified from infected A549 GFP-BirA cells first using nickel
resin and then streptavidin beads. Bio indicates AnkB purified from A549 cells
infected with L. pneumophila expressing His6-Biotin-tagged AnkB. K/A indicates
the negative control which lacks the biotinylation site. His unbound indicates a
sample taken from depleted lysate after His purification. His E1 indicates the first
elution from the His purification. SA unbound indicates a sample taken from the
material left after SA purification. Blots were probed with anti-AnkB.
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Discussion
AnkB is one of the few of nearly 350 L. pneumophila effectors that is
required for robust intracellular proliferation [71]. It is an F-box protein that
substitutes for the host F-box component of the SCF E3 ubiquitin ligase complex
and mediates the accumulation of K48-linked polyubiquitylated proteins around
the LCV [99, 120]. The primary purpose of this process is to generate a surplus
of free host amino acids that drive intracellular replication [120]. AnkB may target
proteins rich in certain amino acids for which L. pneumophila is auxotrophic,
however, AnkB may target proteins in specific cellular pathways to modulate
specific host processes. The identity of the host proteins targeted by AnkB is
currently unknown, and their identification likely provide more insight into the role
of AnkB during infection. We utilized three approaches to identify host proteins
targeted for ubiquitylation by AnkB.
Our first approach employed an in vitro pull-down using AnkB (with the Fbox deleted) as bait and cellular lysates from two different cell lines as prey. We
identified 13 potential interacting partners and tested each by co-IP. None of
these proteins was confirmed as a true specific interacting partner of AnkB.
There are several possible explainations for the failure of this approach. First,
there was a high background in the in vitro pull down (Fig. 2) possibly owing to
less than ideal washing conditions. It is possible that true interacting partners
were masked by high abundance contaminating proteins which were not
adequately washed away. Second, AnkB was recently shown to be posttranslationally modified by hydroxylation within the ankyrin domains [143]. Since
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the AnkB protein used for the in vitro pull-down was purified from E. coli, it did not
have this post-translational modification, which could explain why we were
unable to identify true AnkB interacting partners. Finally, it is possible that AnkB
may require L. pneumophila metaeffectors, which are effectors that control the
activity of other effectors, to properly bind and/or ubiquitylate its target proteins.
Metaeffectors that target other L. pneumophila effectors for ubiquitylation have
been described previously [100].
Our second approach utilized a two-step IP in cells expressing AnkB and
HA-ubiquitin. Cells were treated with the proteasome inhibitor, MG132. From
cellular lysates, AnkB and bound HA-ubiquitin tagged substrates were
immunoprecipitated. In step two, the HA-ubiquitin tagged substrates were
enriched via anti-HA affinity purification and the results were identified by MS.
We identified several peptides for ubiquitin as well as the E3 ubiquitin ligase,
HUWE1. Our follow-up co-IP in cells expressing Flag-AnkB and HA-HUWE1
failed to confirm this protein as a true interactor. Reasons may include that AnkB
requires specific modifications to its substrates that only occur in the context of
an infection. In addition, AnkB-substrate interactions may be too transient and
low affinity to be identified in a co-IP experiment where the percentage of
transfected cells is only 20-25%. Finally, L. pneumophila metaeffectors may be
required to observe interaction with or ubiquitylation of AnkB substrates.
Our final approach was to perform the screen for AnkB targets in the
context of an infection and stabilize protein interactions using formaldehyde
cross-linking. This approach also utilized a two-step enrichment strategy that
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included a biotinylated tag to ensure only AnkB that was translocated into the
host cell would be purified. Despite using 2.3 x 108 infected cells, we failed to
purify detectible amounts of AnkB and did not identify any candidate substrates.
There are several potential explanations. It is possible that cross-linked AnkBhost protein complexes were insoluble under these conditions. The time of
infection may impact if AnkB substrates are available for detection by this
method. Thus, successful purification of AnkB substrates may require sampling
at different time points during the infection. Since AnkB substrates are K48-linked
and targeted for degradation, their isolation and identification may require
treating infected cells with a proteasome inhibitor. In addition, although we
verified that the tagged version of AnkB is expressed well, translocation
efficiency of the tagged protein into the host cell may not be optimal. Finally, the
N-terminal tag on AnkB may be masked by the host SCF complex cross-linked to
the F-box domain requiring purification under denaturing conditions.
There are two technical considerations that may have impacted two of the
three approaches we utilized in our search for AnkB targets. First, it was noted
during the crystallization studies that AnkB is insoluble when expressed in E. coli
without its host binding partner, Skp1. As a result, we used the ankyrin domains
of AnkB, which are soluble, as bait for the in vitro pull down. It is possible that
the entire protein and/or its interacting parter, Skp1, are needed to bind substrate
proteins. If this is the case, we would not have been able to detect AnkB targets
using the in vitro pull down unless we modified our approach by using purified
AnkB/Skp1 complex as bait. Second, if binding of AnkB to Skp1 induces a
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conformational change that allows AnkB to bind substrates, both the in vitro pull
down as well as the two-step IP approach may have been affected. Although we
overexpressed AnkB in HEK293T cells for the two-step IP, there may not have
been enough endogenous Skp1 protein to promote enough stable AnkB-Skp1target protein complexes for successful purification. Although our first two
approaches were subject to these limitations, our third approach, being done in
the context of an infection, should have been unaffected by these technical
consdierations.
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CHAPTER 2
DIVERGENT EVOLUTION OF ER RETENTION VS FARNESYLATION MOTIFMEDIATED ANCHORING OF THE ANKB VIRULENCE EFFECTOR TO THE
LEGIONELLA-CONTAINING VACUOLUAR MEMBRANE1

Results
Episodic Positive Selection in ankB Evolution
Compared to strain AA100/130b, the ankB gene of the Paris strain (ankBParis) has a deletion of an adenine at position 450 (ΔA450), which resulted in a
frame shift mutation (Fig. 10). This has led to a truncation of the last 18 amino
acids that included the CaaX farnesylation motif, which is essential for anchoring
AnkB-AA100/130b into the LCV membrane, which is indispensable for its biologic
function in decorating the LCV with polyubiquitinated proteins [110, 144]. Despite
this frame shift mutation and deletion of the C-terminal CaaX farnesylation motif,
AnkB-Paris is required for decoration of the LCV with polyubiquitinated proteins
[98]. Concurrently, a unique NKYAP sequence motif is generated at amino acids
150-154 in AnkB-Paris. To determine whether this frame shift mutation was
unique to the Paris strain or more widespread among other Legionella isolates,

1

The contents of this chapter are from “Divergent evolution of Di-lysine ER retention vs. farnesylation
motif-mediated anchoring of the AnkB virulence effector to the Legionella-containing vacuolar
membrane”, by J.D. Perpich, et al, 2017, Sci Rep, 7(1), p. 5123. Copyright 2017 by Springer Nature.
Reprinted with permission.
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we examined the abundance of the ΔA450 mutation in fifty-one isolates of clinical
(N=25) and environmental (N=26) origin. Analysis of full-length ankB sequences
revealed 15 distinct ankB alleles (Fig. 10b; Fig. 11). Interestingly, among the
15ankB alleles, ankB1 (Paris strain) was the only ankB allele to harbor the
ΔA450 mutation (Fig. 10b). The data showed that 19 of 51 isolates (37.25%), of
which 17 were environmental and 2 were of clinical origin, contained ankB1 allele
(ank1/ankB-Paris). We conclude that the ankB1/ankB-Paris allele is wide-spread
and is predominant among environmental isolates. To better understand the
forces that shaped ankB evolution, in particular the maintenance and spread of
the ankB1 allele in environmental Legionella isolates, we next analyzed the
selective pressures acting on ankB codons and also on the ankB1 branch using
CODEML and a variety of other methods (materials and methods). We found
preponderance of sites that were constrained by either negative selection or
evolved neutrally. Comparisons of models M7 and M8 also suggested that at
least 4 ankB codons had been subject to positive selection. However, we also
found evidence of recombination in the ankB alignment (Fig. 12). Although the
M7 vs M8 comparison should be robust to model violations introduced due to
recombination, we sought additional evidence to verify positive selection using
REL, FEL, IFEL and MEME methods (materials and methods). Each of these
methods found significant statistical support for site-specific positive selection in
ankB codons (data not shown). Branch site tests implemented in CODEML, and
the GA branch test both provided statistical support for the hypotheses that the
internal branch leading up to ankB1/ankB-Paris and its branch both had
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experienced positive selection. Moreover, the NKYAP C-terminal motif itself was
identified as the target of positive selection (Fig. 13).
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Fig. 10a: Molecular evolution of ankB. Representative sequence
chromatograms indicating the frame shift mutation at nucleotide position 450
(ΔA) in ankB1 compared to other ankB alleles. This mutation in ankB1 alters the
reading frame and predicts a prematurely terminated AnkB protein at residue
154 and generation of a unique NKYAP sequence motif. Arrows mark the
location of the Dot-Icm translocation signal.
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Fig. 10b. ML analysis of ankB alleles variously from clinical (in black text) and
environmental (in red text) isolates. All alleles are indicated. Diamonds indicate
ankB sequence from strains whose complete genomes has been determined.
Bootstrap values are shown above the branches. The tree is drawn to scale,
with branch lengths measured in the number of substitutions per site.
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Fig. 11. Sequence polymorphism and divergence in ankB alleles. Polymorphisms unique to each ankB allele are shown.
Site numbers for each variable position is shown in a vertical format. ankB2 allele sequence was used as a reference. This
analysis was done using MEGA 6.

Fig. 12. Two recombination breakpoints were identified in ankB alignment.
Statistical support for each breakpoint is shown. Breakpoint at position 250 was
also significant for a Kishino Hasegawa test indicating the presence of 2 or more
incongruent topologies for ankB alignment. This analysis was done using
GARD.
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Fig. 13. ankB lineages have experienced variable selective pressures. An
unscaled ankB phylogeny indicating the associated selective pressures for each
branch is shown. This GA Branch analysis indicates a 92.7% and 90.7% support
for positive selection on the ankB1 branch and the internal node leading up to
ankB1, respectively.

67

Decoration of the LCV with Polyubiquitinated Proteins Independent of the
ankB Genotype
We next asked whether the altered C-terminus of AnkB variant encoded
by ankB1 (Fig. 14a) either modified or significantly reduced the ability of AnkB1
strains to recruit polyubiquitinated proteins to the LCV. Overall, we found
extensive variation in the ability of 23 distinct Legionella isolates to recruit
polyubiquitinated proteins to the LCV (Fig. 14a-14b). Specifically, among AnkB1
strains, polyubiquitination varied from 30% to 54%. In contrast, six isolates with
full-length ankB alleles were either similar to the ΔankB mutant or the ΔdotA
translocation-defective mutant in their ability to recruit polyubiquitinated proteins
to the LCV (Fig. 14a-14b). However, a comparison of environmental and clinical
isolates revealed a modest, but statistically significant difference (Student t-test,
P < 0.05), in their ability to recruit polyubiquitinated proteins (Fig. 15). Thus,
while the environmental isolates seem less capable than clinical isolates to
recruit polyubiquitinated proteins to the LCV, the ability to recruit
polyubiquitinated proteins itself seems independent of the ankB genotype.
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Fig. 14a. AnkB-genotype does not predict the ability to recruit
polyubiquitinated proteins to the LCV. Representative confocal microscopy
images of polyubiquitinated protein recruitment to the LCV among 23 different
isolates of L. pneumophila expressing various ankB alleles. Percentages
indicate the number of LCVs positive for ubiquitin. Images in the right panel
were taken using the AA100 strain.
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Fig 14b. Distribution of percent polyubiquitin recruitment among 23 different
isolates of L. pneumophila. Environmental isolates are shown in red and clinical
isolates are shown in black. ‡, indicates strains carrying the ankB1 allele.

% Polyubiquitination

0.01 < p < 0.05

Fig. 15. Environmental and clinical isolates showed modest, but significant,
difference in their ability to recruit polyubiquitinated proteins. Box-plots
show % polyubquitination (ability to recruit polyubiquitinated proteins to the LCV)
among 10 environmental and 22 clinical isolates. Statistical significance was
analyzed via a two tailed Mann-Whitney nonparametric test. The Z-Score was
2.0111; the p-value is 0.04444. The critical value of U at p≤ 0.05 was 29.
Therefore, the difference between clinical and environmental isolates is
significant at p≤ 0.05.
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Localization of AnkB-Paris to the LCV membrane
Ectopic expression of AnkB-AA100/130b within amoeba and HEK293T
cells results in farnesylation-mediated anchoring to the plasma membrane of
both evolutionarily distinct host cells [110, 111, 144, 145]. In contrast to AnkBAA100/130b, AnkB-Paris ectopically expressed within A549 cells is enriched at
the leading edge of lamellipodium formation and co-localizes with α-actinin [98].
Our data showed that in contrast to AnkB-AA100/130b (Fig. 16a), when AnkBParis is ectopically expressed in HEK293T cells, it did not localize to the plasma
membrane; but it exhibited a punctate appearance and a perinuclear distribution,
which is characteristic of sub-cellular localization of the ER (Fig. 16c). This
perinuclear distribution is distinct from the diffuse cytosolic pattern characteristic
of AnkB-C169A, which lacks the farnesylation motif (Fig. 16b). Interestingly,
mutation of both lysines within the di-lysine motif of AnkB-Paris to arginine
(AnkB-Paris K149,151R) seemed to alter the distribution upon ectopic expression
(Fig. 16d). Ectopically expressed AnkB-Paris tended to localize to the
perinuclear ER region while AnkB-ParisK149,151R tended to distribute throughout
the cytoplasm, suggesting the loss of ER localization mediated by the ER
retention motif (Fig. 16). Our data clearly show a distinct sub-cellular localization
of AnkB-Paris and AnkB-AA100/130b.
While AnkB-AA100/130b is localized to the LCV membrane during
infection by host-mediated farnesylation, sub-cellular location of AnkB-Paris
during infection is not known. Since the farnesylation motif is missing from AnkBParis, we set out to determine sub-cellular localization of AnkB-Paris during
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infection of hMDMs. We created an identical ankB-Paris allele and introduced it
into the isogenic ankB null mutant of strain AA100/130b to determine its potential
anchoring to the LCV membrane despite the lack of the farnesylation motif. At 2
hours post-infection, the LCVs were semi-purified from infected hMDMs. Prior to
their permeabilization, the LCVs were labeled with anti-AnkB antibodies to detect
AnkB on the cytosolic side of the LCV membrane, as we described previously
[110]. Analyses by confocal microscopy showed that AnkB-AA100/130b was
anchored to the cytosolic side of the LCV membrane of 80% of WT straincontaining LCVs (Fig. 17a-17b). As expected, complementation of the ankB
mutant of strain AA100/130b with ankB-AA100/130b restored localization of
AnkB to the LCV membrane similar to the wild type strain [110]. Interestingly,
despite the lack of the farnesylation motif, complementation of the AA100/130bderived ankB mutant with the ankB-Paris allele resulted in anchoring AnkB-Paris
to the LCV membrane, similar to AnkB-AA100/130b. Therefore, despite lacking
the farnesylation motif, which is indispensable for anchoring AnkB-AA00/130b to
the ER-derived LCV membrane, AnkB-Paris is also anchored to the LCV
membrane, and this is likely to be mediated the di-lysine ER retention motif.
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Fig. 16. Ectopically expressed AnkB-Paris localizes to the cytoplasm with a
perinuclear distribution. a-d. Localization of AnkB-AA100, AnkB-Paris, AnkBParis K149,151R, and AnkB-C169A in HEK293T cells transiently transfected with
3X Flag-tagged versions of each and stained with anti-flag antibodies and DAPI.
Representative confocal images are shown.

73

Fig. 17a. AnkB-Paris localizes to the LCV during infection. Macrophages
infected with WT L. pneumophila AA100/130b, ankB mutant, or the ankB mutant
complemented with either ankB from AA100/130b or ankB from Paris strain were
fixed at 2 hours post-infection and stained with antibodies to AnkB and Legionella
(Lpn). The percentage of bacteria staining positive for AnkB (mean ±1SD) was
determined by analysis of 100 infected cells in triplicate. Data are representative
of 2 independent experiments.
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Fig. 17b. AnkB-Paris localizes to the LCV during infection. Representative
confocal images of LCVs isolated from macrophages infected with the indicated
strains. To differentiate between intact LCVs and extracellular bacteria, the LCVs
were labeled prior to permeabilization with mouse anti-Lpn antisera and rabbit
anti-AnkB antisera for 1h. LCVs were then permeabilized with -20°C methanol
and counter-labeled with goat anti-Lpn antisera to detect intact LCVs.
Abbreviations: ankB- (ankB null mutant in AA100/130b strain), dotA (dotA null
mutant in AA100/130b strain), WT (wild type AA100/130b strain). Plasmids
indicate the ankB allele used to complement the indicated strain.
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Functional substitution of AnkB-AA100/130b by AnkB-Paris
Compared to AnkB-AA100/130b, the AnkB-Paris has a truncation of the
last 18 amino acids. The crystal structure of AnkB indicates that the C-terminal
truncation of AnkB-Paris eliminates a large portion of the third ankyrin repeat
compared to AnkB-AA100/130b (Fig. 18) [146]. To determine if AnkB-Paris can
functionally substitute for AnkB-AA100/130b strain, we complemented the ankB
null mutant of the AA100/130b strain with the ankB-Paris allele and assessed
intracellular replication and decoration of the LCV with polyubiquitinated proteins
within human monocytes-derived macrophages (hMDMs) [110, 144]. We
assessed polyubiquitination of the vacuole at 2 hours post-infection by confocal
microscopy. The data showed that 20% of ankB mutant-containing LCVs were
decorated with polyubiquitinated proteins (Fig. 19a). In contrast, approximately
75% of strain AA100/130b-containing LCVs were decorated with
polyubiquitinated proteins. Despite truncation of the third ankyrin domain, the
ankB-Paris allele fully complemented the AA100/130b isogenic ankB null mutant
for accumulation of polyubiquitinated proteins, similar to the wild type strain.
We assessed the ability of AnkB-Paris to restore intracellular replication of
the ankB mutant of strain AA100/130b by determination of the frequency of
formation of replicative vacuoles at 10 hours post-infection, by confocal
microscopy (Fig. 19b). The majority of cells infected with the ankB mutant
contained a single bacterium. In contrast, the majority of cells infected with WT
bacteria contained 2-4 bacteria per cell and >20% of the LCVs harbored more
than 5 bacteria per cell. Similarly, the ankB mutant complemented with the
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ankB-Paris allele formed replicative vacuoles at a frequency similar to the WT
strain (Fig. 19b). Taken together, these results indicate that AnkB-Paris is
functionally equivalent to AnkB-AA100/130b in its ability to decorate the LCV with
polyubiquitinated proteins and to power intracellular proliferation of L.
pneumophila.
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Fig. 18. The crystal structure of AnkB. a. The structure of AnkB from the
Philadelphia strain spanning from Lys2 to Ala168 [146]. The F-box domain near
the N-terminus is indicated. Three ankyrin repeats are present rather than the
predicted two repeats based on the sequence (yellow, cyan, and magenta). b.
Predicted structure of AnkB-Paris, which maintains all three ankyrin repeats by
keeping the last half of the last repeat (magenta).
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Fig. 19. AnkB-Paris complements the ankB mutant of strain AA100/130b. a. Co-localization of polyubiquitinated
proteins with the LCV at 2 hours post-infection of hMDMs. Macrophages were infected with either wild type L.
pneumophila strain AA100/130b, its isogenic ankB or dotA mutant, or the ankB mutant complemented with ankB-Paris or
ankB-AA100. Numbers indicate the percentage of LCVs (±1SD) that co-localize with polyubiquitinated proteins. The data
are based on analysis of 100 infected cells performed in triplicate and are representative of three independent
experiments. b. At 10 hours post-infection hMDMs were fixed, stained with anti-Lpn, and analyzed by confocal
microscopy. The number of bacteria per cell was determined and the data are based on analysis of 100 infected cells
(mean ±1SD) performed in triplicate and are representative of three independent experiments. *p<0.05, **p<0.01,
***p<0.001 compared to corresponding value for ankB null mutant.

An indispensable role for the C-terminal Di-lysine Motif of AnkB-Paris in
biological function
The C-terminal 5 residues of AnkB strain Paris (K149NK151YAP) resemble
a eukaryotic di-lysine motif (KxKxx) responsible for ER-to-golgi retrograde protein
trafficking and retention in the ER [113-115, 147]. The AnkB-AA100/130b is
anchored to the LCV membrane by host-mediated farnesylation, which is
essential for biological function. Therefore, we tested the hypotheses that the
generated di-lysine ER-retention motif is also required for biological function of
AnkB-Paris. We constructed single and double substitutions of lysine 149 and
lysine151 in the ankB-Paris allele with arginine. Since L. pneumophila effectors
often have Dot/Icm translocation signals encoded in their C-terminus, we tested
the ER retention motif AnkB-ParisK149R and AnkB-ParisK151R substitution mutants
for Dot/Icm-mediated translocation using an adenylate cyclase reporter assay, as
we described previously [71, 99, 110]. The cya reporter fusions of ankB-Paris,
ankB-ParisK149R, or ankB-ParisK151R were transformed into either the WT strain
AA100/130b or its isogenic translocation-deficient dotA mutant. After 2 hours of
infection, cells were lysed and cAMP levels were determined via ELISA (Fig.
20a-20b). Cells infected with WT bacteria expressing the Cya-AnkB-Paris
reporter fusion showed robust cAMP production compared to cells infected with
dotA mutant bacteria expressing the same reporter fusion or cells infected with
the WT strain expressing the catalytic domain of Cya alone. This indicates that
AnkB-Paris is translocated by the AA100/130b strain. In contrast, substitution of
either K149 or K151 completely abolished translocation of AnkB-Paris. These
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results indicate that the two lysine residues in the putative di-lysine ER-retention
motif are essential for translocation of AnkB-Paris during infection.
In eukaryotic cells, the di-lysine motif is recognized by the coatomer
complex (COPI). Coatomer is a multiprotein complex composed of two
subcomplexes that include a trimer of α-COP, β’-COP, and ε-COP and a
tetramer composed of β-COP, γ-COP, δ-COP, and ζ-COP [148]. The α-COP
and β’-COP subunits of coatomer are responsible for binding di-lysine motifs.
We tested for a physical interaction between AnkB-Paris and α-COP or β’-COP
in vivo by Co-IP but were unable to detect any interaction. It is possible that
overexpression of multiple members of the COPI complex is required to detect a
physical interaction with AnkB-Paris.
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Figure 20. The putative di-lysine motif in the C-terminus of AnkB-Paris is
essential for translocation by the Dot/Icm system. a. Translocation of AnkBParis into U937 cells at 2 hours post-infection by WT or dotA mutant bacteria
expressing either Cya (negative control) or the indicated Cya::AnkB-Paris
fusions. Data represent the mean cAMP concentration of 3 wells (±1SD).
*p<0.005 compared to dotA harboring Cya::AnkB-Paris. b. Proteins derived from
1 x 108 bacteria were loaded onto an SDS-PAGE gel and expression of fusion
constructs was detected by Western blot using an antibody to the M45 epitope
present in all Cya fusions. Blots were re-probed with anti-CAT antibodies. Lanes
1: WT Cya, 2: dotA Cya-AnkB-Paris K151R, 3: WT Cya-AnkB-Paris K151R, 4: dotA
Cya-AnkB-Paris K149R, 5: WT Cya-AnkB-Paris K149R, 6: dotA Cya-AnkB-Paris, 7:
WT Cya-AnkB-Paris.
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The Putative Di-lysine Motif of AnkB-Paris is Required for in-trans Rescue
of the ankB Mutant
Since AnkB-ParisK149R and AnkB-ParisK151R are not translocated by the
Dot/Icm system, we could not test the potential effect of these mutations on
intracellular growth or decoration of the LCV with polyubiquitinated proteins. We
have previously shown that the ankB null mutant of strain AA100/130b is rescued
for intra-vacuolar growth within HEK293T ectopically expressing AnkB but not by
the farnesylation-defective AnkB variant that has a substitution of the cysteine
within the C-terminal CaaX farnesylation motif [110]. This is due to the ability of
ectopically expressed AnkB to be farnesylated and anchored to the cytosolic side
of the plasma membrane where polyubiquitinated proteins are assembled, while
the farnesylation defective variant of AnkB is defective. Since this approach
bypasses the need for translocation, we transfected 3X Flag-tagged versions of
AnkB-Paris, AnkB-ParisK149R and AnkB-ParisK151R or 3X Flag vector control into
HEK293T cells and then infected with the ankB mutants. At 10 hours postinfection, cells were fixed and examined for formation of replicative vacuoles
using confocal microscopy. Our data showed that replication of the ankB mutant
was efficiently trans-rescued by ectopically-expressed AnkB-Paris compared to
the vector control (Fig. 21a-21b). In contrast, replication of the ankB mutant was
not rescued in cells ectopically expressing AnkB-ParisK149R, AnkB-ParisK151R, or
AnkB-ParisK149,151R substitution mutants. Ectopically expressed was localized to
the perinuclear ER region while the AnkB-ParisK149,151R was distributed
throughout the cytoplasm (Fig. 16c-16d). These data indicate that the putative
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di-lysine ER-retention motif is indispensable for function of AnkB-Paris; likely
through membrane anchoring to the ER-derived LCV membrane.
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Figure 21. Requirement of the putative di-lysine motif in the C-terminus of
ectopically expressed AnkB-Paris for trans-rescue of the ankB mutant. a.
HEK293T cells were first transfected with plasmids encoding 3X-Flag empty
vector, 3X-Flag AnkB-Paris, 3X-Flag AnkB-Paris K149, 151R, 3X-Flag AnkB-Paris
K149R, or 3X-Flag AnkB-Paris K151R and then infected with the ankB mutant.
Intracellular replication was analyzed at 10 hours post infection by confocal
microscopy. The results are based on examination of 50 infected/transfected
cells using three biological replicates. The mean number of bacteria per
transfected HEK293T cell is shown. Error bars represent 1 standard deviation.
*p<0.01 compared to cells transfected with empty vector. b. Representative
confocal microscopy images of cells infected with the ankB mutant and
expressing the indicated 3X Flag-ankB fusion. Anti-flag staining is shown in
green and anti-Lpn is shown in red.
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Discussion
Among the more than 300 confirmed and predicted effectors of L.
pneumophila, very few of them are required for intracellular proliferation and
AnkB is one the effectors indispensable for intracellular proliferation [59]. These
have been an emerging common theme of variations in the number of effectors
and their paralogues among various strains and phenotypic differences between
various strains associated with these differences [59, 149]. Loss of the AnkB
AA100/130b effector results in a more severe intracellular defect in macrophage
and amoeba and in vivo compared to AnkB-Paris, despite the observations that
both function similarly in decorating the LCV with polyubiquitinated proteins [71,
98, 99]. Although host proteasomal degradation is essential for intracellular
replication of the Philadelphia-derived Lp02 strain, its AnkB homologue does not
contribute to decoration of the LCV with polyubiquitinated proteins or intracellular
replication [95, 150]. This suggests that other F-box proteins or ubiquitin ligases,
such as SidE and LubX, are involved in decorating the LCV with
polyubiquitinated proteins [103, 151-153]. It is also becoming clear that L.
pneumophila translocate deubiquitinases that remove ubiquitin from the modified
protein, and variation in translocated deubiquitinases between various L.
pneumophila isolates is likely to be a contributing factor for differences between
them in polyubiquitination of the vacuoles and the effectors and metaeffectors
(effectors of effectors) involved [152]. Whether metaeffectors of AnkB varies
between various isolates is not known. In addition, modification of AnkB by K 11linked polyubiquitination and by asparagine hydroxylation has been shown for
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AnkB-AA100 but it is not known how that differs between isolates [141, 143].
Considering the phenotypic differences between isolates as a consequence of
the loss of AnkB and the structural differences in AnkB between the two
characterized strains Paris and AA100/130b, it is important to decipher the
biological bases of these differences for one of the very few effectors required for
intracellular proliferation of L. pneumophila.
Despite the frame shift mutation and deletion of the C-terminal CaaX
farnesylation motif, AnkB-Paris (AnkB1) is required for decoration of the LCV with
polyubiquitinated proteins [98]. Concurrently, a unique NKYAP sequence ER
retention motif is generated at amino acids 150-154 of AnkB-Paris. The crystal
structure of AnkB indicates that the third ankyrin repeat is truncated in AnkBParis [146]. Each ankyrin repeat domain is composed of two α-helices
connected by a β-loop where the substrate binding domain is located [64]. Our
phylogenetic data show that the ankB1 allele is predominant among
environmental isolates. Statistical support for positive selection in ankB codons
and lineages, and variable effects of ankB genotype on recruitment of
polyubiquitinated proteins suggest that AnkB may be functionally pleiotropic and
may engage diverse cellular pathways triggered by various strains to ensure
survival during intracellular residency. Other possibilities include differential
regulation of ankB in different isolates; read through of the stop codon (encoding
a modified aa in place of stop codon) resulting in a full-length functional AnkB
similar to AnkB-AA100/130b. We conclude that positive selection acts on few
ankB codons; that the ankB1 allele itself is maintained in natural populations by
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positive selection specifically on the NKYAP ER retention motif; and that the
relatively high frequency of the ankB1 allele in environmental isolates likely
reflects a functionally advantageous trait conferred by the ankB1 allele. The
selective advantage to harbor the ankB1 allele among environmental isolates of
L. pneumophila could be due to a more efficient anchoring to the LCV membrane
through the di-lysine ER retention motif compared to farnesylation in some
unicellular hosts and/ or the third ankyrin domain that is truncated in AnkB1 does
not interact with host targets in environmental host but interacts with a specific
human target. It is also possible that other effectors expressed by various strains
may compensate for the loss of the third ankyrin domain in the ankB-Paris allele.
Identification of the AnkB-interacting targets and their interacting domains in
AnkB should facilitate deciphering these possibilities.
Despite the lack of the farnesylation motif, AnkB-Paris is anchored to the
cytosolic side of the LCV membrane. However, substitutions of the di-lysine ER
retention motif results in failure to translocate the effector. This indicates an
overlap in the signal for membrane anchoring and Dot/Icm-mediated
translocation of the AnkB-Paris effector. Unfortunately, it is not possible to
determine whether the di-lysine ER retention motif of AnkB-Paris was
responsible for localization to the ER-derived LCV membrane, since the di-lysine
ER-retention motif substitution in AnkB-Paris resulted in loss of translocation by
the Dot/Icm system. In addition, the perinuclear ER-like distribution of
ectopically-expressed AnkB-Paris is lost upon alternation of the di-lysine ER
retention motif. Importantly, the trans-rescue of the ankB mutant within cells
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ectopically expressing AnkB-Paris and the failure of the ER retention di-lysine
mutant in trans-rescue clearly shows that the ER retention di-lysine motif is
essential for the function of AnkB-Paris. This may not be surprising, since
substitution of the cysteine within the CaaX farnesylation motif AnkB-AA100
results in a total loss of function of the effector in trans-rescue of the ankB mutant
for intra-vacuolar proliferation [110]. We conclude that anchoring of AnkB
variants to host membranes is essential for function, regardless of the
mechanism of membrane anchoring by farnensylation or by the di-lysine ERretention motif.
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CHAPTER 3
STRUCTURAL MIMICRY BY A BACTERIAL F-BOX EFFECTOR HIJACKS THE
HOST UBIQUITIN-PROTEASOME SYSTEM2

Results
Structure of AnkB/Skp1
The structure of the AnkB effector was determined in complex with its host
partner, Skp1. It contains one molecule in the asymmetric unit with interpretable
electron density for Pro2-Cys160 of Skp1 and Lys2-Ala165 of AnkB. The
structure of AnkB resembles a step stool, with the F-box clasped into a groove
formed by helices 5 – 8 of Skp1, and the ankyrin domain forming the next step
(Fig. 23a). The F-box adopts a typical fold, with three α-helices in a right-handed
superhelical organization. An overlay of the F-box of AnkB with other F-boxes
reveals high similarity – an RMSD of 0.7 Å over 33 C atoms with a Skp1-Skp2
complex (PDB code 1FQV) (Fig. 23b) [85]. We also solved the structure of the
isolated ankyrin domain (residues 54 to 168) to close to 1 Å resolution. The

2

The work in this chapter was done in collaboration with Kathy Wong, Guennadi Kozlov, Miroslaw Cygler,
and Kalle Gehring. They solved the crystal structure of AnkB. My contribution was the design,
performance, and analysis of the experiments in figures 25 and 26, as well as the writing and editing of
the manuscript. The contents of this chapter are from “Structural Mimicry by a Bacterial F Box Effector
Hijacks the Host Ubiquitin-Proteasome System”, by K. Wong, et al, 2017, Structure, 25(2), p. 376-383.
Copyright 2017 by Elsevier Ltd. Reprinted with permission.
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domain is composed of three ankyrin repeats – one more than originally
predicted – a short middle repeat (Pro97 to Lys116) flanked by two longer
repeats (Ile54 to Lys81 and Pro131 to Glu161). Each repeat adopts a helix-turnhelix fold with connecting loops forming an L-shaped interaction surface typical of
other ankyrin repeats (Fig. 22b and 23a) [154]. The majority of ankyrin domains
contain four to seven repeats, while up to 34 repeats have been reported [155].
The largest sequence differences generally occur in the loop regions and confer
binding specificity. Refinement statistics for both structures are shown in Table 3.
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a

b

Fig. 22. Domain organization of AnkB a. AnkB is composed of two domains:
an F-box (pink) and ankyrin repeats (green). b. Sequence alignment of AnkB with
human proteins containing an F-box [EAW49753.1] and ankyrin repeats
[AAH11608.2]. The secondary structure elements and important residues in
AnkB are highlighted: cyan, hydrogen bonds with Skp1; gray, hydrophobic
interactions with Skp1; yellow, putative substrate binding residues in ankyrin
repeats; red crosses, mutations that prevent intracellular growth; α, alpha-helix.
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b
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Fig. 23. Structure of AnkB as a component of the E3 ubiquitin ligase complex. a. Co-crystal of AnkB (pink, F-box;
green, ankyrin repeats) and Skp1 (cyan). Hydrogen bonds between AnkB and human Skp1 are highlighted. Residues
involved in the hydrophobic interaction surface between Skp1 and F-box are labeled. In addition to the four AnkB residues
involved, Pro10 is also shown. Leu9 and Pro10 are highly conserved between F-boxes and abolish binding when mutated
to alanine [99]. Skp1 secondary structure elements are labeled: H, alpha-helix; S, beta-sheet. AnkB secondary structure
elements are labeled: α, alpha-helix. b. Comparison of AnkB (pink) and the human F-box protein Skp2 (blue) binding to
Skp1 (cyan) (PDB code 1FQV) yields an RMSD of 0.7 Å over the F-box C atoms.

Table 3: Data collection and refinement statistics for AnkB

Data collection

54-168

1-168/Skp1(1-163)

Space group

C2221

P212121

a, b, c (Å)

54.32, 80.49, 54.08

53.58, 57.04, 150.90

α, β, γ (°)

90, 90, 90

90, 90, 90

Resolution (Å)

50-1.15 (1.17-1.15)1

50-2.85 (2.90-2.85)

Rsym

0.104 (0.435)

0.113 (0.622)

I / I

22.3 (3.8)

48.5 (6.42)

Completeness (%)

98.6 (97.9)

100 (100)

Redundancy

3.6 (3.6)

14.2 (14.5)

Resolution (Å)

45.0-1.15

75.45-2.85

No. reflections

39731

10735

Rwork / Rfree

0.173/0.191

0.219/0.275

941

2498

Protein

12.79

40.40

Water

24.50

48.74

Bond lengths (Å)

0.016

0.008

Bond angles ()

1.697

1.253

100.0

95.7

0.0

4.3

Cell dimensions

Refinement

No. atoms
Protein
B-factors

R.m.s deviations

Ramachandran statistics (%)
Most favored regions
Additional allowed regions
1Highest

resolution shell is shown in parentheses.
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Structural basis of AnkB-Skp1 binding
Full-length AnkB was insoluble when expressed without Skp1. The
structure of the complex explains this phenomenon as the F-box is unlikely to
fold without Skp1. A large hydrophobic surface formed by the N-terminal tail and
helices 1 and 2 of AnkB interacts with helices 5, 6, and 7 of Skp1 (Fig. 23a).
Multiple hydrogen bonds with helix 7 and its surrounding loops of Skp1 also
stabilize the interaction. AnkB is insoluble without Skp1 to shield the hydrophobic
surfaces and provide polar contacts.
A previous mutagenesis study showed that a mutation in the AnkB F-box
domain leads to a defect in intracellular bacterial proliferation [99]. The L9A
P10A mutant is unable to interact with host Skp1 and fails to decorate the LCV
with polyubiquitinated proteins, a crucial source of carbon and energy for
intracellular proliferation [99]. The leucine forms part of the hydrophobic
interaction surface with Skp1, while the proline is responsible for initiating the first
F-box α-helix (Fig. 23a). Both residues are highly conserved among F-box
domains and their mutation to alanine likely prevents proper folding of the AnkB
F-box domain [156].
Identification of the substrate-binding site on AnkB
We observed unusually well-ordered crystal contacts between the Cterminal tail of AnkB and the ankyrin domain of another molecule (Fig. 24a). The
contacts also occurred in the crystals of the AnkB-Skp1 complex that adopt a
different space group (data not shown). In the ankyrin domain crystal, a total of
nine hydrogen bonds are formed between the backbone of the C-terminal tail,
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Q160EEKI, and the putative AnkB substrate-binding site. Additional side chain
polar contacts contribute to the structuring of the peptide in the groove formed by
the first two ankyrin repeats.
To validate the identification of the substrate-binding site, we 15N-labeled
the ankyrin domain and acquired NMR 15N-1H correlation spectra following a
stepwise addition of peptides. Titrations of the ankyrin domain with a
pentapeptide QEEKI derived from the AnkB C-terminus, resulted in several
chemical shift changes, indicating weak but significant binding. We also tested
the effects of N-terminal acetylation and C-terminal amidation and single amino
acid substitutions to alanine but these had no significant impact on binding.
Titration with a second peptide, PRLPTL, which binds to the ankyrin domain of
ANKRA2 showed smaller shifts suggestive of weaker binding (Fig. 24b) [157].
Residues within the ankyrin domain of AnkB are essential for recruitment
of polyubiquitinated proteins to the LCV
We selected four residues for mutagenesis that are predicted to be
involved in substrate binding based on the AnkB crystal structure. Tyr91, Leu93
and Tyr127 form a hydrogen-bonding network connecting and stabilizing the loop
residues. We also observed Leu134, located on the first helix of the last ankyrin
repeat, is solvent exposed and potentially provides hydrophobic interactions with
substrates.
To validate our structural prediction that Tyr91, Leu93, Tyr127 and Leu134
are important in the biological function of AnkB during infection, the residues
were substituted with lysine. To verify that the lysine mutants were still correctly
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folded, we acquired 1D NMR spectra of the mutants and wild-type ankyrin
domain. The mutant spectra are similar to that of the native domain, indicating
proper folding (data not shown). Human monocytes-derived macrophages
(hMDM) were then infected with the wild-type strain (AA100/130b), the ankB null
mutant, or the ankB mutant complemented with either a wild-type copy of ankB
or one of the ankB mutant constructs. At 2 hours post-infection, the function of
the AnkB variants was evaluated by assessment of recruitment of
polyubiquitinated proteins using confocal microscopy. The data showed that
approximately 55% of the LCVs of the wild-type strain-infected cells stained
positively for polyubiquitin, whereas only 25% of the LCVs harboring the ankB
null mutant were positive. Complementing the ankB mutant with a wild-type copy
of ankB fully restored recruitment of polyubiquitinated proteins to the LCV with
approximately 53% of the LCVs staining positively (Fig. 25a). The single lysine
ankB mutants and the Y91K L93K double mutant were similarly functional in the
complementation assay. In contrast, the Y91K L93K Y127K triple mutant and the
Y91K L93K Y127K L134K quadruple mutant were defective in recruitment of
polyubiquitinated proteins at levels similar to the ankB null mutant. This confirms
the importance of the substrate binding site on the ankyrin domain for the
recruitment of polyubiquitinated proteins to the LCV [141].
The ankyrin domain is required for intracellular replication
We determined if mutations of these four residues resulted in a replication
defect of the bacteria within the LCV. hMDMs were infected with wild-type L.
pneumophila, its isogenic dotA or ankB mutants, or the ankB mutant
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complemented with a wild-type or mutated copy of ankB. At 10 hours postinfection, the dotA null mutant showed no replication and the ankB null mutant
was markedly compromised compared to the wild-type strain (Fig. 25b).
Complementation of the ankB mutant with a wild-type copy of ankB restored
replication to wild-type levels. The single mutants Y91K, L93K, Y127K, L134K,
and double mutant Y91K L93K were also effective in restoring growth. In
contrast, complementation with the triple and quadruple mutations in the ankyrin
domain showed a significant defect in replication. Similar results were obtained
with the U937 macrophage cell line (data not shown). These data are in
agreement with the decreased ubiquitination of the LCV observed in bacteria
expressing ankB with the same triple and quadruple mutations. Residues Tyr91,
Leu93, Tyr127, and Leu134 within the ankyrin repeats of AnkB are critical both
for recruitment of ubiquitinated proteins to the LCV and for replication within
hMDMs and U937 macrophages (Fig. 25-26).
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a

b
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Fig. 24. Substrate binding by the ankyrin repeats. a. Crystal contacts in the AnkB ankyrin repeats mimic substrate
binding. The C-terminal tail (residues 160 to 164, QEEKI) of one molecule (wheat) binds to the ankyrin repeats of another
(green). Hydrogen bonds are indicated by dashed black lines. Residues involved in contacting the peptide and residues
that were mutated for further functional studies are labeled in black. An omit map of the substrate is colored and labeled in
wheat. See also Figure S1. b. Downfield region of HSQC spectra of the 15N-labeled ankyrin domain show chemical shifts
upon titration with the QEEKI peptide (C-terminal tail) and weaker binding upon titration with the PRLPTL peptide
(negative control) at 0 mM (red) and 8 mM (blue).

a

b
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Fig. 25 Replication and Ubiquitylation Defect in hMDMs. a. Percentage of LCVs colocalizing with polyubiquitinated
proteins by confocal microscopy at 2 hours post-infection. Human monocytes-derived macrophages (hMDMs) were
infected with wild type L. pneumophila, ankB mutant, or the ankB mutant complemented with either a wild type copy of
ankB or ankB containing the indicated single or multiple mutations. The data are representative of three independent
experiments and are based on analysis of 100 infected cells per strain with each strain analyzed in duplicate. Error bars
indicate +/- 1 SD. Abbreviations: 3K and 4K refer to Y91K/L93K/Y127K and Y91K/L93K/Y127K/L134K, respectively.
*p<0.02 compared to ankB mutant complemented with wild type ankB. NS, not significant. See also Figure S2. b. hMDMs
were infected with wild type, dotA mutant, ankB mutant, or the ankB mutant complemented with either wild type ankB or
ankB containing the indicated mutations at an MOI of 1 followed by 1 hour treatment with gentamicin to kill extracellular
bacteria. After 10 h, 100 infected cells were analyzed by confocal microscopy and the number of bacteria per cell was
determined. The data are representative of two independent experiments with each strain analyzed in duplicate. Error
bars indicate +/- 1 SD. Abbreviations: 3K, and 4K refer to Y91K/L93K/Y127K and Y91K/L93K/Y127K/L134K, respectively.
*p <0.05 compared to ankB mutant complemented with wild type ankB.
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Fig. 26 Mutation of three or more key residues within the Ankyrin domain of AnkB causes a replication defect in
U937 macrophages U937 cells were infected with wild type, dotA mutant, ankB mutant, or the ankB mutant
complemented with either wild type ankB or ankB containing the indicated mutations at an MOI of 1 followed by 1 hour
treatment with gentamicin to kill extracellular bacteria. After 10 h, 100 infected cells were analyzed by confocal
microscopy and the number of bacteria per cell was counted. Each strain was analyzed in duplicate and the results are
representative of two independent experiments. Error bars indicate +/- 1 SD. Abbreviations: 2K, 3K, and 4K refer to ankB
Y91K L93K, ankB Y91K L93K Y127K, and ankB Y91K L93K Y127K L134K, respectively. *p <0.05 compared to ankB
mutant complemented with wild type ankB.

Discussion
Here, we present the first structure of a bacterial F-box protein, the
targeting subunits of SCF ligases. There are close to 70 F-box proteins in
humans that are involved in a wide range of diseases. These proteins are
composed of an F-box domain and a variable targeting domain which belongs to
three main classes: WD40 domains, leucine-rich repeats, and other domains.
AnkB represents a unique association of an F-box and ankyrin repeats that
appears to be unique to a small number of lower eukaryotes, bacteria, and
viruses [158]. Two other F-box effectors exist in the Legionella genome that
could interact with the host SCF complex, but do not contain an ankyrin domain.
One has a coiled coil domain (lpp2486) and the other consists of only an F-box
(lpp0233). Previous mutagenesis studies have shown the importance of the
AnkB F-box for acquisition of polyubiquitinated proteins to the LCV and bacterial
proliferation [99]. The ankyrin domain of AnkB is likely involved in recruiting
substrates for ubiquitination. The structures of a large number of ankyrin protein
complexes have been determined and reveal a wide range of types of
interactions. Generally, ankyrin domains use the inter-repeat loops and inner row
of α-helices to bind other proteins; however, there is no consensus for the
structure of the bound partner [154]. Ankyrin repeats can bind discontinuous
protein surfaces, α-helices, and extended strands as observed for AnkB. The
interactions of AnkB with its C-terminal tail most closely resemble the complex of
ANKRA2 with a PxLPxI/L motif found in some histone deacetylases and other
proteins we observed low affinity binding of AnkB to the peptide PRLPTL [157].
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The ankyrin domain of AnkB shows broad specificity. This is typical of
ankyrin domains that bind unfolded or extended peptide sequences and likely
reflects the preponderance of AnkB interactions with the backbone atoms in the
bound peptide. Fitting of the NMR titration curve suggested a dissociation
constant (Kd) greater than 8 mM for the QEEKI peptide (Fig. 24b). Single amino
acid substitutions in the peptide did not result in significant changes in the
titration behavior, which is consistent with low specificity and a distributed binding
interface. Similarly, single point mutations in the AnkB ankyrin domain did not
perturb its function in poly-ubiquitination of LCVs and promoting Legionella
proliferation (Fig. 25a and 25b).
In cells, AnkB is unlikely to bind its own tail or that of another AnkB
molecule. The QEEKI motif extends from the final helix in the third ankyrin
repeat and is unable to bind to the first two repeats. The interactions between
two AnkB molecules is also unlikely as the QEEKI motif is separated by only four
residues from the AnkB CaaX farnesylation site. The tethering of AnkB to the
membrane would block access of the QEEKI of one molecule to the ankyrin
domain of another. Sequence alignment of the AnkB gene between different
strains reveals that the Paris strain homolog is a truncated version of the AnkB
structure presented in this paper. While the last α-helix of the last ankyrin repeat
is absent, the Paris homolog retains the last loop and half of the last repeat.
From analysis of the crystal structures, this would suggest that the Paris homolog
would still have a functional substrate-binding interface.
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To date, two interacting partners of AnkB have been identified. Parvin B
(ParvB), a target of AnkB ubiquitination was identified by a yeast two-hybrid
screen and co-immunoprecipitation [98]. ParvB functions in regulating the actin
cytoskeleton for cell adhesion and migration [159]. Solubility issues prevented us
from detecting direct binding of ParvB to the purified AnkB ankyrin domain. More
recently, TRIM21 was identified by coimmunoprecipitation as a partner of AnkB.
TRIM21 attaches Lys11-linked polyubiquitin chains on Lys76 of AnkB without
affecting AnkB stability [141].
Studies have elucidated two roles of AnkB in Legionella virulence.
Following phagocytosis, L. pneumophila injects effector proteins into the host cell
cytosol via the Dot/Icm secretion system. Considerable redundancy exists
between effectors and loss of the dotA gene (equivalent to a knockout of all 300
effectors) gives rise to a much stronger ubiquitination and replication deficiency
than the loss of only ankB (Fig. 25a-25b). Nonetheless, AnkB is effectively
essential for virulence and acts as a linker to recruit the SCF complex to the LCV.
Farnesylation of AnkB appears to be essential for its function; however, there is
strain specificity as AnkB from the Legionella strain Paris lacks the CaaX motif
but retains function [98, 110, 145]. By co-opting the host SCF complex, AnkB
redirects host ubiquitination to the LCV and substrates selected by AnkB. We
have built a model of AnkB in context of the SCF ubiquitination complex and the
connected UbcH7 (E2 conjugating enzyme), by aligning AnkB onto the F-box of a
Cul1-Rbx1-Skp1-Skp2 (PDB code 1LDK) and docking UbcH7 onto the Rbx1
RING domain based on a c-Cbl-UbcH7 structure (PDB code 1FBV) (Fig. 27)
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[132, 160]. In the model, the active cysteine (Cys86) of the E2 points towards
the putative substrate-binding site of the AnkB ankyrin repeats, positioning the
substrate to receive ubiquitin. Lys48-linked poly-ubiquitination of the LCV is a
critical step in the maturation of the LCV and required to prevent fusion with the
lysosome. We observed a strong correlation between loss of ubiquitination
activity and loss of Legionella proliferation for the AnkB mutations tested.
Legionella hijacks members of the secretory pathway to fuse endoplasmic
reticulum (ER)-derived vesicles to the (LCV). As Lys48-linked polyubiquitin chains
are also associated with recruitment of the autophagy machinery, the reported
association of AnkB with E3 ligases containing different chain specificities, such
as TRIM21, is particularly interesting [141].
AnkB also plays a role in enriching the cytosolic pool of free amino acids
through triggering Lys48-linked polyubiquitination and increased protein turnover
[120]. The levels of amino acids in the infected host cell are insufficient sources
of carbon, nitrogen and energy for L. pneumophila [161]. AnkB promotes intravacuolar proliferation by ubiquitinating host proteins for their degradation into free
amino acids [120, 162]. The growth defect of the ankB null mutant in both
protozoan and eukaryotic cells can be rescued by supplementation with a
mixture of free amino acids [118, 120]. AnkB likely functions by directly recruiting
substrate proteins through the ankyrin domain. Mutating either the F-box or the
ankyrin domain of AnkB results in the same phenotype, suggesting that the
ability of Legionella to co-opt host E3 ubiquitin ligases through molecular mimicry
plays a key role in pathogenesis.
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Fig. 27. Model in Context of Ubiquitylation. Model of AnkB as the F-box
protein in the SCF E3 ubiquitin ligase complex (PBD code 1LDK) with an E2
conjugating enzyme (UbcH7) (PDB code 1FBV) docked. The active cysteine of
UbcH7 (C86) is labeled. The color code is as follows: pink and green (F-box and
Ankyrin domain of AnkB), cyan (Skp1), red (Cul1), blue (Rbx1), magenta
(UbcH7).
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CONCLUSIONS AND FUTURE DIRECTIONS

I identified a unique KNKYAP motif present within the C-terminus of AnkBParis that resembles an eukaryotic ER retention di-lysine motif. I show that this
allele is predominant among environmental isolates and that the di-lysine motif is
acted upon by positive selection. I also demonstrated that AnkB-Paris, like
AnkB-AA100, is anchored to the cytosolic face of the LCV membrane, albeit by a
mechanism distinct from farnesylation. The di-lysine motif is essential for the
translocation of AnkB-Paris via the Dot/Icm system as mutations in either lysine
of the motif abrogate translocation. Because of this, I was unable to determine if
the di-lysine motif is essential for localization to the cytosolic face of the ERderived LCV membrane. However, I showed the di-lysine motif is essential for
trans-rescue of the ankB mutant in cells ectopically expressing AnkB-Paris,
indicating a critical biological function of the motif that is distinct from
translocation. The di-lysine motif is, most likely, acting as an ER retention motif
anchoring AnkB-Paris to the ER-derived LCV membrane.
There are at least two alternative hypotheses that could explain the failure
of the di-lysine mutants to trans-rescue the ankB mutant. First, the KNKYAP
motif, which is unique to AnkB-Paris, may be crucial for anchoring the protein to
the LCV surface by interacting with host and/or L. pneumophila proteins present
on the LCV that are not involved in binding to di-lysine motifs. Mutation of the
107

lysine residues within C-terminus of AnkB-Paris may disrupt the interactions with
these proteins resulting in loss of LCV localization and failure to trans-rescue the
ankB mutant. Second, the di-lysine motif is contained within the last ankyrin
repeat. Therefore, it is possible that substitution of these residues may impact
the stability of the ankyrin domain and prevent AnkB-Paris from binding to its
substrates. This would produce a loss of function in the trans-rescue experiment
not by disruption of anchoring to the LCV membrane, but by loss of ability to bind
and ubiquitylate substrates. Evidence in favor of the di-lysine hypothesis
includes the striking similarity of the C-terminus of AnkB-Paris to the di-lysine
consensus, the perinuclear distribution of AnkB-Paris upon ectopic expression,
and the fact that the LCV is derived from ER and contains coatomer proteins
known to bind di-lysine motifs.
Inside eukaryotic cells, the coatomer protein complex is responsible for
binding di-lysine motifs and trafficking proteins from the Golgi to the ER [163,
164]. The coatomer complex is composed of a trimer (α-COP, β’-COP, ε-COP)
and a tetramer (β-COP, γ-COP, δ-COP, and ζ-COP) [148]. I was unable to show
an interaction between β’-COP and AnkB-Paris by co-IP in cells overexpressing
both proteins. However, it is possible that overexpression of all members of the
trimer subcomplex would be required for binding to AnkB-Paris as was shown for
the di-lysine motif contained within diphtheria toxin [113]. Alternatively, we could
test for binding to the coatomer subcomplex in vitro using fragments of AnkBParis fused to GST and immobilized on glutathione beads [147]. Since I have
established that AnkB-Paris localizes to the ER-derived LCV membrane during
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infection, we could also assess binding of AnkB-Paris to members of the
coatomer complex by siRNA knockdown. In this scenario, cells would be treated
with siRNA targeting one or more coatomer subunits and then infected with L.
pneumophila expressing AnkB-Paris. Localization of AnkB-Paris to the LCV
would be assessed by confocal microscopy. In support of this approach,
coatomer subunits α, β, β’, and γ were all shown to localize to the LCV in a study
of the complete proteome of the WT LCV [162]. Such studies would provide
additional evidence that the KNKYAP motif present in AnkB-Paris is functioning
as a di-lysine motif.
Overall, I conclude that anchoring of AnkB variants to host membranes is
essential for function, regardless of the mechanism of membrane anchoring by
farnesylation or di-lysine ER retention. It will be interesting to explore the exact
molecular interactions responsible for tethering the AnkB-Paris to the LCV
membrane.
I identified residues within the three ankyrin domains of AnkB that are
essential for function and likely involved in binding substrates. The crystal
structure of AnkB revealed that it has a large hydrophobic surface in its Nterminus that interacts with helices 5, 6, and 7 of Skp1. The structure also
revealed three ankyrin domains within AnkB. Each repeat adopts a helix-turnhelix fold with connecting loops in between that is typical of other ankyrin
repeats. Three residues, Tyr91, Leu93, and Tyr127, were predicted to form a
hydrogen-bonding network important for binding substrate proteins and one
solvent-exposed hydrophobic residue, Leu134, potentially involved in making
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hydrophobic interactions with substrates. Single or double substitutions in these
residues had no effect on AnkB biological function in recruiting ubiquitylated
proteins to the LCV or promoting intracellular replication. On the other hand,
substituting three or four of these residues resulted in a complete loss of
ubiquitylated protein recruitment and replication similar to an ankB null mutant.
These data suggest that these residues are likely to be involved in binding to
AnkB substrates that are ubiquitylated during infection. Once substrates of AnkB
are identified, we will be able to confirm these key residues within AnkB are
responsible for binding to its targets.
I sought to identify the specific host proteins targeted by AnkB for
ubiquitylation. Despite using three different approaches, I was unable to identify
AnkB-interacting proteins under our experimental conditions. This knowledge is
important, as it may confirm the role of AnkB as a virulence factor involved in
harvesting amino acids from the host. In this case, identification of substrates
could reveal that AnkB targets host proteins rich in amino acids that are most
favorable for energy production via the TCA cycle, such as Ser, Cys, or Ala. On
the other hand, identification of specific substrates may reveal that AnkB is
involved in modulating certain host cell pathways by altering the ubiquitylation
state of key members.
Characterization of E3 ubiquitin ligase substrates in mammalian cells is
challenging [165]. It is estimated that > 80% of the human proteome is subject to
ubiquitin-mediated degradation, suggesting this process is involved in many
cellular pathways [166]. There are approximately 600 E3 ligases in the human
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genome and the substrates of these ligases are largely uncharacterized [140,
165]. Characterization of substrates is technically challenging for several
reasons. First, E3 ligase activity is under tight control and deubiquitylases (DUB)
act to reverse their activity making the entire process very dynamic [165].
Interactions between F-box protein and substrate are weak and transient with
most encounters being unproductive since the dissociation rate is faster than the
ubiquitylation rate [167]. In addition, there is significant redundancy as any
particular substrate can be the target of multiple E3 ligases and one ligase can
target multiple substrates depending on the cellular conditions [165]. Finally, the
ubiquitylated substrates are rapidly degraded by the proteasome in many cases.
These factors make isolation of substrates of a given E3 ligase challenging by
traditional immunoprecipitation methods and may explain why I was unable to do
so for AnkB.
A modified immunoprecipitation-based method has been successful in
identifying F-box protein substrates [168]. Parallel adaptor capture proteomics
(PAC) utilizes immunoaffinity-based purification of F-box substrates and couples
it with the Comparative Proteomics Analysis Software Suite (CompPASS) [168].
The method involves transfecting cells with the F-box protein of interest and
inhibiting the proteasome to increase the abundance of F-box-substrate
complexes. The complexes are purified by immunoprecipitation and interacting
proteins are identified by MS. The primary advantage of this approach is the use
of the CompPASS software to identify high-confidence interacting proteins. This
software compares results from an experiment to a table of 174 unrelated bait

111

proteins and calculates a probability that putative substrates are bona fide
interacting proteins [168]. This approach successfully identified substrates of 19
different F-box proteins with an overall validation rate of 80% [168]. This
approach could be readily applied to AnkB without the need for creating new
constructs.
An alternative approach that does not rely on purification of F-boxsubstrate protein complexes is the BioID-based method, which is a proximitybased biotinylation method [135]. The E3 ligase of interest is fused to the E. coli
biotin conjugating enzyme BirA, which can activate biotin but does not bind the
activated molecule. As a result, the activated biotin diffuses away and reacts
with any protein in close proximity, usually physically interacting proteins. Using
this method, E3 ligase substrates can be efficiently biotinylated and purified on
streptavidin under harsh lysis conditions [135]. This method overcomes the
potential limitation, inherent to immunoaffinity-based methods, for transient lowaffinity interactions encountered when working with E3 ligases and their
substrates [135]. If AnkB interacts weakly or transiently with its substrate
proteins, this method could result in identification of AnkB substrates that were
not detected under our conditions.
A recently described method, thermophoresis, could be used for
identification of novel AnkB interacting proteins. In this method, protein solutions
are heated with a focused IR laser beam that causes a local movement of
molecules either away from (positive) or toward (negative) the heating beam
[169]. These movements are characteristic of the protein and can be altered by
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changes in the protein’s size, charge, or hydration shell, which can all change in
response to binding to another protein [169]. This change in thermophoretic
property can be measured and protein interactions detected at the picomolar
level [169]. This technique could be applied to discovery of AnkB interacting
proteins by testing fractions of cellular lysates for their binding to AnkB.
Fractions could be further divided and purified to a degree that would allow
identification of the proteins in the mixture that interact with AnkB. This
technique could also be used to monitor for changes in binding of substrates to
mutant versions of AnkB such as the ones described in chapter 3.
Overall, while I was not able to identify specific substrate proteins targeted
for ubiquitylation by AnkB, I was able to identify key residues within the ankyrin
domains that are likely responsible for binding specific substrates and promoting
their ubiquitylation. I found that AnkB-Paris, which lacks the farnesylation motif
found in the AA100/130b strain, contains a putative di-lysine ER retention motif. I
show that the lysine residues within this motif are essential for it’s biological
function during infection. Similar to AnkB from the AA100/130b strain, AnkBParis localizes to the cytosolic face of the LCV most likely by virtue of its di-lysine
ER retention motif.
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APPENDIX 1

Potential AnkB interacting proteins from HEK293T
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Table 4. Proteins identified in band 3 in HEK293T
Protein Name
Accession
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Isoform 2 of Acidic leucine-rich nuclear
phosphoprotein 32 family member B
OS=Homo sapiens GN=ANP32B
Keratin, type I cytoskeletal 10
OS=Homo sapiens GN=KRT10 PE=1
SV=6
Ankyrin-repeat protein B OS=Legionella
pneumophila GN=ankB PE=4 SV=1
Cluster of Amino-terminal enhancer of
split OS=Homo sapiens GN=AES PE=1
SV=4 (sp|Q08117|AES_HUMAN)
TATA box-binding protein-like protein 1
OS=Homo sapiens GN=TBPL1 PE=1
SV=1
ER membrane protein complex subunit
8 OS=Homo sapiens GN=EMC8 PE=1
SV=1
Cluster of Keratin, type I cytoskeletal 14
OS=Homo sapiens GN=KRT14 PE=1
SV=4 (sp|P02533|K1C14_HUMAN)
Isoform 2 of 60S ribosomal protein L15
OS=Homo sapiens GN=RPL15
Protein SETSIP OS=Homo sapiens
GN=SETSIP PE=1 SV=1
Cytochrome c1, heme protein,
mitochondrial OS=Homo sapiens
GN=CYC1 PE=1 SV=3

MW

sp|Q92688-2|AN32B_HUMAN (+1)

Norm
IBAQ
1.78E+07

22 kDa

MW on
gel
25 kDa

sp|P13645|K1C10_HUMAN

9.64E+06

59 kDa

25 kDa

tr|A0A0A1EKG7|A0A0A1EKG7_LEGPN

6.81E+06

20 kDa

25 kDa

sp|Q08117|AES_HUMAN

3.48E+06

22 kDa

25 kDa

sp|P62380|TBPL1_HUMAN

3.44E+06

21 kDa

25 kDa

sp|O43402|EMC8_HUMAN (+1)

1.57E+06

24 kDa

25 kDa

sp|P02533|K1C14_HUMAN

1.37E+06

52 kDa

25 kDa

sp|P61313-2|RL15_HUMAN (+3)

1.01E+06

17 kDa

25 kDa

sp|P0DME0|SETLP_HUMAN (+6)

7.66E+05

35 kDa

25 kDa

sp|P08574|CY1_HUMAN

5.51E+05

35 kDa

25 kDa
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Protease-associated domain-containing
protein 1 OS=Homo sapiens
GN=PRADC1 PE=1 SV=1
Transducin-like enhancer protein 1
OS=Homo sapiens GN=TLE1 PE=1
SV=2

sp|Q9BSG0|PADC1_HUMAN

7.18E+05

21 kDa

25 kDa

sp|Q04724|TLE1_HUMAN (+2)

4.61E+05

83 kDa

25 kDa

DDB1- and CUL4-associated factor 7
OS=Homo sapiens GN=DCAF7 PE=1
SV=1
Proteasome subunit beta type-3
OS=Homo sapiens GN=PSMB3 PE=1
SV=2
28 kDa heat- and acid-stable
phosphoprotein OS=Homo sapiens
GN=PDAP1 PE=1 SV=1
Isoform 2 of Coronin-1C OS=Homo
sapiens GN=CORO1C
Casein kinase I isoform epsilon
OS=Homo sapiens GN=CSNK1E PE=1
SV=1
Isoform 2 of Paraspeckle component 1
OS=Homo sapiens GN=PSPC1
Isoform 2 of Myc-associated zinc finger
protein OS=Homo sapiens GN=MAZ
GTP-binding nuclear protein Ran
OS=Homo sapiens GN=RAN PE=1
SV=3

sp|P61962|DCAF7_HUMAN

4.18E+05

39 kDa

25 kDa

sp|P49720|PSB3_HUMAN (+1)

3.21E+05

23 kDa

25 kDa

sp|Q13442|HAP28_HUMAN

2.11E+05

21 kDa

25 kDa

sp|Q9ULV4-2|COR1C_HUMAN (+3)

1.61E+05

54 kDa

25 kDa

sp|P49674|KC1E_HUMAN

1.37E+05

47 kDa

25 kDa

sp|Q8WXF1-2|PSPC1_HUMAN (+2)

1.35E+05

46 kDa

25 kDa

sp|P56270-2|MAZ_HUMAN

1.24E+05

51 kDa

25 kDa

sp|P62826|RAN_HUMAN (+2)

7.27E+04

24 kDa

25 kDa

40S ribosomal protein S4, X isoform
OS=Homo sapiens GN=RPS4X PE=1
SV=2
Isoform 2 of Oxidation resistance protein
1 OS=Homo sapiens GN=OXR1
Isoform 2 of Heat shock 70 kDa protein
1A OS=Homo sapiens GN=HSPA1A
Isoform 2 of Heat shock cognate 71 kDa
protein OS=Homo sapiens GN=HSPA8
Isoform 2 of Keratin, type II cytoskeletal
78 OS=Homo sapiens GN=KRT78

sp|P62701|RS4X_HUMAN

6.47E+04

30 kDa

25 kDa

sp|Q8N573-2|OXR1_HUMAN (+5)

4.65E+04

94 kDa

25 kDa

sp|P0DMV8-2|HS71A_HUMAN (+2)

4.29E+04

64 kDa

25 kDa

sp|P11142-2|HSP7C_HUMAN (+6)

3.78E+04

54 kDa

25 kDa

sp|Q8N1N4-2|K2C78_HUMAN (+1)

7310

45 kDa

25 kDa
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Table 5. Proteins identified in band 4 from HEK293T cells
Protein Name
Accession
Acidic leucine-rich nuclear
phosphoprotein 32 family member A
OS=Homo sapiens GN=ANP32A PE=1
SV=1
Isoform 2 of Protein SET OS=Homo
sapiens GN=SET
Small acidic protein OS=Homo sapiens
GN=SMAP PE=1 SV=1
Putative RNA-binding protein Luc7-like 2
OS=Homo sapiens GN=LUC7L2 PE=1
SV=2
Cluster of Isoform Long of Proteasome
subunit alpha type-1 OS=Homo sapiens

Norm IBAQ MW

sp|P39687|AN32A_HUMAN (+1)

5.37E+07

29 kDa

MW
on gel
30 kDa

sp|Q01105-2|SET_HUMAN (+4)

1.64E+07

32 kDa

30 kDa

sp|O00193|SMAP_HUMAN

4.05E+06

20 kDa

30 kDa

sp|Q9Y383|LC7L2_HUMAN

2.37E+06

47 kDa

30 kDa

sp|P25786-2|PSA1_HUMAN [2]

1.80E+06

30 kDa

30 kDa
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GN=PSMA1 (sp|P257862|PSA1_HUMAN)
Isoform 2 of Nucleophosmin OS=Homo
sapiens GN=NPM1
WD repeat-containing protein 82
OS=Homo sapiens GN=WDR82 PE=1
SV=1
Isoform 2 of Protein FAM76A OS=Homo
sapiens GN=FAM76A
Isoform 2 of Protein FAM64A OS=Homo
sapiens GN=FAM64A
Malonyl-CoA-acyl carrier protein
transacylase, mitochondrial OS=Homo
sapiens GN=MCAT PE=1 SV=2
RWD domain-containing protein 2B
OS=Homo sapiens GN=RWDD2B PE=1
SV=1
Proteasome subunit alpha type-4
OS=Homo sapiens GN=PSMA4 PE=1
SV=1
Ubiquitin carboxyl-terminal hydrolase
isozyme L3 OS=Homo sapiens
GN=UCHL3 PE=1 SV=1
Zinc finger BED domain-containing
protein 3 OS=Homo sapiens
GN=ZBED3 PE=1 SV=1
Geminin OS=Homo sapiens GN=GMNN
PE=1 SV=1

sp|P06748-2|NPM_HUMAN (+1)

1.34E+06

29 kDa

30 kDa

sp|Q6UXN9|WDR82_HUMAN

9.71E+05

35 kDa

30 kDa

sp|Q8TAV0-2|FA76A_HUMAN (+5)

9.45E+05

32 kDa

30 kDa

sp|Q9BSJ6-2|FA64A_HUMAN (+2)

6.62E+05

26 kDa

30 kDa

sp|Q8IVS2|FABD_HUMAN

6.28E+05

43 kDa

30 kDa

sp|P57060|RWD2B_HUMAN

4.58E+05

36 kDa

30 kDa

sp|P25789|PSA4_HUMAN (+3)

3.76E+05

29 kDa

30 kDa

sp|P15374|UCHL3_HUMAN (+2)

3.76E+05

26 kDa

30 kDa

sp|Q96IU2|ZBED3_HUMAN

3.54E+05

25 kDa

30 kDa

sp|O75496|GEMI_HUMAN (+3)

3.41E+05

24 kDa

30 kDa
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WD repeat-containing protein 61
OS=Homo sapiens GN=WDR61 PE=1
SV=1
Isoform 2 of ER membrane protein
complex subunit 3 OS=Homo sapiens
GN=EMC3
Isoform 2 of Mitogen-activated protein
kinase 1 OS=Homo sapiens
GN=MAPK1
Isoform 2 of Ribonuclease P protein
subunit p30 OS=Homo sapiens
GN=RPP30
Elongation factor 1-beta OS=Homo
sapiens GN=EEF1B2 PE=1 SV=3
Complement component 1 Q
subcomponent-binding protein,
mitochondrial OS=Homo sapiens
GN=C1QBP PE=1 SV=1
Isoform 2 of Na(+)/H(+) exchange
regulatory cofactor NHE-RF2 OS=Homo
sapiens GN=SLC9A3R2
TP53-regulating kinase OS=Homo
sapiens GN=TP53RK PE=1 SV=2
Glutamate dehydrogenase 1,
mitochondrial OS=Homo sapiens
GN=GLUD1 PE=1 SV=2
Isoform 2 of Cleavage and
polyadenylation specificity factor subunit
7 OS=Homo sapiens GN=CPSF7

sp|Q9GZS3|WDR61_HUMAN

3.41E+05

34 kDa

30 kDa

sp|Q9P0I2-2|EMC3_HUMAN (+1)

2.99E+05

25 kDa

30 kDa

sp|P28482-2|MK01_HUMAN (+1)

2.86E+05

36 kDa

30 kDa

sp|P78346-2|RPP30_HUMAN (+2)

2.60E+05

36 kDa

30 kDa

sp|P24534|EF1B_HUMAN

2.39E+05

25 kDa

30 kDa

sp|Q07021|C1QBP_HUMAN (+2)

2.20E+05

31 kDa

30 kDa

sp|Q15599-2|NHRF2_HUMAN (+2)

1.85E+05

36 kDa

30 kDa

sp|Q96S44|PRPK_HUMAN

1.55E+05

28 kDa

30 kDa

sp|P00367|DHE3_HUMAN

1.51E+05

61 kDa

30 kDa

sp|Q8N684-2|CPSF7_HUMAN (+3)

1.51E+05

51 kDa

30 kDa
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COP9 signalosome complex subunit 7a
OS=Homo sapiens GN=COPS7A PE=1
SV=1
Isoform 2 of 2,4-dienoyl-CoA reductase,
mitochondrial OS=Homo sapiens
GN=DECR1
Isoform 2 of Mitotic checkpoint protein
BUB3 OS=Homo sapiens GN=BUB3
Isoform 3 of Phosphatidylinositol 5phosphate 4-kinase type-2 gamma
OS=Homo sapiens GN=PIP4K2C
Isoform 2 of Inhibitor of growth protein 4
OS=Homo sapiens GN=ING4
Isoform 2 of Plasminogen activator
inhibitor 1 RNA-binding protein
OS=Homo sapiens GN=SERBP1
Pre-rRNA-processing protein TSR1
homolog OS=Homo sapiens GN=TSR1
PE=1 SV=1

sp|Q9UBW8|CSN7A_HUMAN (+4)

1.36E+05

30 kDa

30 kDa

sp|Q16698-2|DECR_HUMAN (+4)

1.29E+05

35 kDa

30 kDa

sp|O43684-2|BUB3_HUMAN (+2)

1.01E+05

37 kDa

30 kDa

sp|Q8TBX8-3|PI42C_HUMAN (+1)

7.76E+04

45 kDa

30 kDa

sp|Q9UNL4-2|ING4_HUMAN (+7)

7.01E+04

28 kDa

30 kDa

sp|Q8NC51-2|PAIRB_HUMAN (+3)

4.61E+04

44 kDa

30 kDa

sp|Q2NL82|TSR1_HUMAN

3.74E+04

92 kDa

30 kDa

Table 6. Proteins identified in band 5 from HEK293T cells
Protein Name
Accession
Translational activator of cytochrome c
oxidase 1 OS=Homo sapiens
GN=TACO1 PE=1 SV=1
Isoform 3 of Acidic leucine-rich nuclear
phosphoprotein 32 family member E
OS=Homo sapiens GN=ANP32E

MW

sp|Q9BSH4|TACO1_HUMAN

Norm
IBAQ
5.42E+06

32 kDa

MW on
gel
33 kDa

sp|Q9BTT0-3|AN32E_HUMAN (+2)

2.78E+06

25 kDa

33 kDa
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Pyrroline-5-carboxylate reductase 3
OS=Homo sapiens GN=PYCRL PE=1
SV=3
Cluster of Isoform 2 of Mitogenactivated protein kinase 1 OS=Homo
sapiens GN=MAPK1 (sp|P284822|MK01_HUMAN)
40S ribosomal protein SA OS=Homo
sapiens GN=RPSA PE=1 SV=4
Casein kinase II subunit alpha
OS=Homo sapiens GN=CSNK2A1
PE=1 SV=1
Splicing factor U2AF 35 kDa subunitlike protein OS=Homo sapiens
GN=U2AF1L5 PE=3 SV=1
Multiple myeloma tumor-associated
protein 2 OS=Homo sapiens
GN=MMTAG2 PE=1 SV=1
Transcription initiation factor IIA subunit
1 OS=Homo sapiens GN=GTF2A1
PE=1 SV=1
Isoform 3 of Protein FRA10AC1
OS=Homo sapiens GN=FRA10AC1
Regulation of nuclear pre-mRNA
domain-containing protein 1B
OS=Homo sapiens GN=RPRD1B PE=1
SV=1
Developmentally-regulated GTPbinding protein 1 OS=Homo sapiens
GN=DRG1 PE=1 SV=1

sp|Q53H96|P5CR3_HUMAN (+1)

1.90E+06

29 kDa

33 kDa

sp|P28482-2|MK01_HUMAN [2]

6.24E+05

36 kDa

33 kDa

sp|P08865|RSSA_HUMAN (+3)

5.69E+05

33 kDa

33 kDa

sp|P68400|CSK21_HUMAN (+2)

4.75E+05

45 kDa

33 kDa

sp|P0DN76|U2AF5_HUMAN

3.23E+05

28 kDa

33 kDa

sp|Q9BU76|MMTA2_HUMAN

3.22E+05

29 kDa

33 kDa

sp|P52655|TF2AA_HUMAN (+1)

2.78E+05

42 kDa

33 kDa

sp|Q70Z53-3|F10C1_HUMAN

2.62E+05

37 kDa

33 kDa

sp|Q9NQG5|RPR1B_HUMAN

2.50E+05

37 kDa

33 kDa

sp|Q9Y295|DRG1_HUMAN

2.11E+05

41 kDa

33 kDa
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Isoform 2 of Elongation factor 1-delta
OS=Homo sapiens GN=EEF1D
Isoform 2 of F-actin-capping protein
subunit beta OS=Homo sapiens
GN=CAPZB
Pre-mRNA-splicing factor 38A
OS=Homo sapiens GN=PRPF38A
PE=1 SV=1
Peptidyl-prolyl cis-trans isomerase-like
4 OS=Homo sapiens GN=PPIL4 PE=1
SV=1
Translin-associated protein X
OS=Homo sapiens GN=TSNAX PE=1
SV=1
Enhancer of mRNA-decapping protein
3 OS=Homo sapiens GN=EDC3 PE=1
SV=1
Isoform 2 of Endonuclease III-like
protein 1 OS=Homo sapiens
GN=NTHL1
Isoform 2 of RNA pseudouridylate
synthase domain-containing protein 3
OS=Homo sapiens GN=RPUSD3
BTB/POZ domain-containing protein
KCTD12 OS=Homo sapiens
GN=KCTD12 PE=1 SV=1
Heterogeneous nuclear
ribonucleoprotein A0 OS=Homo
sapiens GN=HNRNPA0 PE=1 SV=1

sp|P29692-2|EF1D_HUMAN (+14)

1.99E+05

71 kDa

33 kDa

sp|P47756-2|CAPZB_HUMAN (+3)

1.95E+05

31 kDa

33 kDa

sp|Q8NAV1|PR38A_HUMAN

1.91E+05

37 kDa

33 kDa

sp|Q8WUA2|PPIL4_HUMAN

1.73E+05

57 kDa

33 kDa

sp|Q99598|TSNAX_HUMAN

1.69E+05

33 kDa

33 kDa

sp|Q96F86|EDC3_HUMAN

1.59E+05

56 kDa

33 kDa

sp|P78549-2|NTH_HUMAN (+3)

1.29E+05

34 kDa

33 kDa

sp|Q6P087-2|RUSD3_HUMAN (+1)

1.27E+05

37 kDa

33 kDa

sp|Q96CX2|KCD12_HUMAN

1.20E+05

36 kDa

33 kDa

sp|Q13151|ROA0_HUMAN

1.18E+05

31 kDa

33 kDa
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Cluster of Serine/threonine-protein
phosphatase PP1-beta catalytic subunit
OS=Homo sapiens GN=PPP1CB PE=1
SV=3 (sp|P62140|PP1B_HUMAN)
Isoform 2 of 60S acidic ribosomal
protein P0 OS=Homo sapiens
GN=RPLP0
Isoform 2 of V-type proton ATPase
subunit E 1 OS=Homo sapiens
GN=ATP6V1E1
Isoform 2 of Septin-2 OS=Homo
sapiens GN=SEPT2
Ribose-5-phosphate isomerase
OS=Homo sapiens GN=RPIA PE=1
SV=3
Isoform 2 of Phosphatidylinositol 5phosphate 4-kinase type-2 alpha
OS=Homo sapiens GN=PIP4K2A
Isoform 1 of RNA demethylase
ALKBH5 OS=Homo sapiens
GN=ALKBH5
Ribonucleoprotein PTB-binding 1
OS=Homo sapiens GN=RAVER1 PE=1
SV=1
FACT complex subunit SSRP1
OS=Homo sapiens GN=SSRP1 PE=1
SV=1
Casein kinase II subunit alpha'
OS=Homo sapiens GN=CSNK2A2
PE=1 SV=1

sp|P62140|PP1B_HUMAN

1.10E+05

37 kDa

33 kDa

sp|P05388-2|RLA0_HUMAN (+2)

1.02E+05

27 kDa

33 kDa

sp|P36543-2|VATE1_HUMAN (+2)

1.01E+05

24 kDa

33 kDa

sp|Q15019-2|SEPT2_HUMAN (+3)

8.81E+04

45 kDa

33 kDa

sp|P49247|RPIA_HUMAN

8.18E+04

33 kDa

33 kDa

sp|P48426-2|PI42A_HUMAN (+1)

7.86E+04

40 kDa

33 kDa

sp|Q6P6C2-1|ALKB5_HUMAN (+1)

5.33E+04

52 kDa

33 kDa

tr|A0A087WZ13|A0A087WZ13_HUMAN
(+1)

4.61E+04

78 kDa

33 kDa

sp|Q08945|SSRP1_HUMAN (+1)

4.54E+04

81 kDa

33 kDa

sp|P19784|CSK22_HUMAN

4.09E+04

41 kDa

33 kDa
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ATP synthase subunit gamma,
mitochondrial OS=Homo sapiens
GN=ATP5C1 PE=1 SV=1
Isoform 2 of Pre-B-cell leukemia
transcription factor-interacting protein 1
OS=Homo sapiens GN=PBXIP1
Isoform 2 of Transducin-like enhancer
protein 3 OS=Homo sapiens GN=TLE3
Erythrocyte band 7 integral membrane
protein OS=Homo sapiens GN=STOM
PE=1 SV=3
Isoform 3 of Ubiquitin carboxyl-terminal
hydrolase 7 OS=Homo sapiens
GN=USP7
Hornerin OS=Homo sapiens
GN=HRNR PE=1 SV=2
Serum albumin OS=Homo sapiens
GN=ALB PE=1 SV=2

sp|P36542|ATPG_HUMAN

3.53E+04

33 kDa

33 kDa

sp|Q96AQ6-2|PBIP1_HUMAN (+1)

3.30E+04

78 kDa

33 kDa

sp|Q04726-2|TLE3_HUMAN (+12)

2.96E+04

82 kDa

33 kDa

sp|P27105|STOM_HUMAN (+1)

2.37E+04

32 kDa

33 kDa

sp|Q93009-3|UBP7_HUMAN (+1)

2.11E+04

126
kDa

33 kDa

sp|Q86YZ3|HORN_HUMAN

1.43E+04

33 kDa

sp|P02768|ALBU_HUMAN (+1)

7190

282
kDa
69 kDa

Table 7. Proteins identified in band 6 from HEK293T cells
Protein Name
Accession
Pyrroline-5-carboxylate reductase 2
OS=Homo sapiens GN=PYCR2 PE=1
SV=1
Isoform 3 of Pyrroline-5-carboxylate
reductase 1, mitochondrial OS=Homo
sapiens GN=PYCR1

Norm IBAQ MW

33 kDa

sp|Q96C36|P5CR2_HUMAN

7.62E+06

34 kDa

MW
on gel
39 kDa

sp|P32322-3|P5CR1_HUMAN (+1)

3.36E+06

36 kDa

39 kDa
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Isoform 2 of RNA-binding protein with
serine-rich domain 1 OS=Homo sapiens
GN=RNPS1
Splicing factor 3B subunit 4 OS=Homo
sapiens GN=SF3B4 PE=1 SV=1
Isoform 2 of Pyrroline-5-carboxylate
reductase 3 OS=Homo sapiens
GN=PYCRL
Isoform 2 of Protein FAM98A OS=Homo
sapiens GN=FAM98A
Phosphatidylinositol 5-phosphate 4kinase type-2 beta OS=Homo sapiens
GN=PIP4K2B PE=1 SV=1
60S ribosomal protein L5 OS=Homo
sapiens GN=RPL5 PE=1 SV=3
Zinc finger and SCAN domain-containing
protein 26 OS=Homo sapiens
GN=ZSCAN26 PE=1 SV=2
Casein kinase I isoform alpha OS=Homo
sapiens GN=CSNK1A1 PE=1 SV=2
Isoform 3 of Ubiquitin carboxyl-terminal
hydrolase 46 OS=Homo sapiens
GN=USP46
Isoform 2 of Eukaryotic peptide chain
release factor subunit 1 OS=Homo
sapiens GN=ETF1
Isoform 3 of Serine
hydroxymethyltransferase, mitochondrial
OS=Homo sapiens GN=SHMT2

sp|Q15287-2|RNPS1_HUMAN (+6)

7.88E+05

32 kDa

39 kDa

sp|Q15427|SF3B4_HUMAN

6.44E+05

44 kDa

39 kDa

sp|Q53H96-2|P5CR3_HUMAN (+2)

5.93E+05

26 kDa

39 kDa

sp|Q8NCA5-2|FA98A_HUMAN (+1)

5.77E+05

55 kDa

39 kDa

sp|P78356|PI42B_HUMAN

5.44E+05

47 kDa

39 kDa

sp|P46777|RL5_HUMAN (+1)

4.32E+05

34 kDa

39 kDa

sp|Q16670|ZSC26_HUMAN (+2)

4.17E+05

55 kDa

39 kDa

sp|P48729|KC1A_HUMAN

3.94E+05

39 kDa

39 kDa

sp|P62068-3|UBP46_HUMAN (+3)

3.22E+05

42 kDa

39 kDa

sp|P62495-2|ERF1_HUMAN (+2)

2.93E+05

45 kDa

39 kDa

sp|P34897-3|GLYM_HUMAN (+1)

2.81E+05

53 kDa

39 kDa
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Crk-like protein OS=Homo sapiens
GN=CRKL PE=1 SV=1
Isoform 2 of Microtubule-associated
protein RP/EB family member 2
OS=Homo sapiens GN=MAPRE2
Inositol hexakisphosphate kinase 2
OS=Homo sapiens GN=IP6K2 PE=1
SV=2
Isoform 2 of Isovaleryl-CoA
dehydrogenase, mitochondrial
OS=Homo sapiens GN=IVD
Aurora kinase A OS=Homo sapiens
GN=AURKA PE=1 SV=2
RNA-binding protein NOB1 OS=Homo
sapiens GN=NOB1 PE=1 SV=1
Isoform 2 of Probable RNA-binding
protein 23 OS=Homo sapiens
GN=RBM23
Isoform 4 of Casein kinase I isoform
gamma-3 OS=Homo sapiens
GN=CSNK1G3
Isoform 2 of ATP-dependent RNA
helicase DDX42 OS=Homo sapiens
GN=DDX42
Lactadherin OS=Homo sapiens
GN=MFGE8 PE=1 SV=2
Isoform 2 of Poly(rC)-binding protein 2
OS=Homo sapiens GN=PCBP2
Zinc finger protein 696 OS=Homo
sapiens GN=ZNF696 PE=2 SV=2

sp|P46109|CRKL_HUMAN

2.54E+05

34 kDa

39 kDa

sp|Q15555-2|MARE2_HUMAN (+6)

2.47E+05

29 kDa

39 kDa

sp|Q9UHH9|IP6K2_HUMAN

2.40E+05

49 kDa

39 kDa

sp|P26440-2|IVD_HUMAN (+2)

2.37E+05

43 kDa

39 kDa

sp|O14965|AURKA_HUMAN

2.14E+05

46 kDa

39 kDa

sp|Q9ULX3|NOB1_HUMAN

2.06E+05

47 kDa

39 kDa

sp|Q86U06-2|RBM23_HUMAN (+4)

1.96E+05

47 kDa

39 kDa

sp|Q9Y6M4-4|KC1G3_HUMAN

1.33E+05

49 kDa

39 kDa

sp|Q86XP3-2|DDX42_HUMAN (+2)

1.30E+05

90 kDa

39 kDa

sp|Q08431|MFGM_HUMAN

1.10E+05

43 kDa

39 kDa

sp|Q15366-2|PCBP2_HUMAN (+10)

1.02E+05

39 kDa

39 kDa

sp|Q9H7X3|ZN696_HUMAN (+1)

1.01E+05

41 kDa

39 kDa
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tRNA (adenine(58)-N(1))methyltransferase, mitochondrial
OS=Homo sapiens GN=TRMT61B PE=1
SV=2
E3 ubiquitin-protein ligase RING2
OS=Homo sapiens GN=RNF2 PE=1
SV=1
Phenylalanine--tRNA ligase,
mitochondrial OS=Homo sapiens
GN=FARS2 PE=1 SV=1
26S proteasome non-ATPase regulatory
subunit 7 OS=Homo sapiens
GN=PSMD7 PE=1 SV=2
Isoform 2 of ATP synthase subunit alpha,
mitochondrial OS=Homo sapiens
GN=ATP5A1
Isoform 2 of 6-phosphofructo-2kinase/fructose-2,6-bisphosphatase 3
OS=Homo sapiens GN=PFKFB3
AMME syndrome candidate gene 1
protein OS=Homo sapiens
GN=AMMECR1 PE=1 SV=1
Isoform 2 of DNA replication licensing
factor MCM3 OS=Homo sapiens
GN=MCM3
Isoform C1 of Heterogeneous nuclear
ribonucleoproteins C1/C2 OS=Homo
sapiens GN=HNRNPC
Lupus La protein OS=Homo sapiens
GN=SSB PE=1 SV=2

sp|Q9BVS5|TR61B_HUMAN

9.83E+04

53 kDa

39 kDa

sp|Q99496|RING2_HUMAN (+1)

9.62E+04

38 kDa

39 kDa

sp|O95363|SYFM_HUMAN

9.49E+04

52 kDa

39 kDa

sp|P51665|PSMD7_HUMAN

6.47E+04

37 kDa

39 kDa

sp|P25705-2|ATPA_HUMAN (+1)

6.04E+04

54 kDa

39 kDa

sp|Q16875-2|F263_HUMAN (+6)

5.80E+04

59 kDa

39 kDa

sp|Q9Y4X0|AMMR1_HUMAN

5.56E+04

35 kDa

39 kDa

sp|P25205-2|MCM3_HUMAN (+1)

5.46E+04

96 kDa

39 kDa

sp|P07910-2|HNRPC_HUMAN (+8)

4.65E+04

32 kDa

39 kDa

sp|P05455|LA_HUMAN

4.61E+04

47 kDa

39 kDa
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Nucleolin OS=Homo sapiens GN=NCL
PE=1 SV=3
Protein KTI12 homolog OS=Homo
sapiens GN=KTI12 PE=1 SV=1
Isoform 2 of Multifunctional protein ADE2
OS=Homo sapiens GN=PAICS
T-complex protein 1 subunit beta
OS=Homo sapiens GN=CCT2 PE=1
SV=4
Isoform 2 of Septin-7 OS=Homo sapiens
GN=SEPT7
Elongation factor Tu, mitochondrial
OS=Homo sapiens GN=TUFM PE=1
SV=2
Isoform 2 of Polypeptide Nacetylgalactosaminyltransferase 2
OS=Homo sapiens GN=GALNT2
Isoform 1 of Growth factor receptorbound protein 10 OS=Homo sapiens
GN=GRB10
Isoform 2 of DnaJ homolog subfamily B
member 1 OS=Homo sapiens
GN=DNAJB1
DDB1- and CUL4-associated factor 13
OS=Homo sapiens GN=DCAF13 PE=1
SV=2
Isoform 2 of Sentrin-specific protease 6
OS=Homo sapiens GN=SENP6

sp|P19338|NUCL_HUMAN (+1)

4.46E+04

77 kDa

39 kDa

sp|Q96EK9|KTI12_HUMAN

4.42E+04

39 kDa

39 kDa

sp|P22234-2|PUR6_HUMAN (+2)

4.11E+04

48 kDa

39 kDa

sp|P78371|TCPB_HUMAN (+2)

3.95E+04

57 kDa

39 kDa

sp|Q16181-2|SEPT7_HUMAN (+5)

3.46E+04

51 kDa

39 kDa

sp|P49411|EFTU_HUMAN

2.06E+04

50 kDa

39 kDa

sp|Q10471-2|GALT2_HUMAN (+1)

2.00E+04

30 kDa

39 kDa

sp|Q13322-2|GRB10_HUMAN (+3)

1.49E+04

62 kDa

39 kDa

sp|P25685-2|DNJB1_HUMAN (+1)

1.06E+04

27 kDa

39 kDa

sp|Q9NV06|DCA13_HUMAN (+1)

6180

51 kDa

39 kDa

sp|Q9GZR1-2|SENP6_HUMAN (+1)

4480

125
kDa

39 kDa

Table 8. Proteins identified in band 8 from HEK293T cells
Protein Name
Accession
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2-hydroxyacylsphingosine 1-betagalactosyltransferase OS=Homo
sapiens GN=UGT8 PE=2 SV=2
Lariat debranching enzyme OS=Homo
sapiens GN=DBR1 PE=1 SV=2
F-box-like/WD repeat-containing
protein TBL1XR1 OS=Homo sapiens
GN=TBL1XR1 PE=1 SV=1
Isoform 2 of Creatine kinase U-type,
mitochondrial OS=Homo sapiens
GN=CKMT1A
Isoform 2 of Replication initiator 1
OS=Homo sapiens GN=REPIN1
Zinc finger protein ZIC 2 OS=Homo
sapiens GN=ZIC2 PE=1 SV=2
Isoform 2 of Adenylosuccinate lyase
OS=Homo sapiens GN=ADSL
Cluster of Pyrroline-5-carboxylate
reductase 2 OS=Homo sapiens
GN=PYCR2 PE=1 SV=1
(sp|Q96C36|P5CR2_HUMAN)
Cluster of Isoform 2 of Transducin-like
enhancer protein 3 OS=Homo sapiens
GN=TLE3 (sp|Q047262|TLE3_HUMAN)
Coronin-1B OS=Homo sapiens
GN=CORO1B PE=1 SV=1

Norm IBAQ

MW

sp|Q16880|CGT_HUMAN

1.55E+06

61 kDa

MW on
gel
54 kDa

sp|Q9UK59|DBR1_HUMAN

1.16E+06

62 kDa

54 kDa

sp|Q9BZK7|TBL1R_HUMAN

1.00E+06

56 kDa

54 kDa

sp|P12532-2|KCRU_HUMAN (+1)

8.59E+05

50 kDa

54 kDa

sp|Q9BWE0-4|REPI1_HUMAN (+3)

8.18E+05

70 kDa

54 kDa

sp|O95409|ZIC2_HUMAN (+1)

7.29E+05

55 kDa

54 kDa

sp|P30566-2|PUR8_HUMAN (+1)

6.93E+05

48 kDa

54 kDa

sp|Q96C36|P5CR2_HUMAN

6.04E+05

34 kDa

54 kDa

sp|Q04726-2|TLE3_HUMAN [9]

5.83E+05

82 kDa

54 kDa

sp|Q9BR76|COR1B_HUMAN

4.96E+05

54 kDa

54 kDa
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Isoform 2 of H/ACA ribonucleoprotein
complex non-core subunit NAF1
OS=Homo sapiens GN=NAF1
Desmoglein-1 OS=Homo sapiens
GN=DSG1 PE=1 SV=2
LanC-like protein 2 OS=Homo sapiens
GN=LANCL2 PE=1 SV=1
Isoform 2 of Myc proto-oncogene
protein OS=Homo sapiens GN=MYC
Suppressor of fused homolog
OS=Homo sapiens GN=SUFU PE=1
SV=2
Isoform 2 of Dynactin subunit 4
OS=Homo sapiens GN=DCTN4
Myotubularin-related protein 9
OS=Homo sapiens GN=MTMR9 PE=1
SV=1
Isoform 3 of Src substrate cortactin
OS=Homo sapiens GN=CTTN
Microfibrillar-associated protein 1
OS=Homo sapiens GN=MFAP1 PE=1
SV=2
Isoform 1 of Rab-3A-interacting protein
OS=Homo sapiens GN=RAB3IP
Isoform 2 of Signal recognition particle
54 kDa protein OS=Homo sapiens
GN=SRP54
Isoform 2 of Bifunctional arginine
demethylase and lysyl-hydroxylase
JMJD6 OS=Homo sapiens GN=JMJD6

sp|Q96HR8-2|NAF1_HUMAN (+1)

3.95E+05

42 kDa

54 kDa

sp|Q02413|DSG1_HUMAN

3.94E+05

54 kDa

sp|Q9NS86|LANC2_HUMAN

3.87E+05

114
kDa
51 kDa

sp|P01106-2|MYC_HUMAN (+3)

3.13E+05

51 kDa

54 kDa

sp|Q9UMX1|SUFU_HUMAN

2.89E+05

54 kDa

54 kDa

sp|Q9UJW0-2|DCTN4_HUMAN (+2)

2.82E+05

46 kDa

54 kDa

sp|Q96QG7|MTMR9_HUMAN

2.58E+05

63 kDa

54 kDa

sp|Q14247-3|SRC8_HUMAN (+1)

2.28E+05

57 kDa

54 kDa

sp|P55081|MFAP1_HUMAN

2.11E+05

52 kDa

54 kDa

sp|Q96QF0-2|RAB3I_HUMAN (+2)

1.84E+05

51 kDa

54 kDa

sp|P61011-2|SRP54_HUMAN (+2)

1.78E+05

50 kDa

54 kDa

sp|Q6NYC1-2|JMJD6_HUMAN (+5)

1.61E+05

43 kDa

54 kDa

54 kDa
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Isoform 2 of Nucleolar and spindleassociated protein 1 OS=Homo
sapiens GN=NUSAP1
Probable asparagine--tRNA ligase,
mitochondrial OS=Homo sapiens
GN=NARS2 PE=1 SV=3
7SK snRNA methylphosphate capping
enzyme OS=Homo sapiens
GN=MEPCE PE=1 SV=1
DNA primase large subunit OS=Homo
sapiens GN=PRIM2 PE=1 SV=2
Isoform 2 of U4/U6.U5 tri-snRNPassociated protein 2 OS=Homo
sapiens GN=USP39
Isoform 2 of Protein SMG8 OS=Homo
sapiens GN=SMG8
Parafibromin OS=Homo sapiens
GN=CDC73 PE=1 SV=1
Isoform 2 of Brain-specific
angiogenesis inhibitor 1-associated
protein 2 OS=Homo sapiens
GN=BAIAP2
Isoform 2 of Myotubularin-related
protein 12 OS=Homo sapiens
GN=MTMR12
Suprabasin OS=Homo sapiens
GN=SBSN PE=1 SV=2
Isoform 3 of RNA polymerase IIassociated factor 1 homolog OS=Homo
sapiens GN=PAF1

sp|Q9BXS6-2|NUSAP_HUMAN (+6)

1.50E+05

49 kDa

54 kDa

sp|Q96I59|SYNM_HUMAN

1.48E+05

54 kDa

54 kDa

sp|Q7L2J0|MEPCE_HUMAN

1.46E+05

74 kDa

54 kDa

sp|P49643|PRI2_HUMAN

1.29E+05

59 kDa

54 kDa

sp|Q53GS9-2|SNUT2_HUMAN (+4)

1.08E+05

54 kDa

54 kDa

sp|Q8ND04-2|SMG8_HUMAN (+1)

7.63E+04

54 kDa

sp|Q6P1J9|CDC73_HUMAN

7.00E+04

113
kDa
61 kDa

sp|Q9UQB8-2|BAIP2_HUMAN (+7)

6.87E+04

59 kDa

54 kDa

sp|Q9C0I1-2|MTMRC_HUMAN (+2)

5.16E+04

80 kDa

54 kDa

sp|Q6UWP8|SBSN_HUMAN

3.76E+04

61 kDa

54 kDa

sp|Q8N7H5-3|PAF1_HUMAN (+2)

3.29E+04

55 kDa

54 kDa

54 kDa

Isoform DPII of Desmoplakin
OS=Homo sapiens GN=DSP
Transitional endoplasmic reticulum
ATPase OS=Homo sapiens GN=VCP
PE=1 SV=4

sp|P15924-2|DESP_HUMAN (+2)

1.62E+04

sp|P55072|TERA_HUMAN

7090

260
kDa
89 kDa

54 kDa
54 kDa
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APPENDIX 2

Potential AnkB interacting proteins from U937 Cells
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Table 9. Proteins identified in band 1 from U937 cells
Protein Name
Accession
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Isoform 2 of Nucleophosmin OS=Homo
sapiens GN=NPM1
40S ribosomal protein S18 OS=Homo
sapiens GN=RPS18 PE=1 SV=3
Casein kinase II subunit alpha OS=Homo
sapiens GN=CSNK2A1 PE=1 SV=1
Nucleoplasmin-3 OS=Homo sapiens
GN=NPM3 PE=1 SV=3
Isoform SM-B of Small nuclear
ribonucleoprotein-associated proteins B
and B' OS=Homo sapiens GN=SNRPB
60S ribosomal protein L12 OS=Homo
sapiens GN=RPL12 PE=1 SV=1
Isoform 2 of Peptidyl-prolyl cis-trans
isomerase H OS=Homo sapiens
GN=PPIH
40S ribosomal protein S15 OS=Homo
sapiens GN=RPS15 PE=1 SV=2
Isoform 2 of 60S ribosomal protein L18
OS=Homo sapiens GN=RPL18
Isoform 1 of Growth factor receptor-bound
protein 10 OS=Homo sapiens
GN=GRB10
Isoform 2 of DNA-3-methyladenine
glycosylase OS=Homo sapiens GN=MPG
Isoform 2 of Paraspeckle component 1
OS=Homo sapiens GN=PSPC1

Norm iBAQ

MW

sp|P06748-2|NPM_HUMAN (+2)

4.15E+06

29 kDa

MW on
gel
17 kDa

sp|P62269|RS18_HUMAN

9.80E+05

18 kDa

17 kDa

sp|P68400|CSK21_HUMAN (+3)

4.65E+05

45 kDa

17 kDa

sp|O75607|NPM3_HUMAN

3.75E+05

19 kDa

17 kDa

sp|P14678-2|RSMB_HUMAN (+1)

3.50E+05

24 kDa

17 kDa

sp|P30050|RL12_HUMAN

2.97E+05

18 kDa

17 kDa

sp|O43447-2|PPIH_HUMAN (+2)

1.85E+05

14 kDa

17 kDa

sp|P62841|RS15_HUMAN (+7)

1.10E+05

17 kDa

17 kDa

sp|Q07020-2|RL18_HUMAN (+5)

9.76E+04

18 kDa

17 kDa

sp|Q13322-2|GRB10_HUMAN (+3)

6.66E+04

62 kDa

17 kDa

sp|P29372-2|3MG_HUMAN (+4)

1.22E+04

32 kDa

17 kDa

sp|Q8WXF1-2|PSPC1_HUMAN (+1)

9230

46 kDa

17 kDa

Isoform 2 of Obg-like ATPase 1
OS=Homo sapiens GN=OLA1

sp|Q9NTK5-2|OLA1_HUMAN (+2)

8430

28 kDa

17 kDa

Norm iBAQ

MW

sp|Q92688-2|AN32B_HUMAN (+1)

5.94E+06

22 kDa

MW on
gel
19 kDa

sp|O75607|NPM3_HUMAN

1.98E+06

19 kDa

19 kDa

sp|P08621-2|RU17_HUMAN (+1)

6.30E+05

51 kDa

19 kDa

tr|A0A0A1EKG7|A0A0A1EKG7_LEGPN 4.42E+05

20 kDa

19 kDa

sp|Q9ULC4-2|MCTS1_HUMAN (+2)

2.88E+05

19 kDa

19 kDa

sp|Q07020-2|RL18_HUMAN (+5)

1.09E+05

18 kDa

19 kDa

sp|P0DME0|SETLP_HUMAN (+6)

9.91E+04

35 kDa

19 kDa

sp|Q15717-2|ELAV1_HUMAN

9.07E+04

39 kDa

19 kDa

sp|P25205-2|MCM3_HUMAN (+1)

8.67E+04

96 kDa

19 kDa

Table 10. Proteins identified in band 2 from U937 cells
Protein Name
Accession
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Isoform 2 of Acidic leucine-rich nuclear
phosphoprotein 32 family member B
OS=Homo sapiens GN=ANP32B
Nucleoplasmin-3 OS=Homo sapiens
GN=NPM3 PE=1 SV=3
Isoform 2 of U1 small nuclear
ribonucleoprotein 70 kDa OS=Homo
sapiens GN=SNRNP70
Ankyrin-repeat protein B OS=Legionella
pneumophila GN=ankB PE=4 SV=1
Isoform 2 of Malignant T-cell-amplified
sequence 1 OS=Homo sapiens
GN=MCTS1
Isoform 2 of 60S ribosomal protein L18
OS=Homo sapiens GN=RPL18
Protein SETSIP OS=Homo sapiens
GN=SETSIP PE=1 SV=1
Isoform 2 of ELAV-like protein 1
OS=Homo sapiens GN=ELAVL1
Isoform 2 of DNA replication licensing
factor MCM3 OS=Homo sapiens
GN=MCM3
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Elongation factor Tu, mitochondrial
OS=Homo sapiens GN=TUFM PE=1
SV=2
Isoform 2 of E3 ubiquitin-protein ligase
Hakai OS=Homo sapiens GN=CBLL1
Mitochondrial assembly of ribosomal
large subunit protein 1 OS=Homo
sapiens GN=MALSU1 PE=1 SV=1
Casein kinase II subunit beta OS=Homo
sapiens GN=CSNK2B PE=1 SV=1
Nucleolin OS=Homo sapiens GN=NCL
PE=1 SV=3
Pre-mRNA-splicing factor ATPdependent RNA helicase DHX15
OS=Homo sapiens GN=DHX15 PE=1
SV=2
Zinc finger and BTB domain-containing
protein 45 OS=Homo sapiens
GN=ZBTB45 PE=2 SV=1
Mothers against decapentaplegic
homolog 3 OS=Homo sapiens
GN=SMAD3 PE=1 SV=1
Isoform 2 of RNA-binding protein 26
OS=Homo sapiens GN=RBM26

sp|P49411|EFTU_HUMAN

6.94E+04

50 kDa

19 kDa

sp|Q75N03-2|HAKAI_HUMAN (+1)

4.37E+04

54 kDa

19 kDa

sp|Q96EH3|MASU1_HUMAN

3.74E+04

26 kDa

19 kDa

sp|P67870|CSK2B_HUMAN (+2)

3.25E+04

25 kDa

19 kDa

sp|P19338|NUCL_HUMAN

2.64E+04

77 kDa

19 kDa

sp|O43143|DHX15_HUMAN

2.52E+04

91 kDa

19 kDa

sp|Q96K62|ZBT45_HUMAN

2.07E+04

54 kDa

19 kDa

sp|P84022|SMAD3_HUMAN

1.63E+04

48 kDa

19 kDa

sp|Q5T8P6-2|RBM26_HUMAN (+5)

8680

111 kDa

19 kDa

Table 11. Proteins identified in band 3 from U937 cells
Protein Name
Accession
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Casein kinase II subunit beta OS=Homo
sapiens GN=CSNK2B PE=1 SV=1
Isoform 2 of Heterogeneous nuclear
ribonucleoprotein A3 OS=Homo sapiens
GN=HNRNPA3
40S ribosomal protein SA OS=Homo
sapiens GN=RPSA PE=1 SV=4
Protein SETSIP OS=Homo sapiens
GN=SETSIP PE=1 SV=1
Cluster of Keratin, type I cytoskeletal 14
OS=Homo sapiens GN=KRT14 PE=1
SV=4 (sp|P02533|K1C14_HUMAN)
Nucleolin OS=Homo sapiens GN=NCL
PE=1 SV=3
Elongation factor Tu, mitochondrial
OS=Homo sapiens GN=TUFM PE=1
SV=2
Lupus La protein OS=Homo sapiens
GN=SSB PE=1 SV=2
Proteasome subunit alpha type-5
OS=Homo sapiens GN=PSMA5 PE=1
SV=3
Tyrosine--tRNA ligase, cytoplasmic
OS=Homo sapiens GN=YARS PE=1
SV=4

Norm iBAQ

MW

sp|P67870|CSK2B_HUMAN (+2)

7.17E+05

25 kDa

MW on
gel
25 kDa

sp|P51991-2|ROA3_HUMAN (+1)

3.94E+05

37 kDa

25 kDa

sp|P08865|RSSA_HUMAN (+2)

3.85E+05

33 kDa

25 kDa

sp|P0DME0|SETLP_HUMAN (+6)

2.25E+05

35 kDa

25 kDa

sp|P02533|K1C14_HUMAN

1.82E+05

52 kDa

25 kDa

sp|P19338|NUCL_HUMAN (+1)

1.56E+05

77 kDa

25 kDa

sp|P49411|EFTU_HUMAN

9.69E+04

50 kDa

25 kDa

sp|P05455|LA_HUMAN (+2)

8.48E+04

47 kDa

25 kDa

sp|P28066|PSA5_HUMAN

7.78E+04

26 kDa

25 kDa

sp|P54577|SYYC_HUMAN (+1)

7.37E+04

59 kDa

25 kDa

Isoform A1-A of Heterogeneous nuclear
ribonucleoprotein A1 OS=Homo sapiens
GN=HNRNPA1
Splicing factor U2AF 35 kDa subunit-like
protein OS=Homo sapiens
GN=U2AF1L5 PE=3 SV=1
Na(+)/H(+) exchange regulatory cofactor
NHE-RF1 OS=Homo sapiens
GN=SLC9A3R1 PE=1 SV=4
sp|DHE3_BOVIN|
Isoform 2 of DNA replication licensing
factor MCM3 OS=Homo sapiens
GN=MCM3
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sp|P09651-2|ROA1_HUMAN (+4)

7.26E+04

34 kDa

25 kDa

sp|P0DN76|U2AF5_HUMAN

3.81E+04

28 kDa

25 kDa

sp|O14745|NHRF1_HUMAN (+1)

1.37E+04

39 kDa

25 kDa

sp|DHE3_BOVIN| (+3)
sp|P25205-2|MCM3_HUMAN (+2)

9410
0

62 kDa
96 kDa

25 kDa
25 kDa

Norm iBAQ

MW

sp|Q01105|SET_HUMAN [2]

1.65E+07

33 kDa

MW on
gel
34 kDa

sp|P68400|CSK21_HUMAN (+3)

1.53E+06

45 kDa

34 kDa

sp|P55209-2|NP1L1_HUMAN [11]

1.48E+06

43 kDa

34 kDa

sp|P08865|RSSA_HUMAN (+2)

7.86E+05

33 kDa

34 kDa

sp|P19784|CSK22_HUMAN

4.55E+05

41 kDa

34 kDa

Table 12. Proteins identified in band 4 from U937 cells
Protein Name
Accession
Cluster of Protein SET OS=Homo sapiens
GN=SET PE=1 SV=3
(sp|Q01105|SET_HUMAN)
Casein kinase II subunit alpha OS=Homo
sapiens GN=CSNK2A1 PE=1 SV=1
Cluster of Isoform 2 of Nucleosome
assembly protein 1-like 1 OS=Homo
sapiens GN=NAP1L1 (sp|P552092|NP1L1_HUMAN)
40S ribosomal protein SA OS=Homo
sapiens GN=RPSA PE=1 SV=4
Casein kinase II subunit alpha' OS=Homo
sapiens GN=CSNK2A2 PE=1 SV=1
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Isoform 2 of Glyceraldehyde-3-phosphate
dehydrogenase OS=Homo sapiens
GN=GAPDH
Eukaryotic translation initiation factor 2
subunit 1 OS=Homo sapiens GN=EIF2S1
PE=1 SV=3
Isoform 2 of Transducin-like enhancer
protein 3 OS=Homo sapiens GN=TLE3
Isoform 2 of Heterogeneous nuclear
ribonucleoprotein R OS=Homo sapiens
GN=HNRNPR
WD repeat-containing protein 5
OS=Homo sapiens GN=WDR5 PE=1
SV=1
Isoform 2 of Heterogeneous nuclear
ribonucleoprotein Q OS=Homo sapiens
GN=SYNCRIP
Obg-like ATPase 1 OS=Homo sapiens
GN=OLA1 PE=1 SV=2
Nucleolin OS=Homo sapiens GN=NCL
PE=1 SV=3
X-ray repair cross-complementing protein
6 OS=Homo sapiens GN=XRCC6 PE=1
SV=2
Tyrosine--tRNA ligase, cytoplasmic
OS=Homo sapiens GN=YARS PE=1
SV=4
Beta-adrenergic receptor kinase 1
OS=Homo sapiens GN=ADRBK1 PE=1
SV=2

sp|P04406-2|G3P_HUMAN (+2)

3.68E+05

32 kDa

34 kDa

sp|P05198|IF2A_HUMAN

3.64E+05

36 kDa

34 kDa

sp|Q04726-2|TLE3_HUMAN (+11)

2.72E+05

82 kDa

34 kDa

sp|O43390-2|HNRPR_HUMAN (+2)

2.47E+05

71 kDa

34 kDa

sp|P61964|WDR5_HUMAN

1.39E+05

37 kDa

34 kDa

sp|O60506-2|HNRPQ_HUMAN (+4)

1.38E+05

66 kDa

34 kDa

sp|Q9NTK5|OLA1_HUMAN (+1)

8.51E+04

45 kDa

34 kDa

sp|P19338|NUCL_HUMAN

8.07E+04

77 kDa

34 kDa

sp|P12956|XRCC6_HUMAN

5.33E+04

70 kDa

34 kDa

sp|P54577|SYYC_HUMAN (+1)

3.94E+04

59 kDa

34 kDa

sp|P25098|ARBK1_HUMAN

3.69E+04

80 kDa

34 kDa

149

Cluster of Beta-actin-like protein 2
OS=Homo sapiens GN=ACTBL2 PE=1
SV=2 (sp|Q562R1|ACTBL_HUMAN)
Isoform 2 of Arf-GAP with GTPase, ANK
repeat and PH domain-containing protein
2 OS=Homo sapiens GN=AGAP2
Cluster of Casein kinase I isoform
gamma-2 OS=Homo sapiens
GN=CSNK1G2 PE=1 SV=1
(sp|P78368|KC1G2_HUMAN)
DNA replication licensing factor MCM5
OS=Homo sapiens GN=MCM5 PE=1
SV=5
Isoform 3 of Phosphatidylinositol 5phosphate 4-kinase type-2 gamma
OS=Homo sapiens GN=PIP4K2C
Isoform 2 of Splicing factor 1 OS=Homo
sapiens GN=SF1
Isoform 2 of Exosome component 10
OS=Homo sapiens GN=EXOSC10
Isoform 2 of Phosphatidylinositol 3,4,5trisphosphate 5-phosphatase 1
OS=Homo sapiens GN=INPP5D
RNA-binding protein 33 OS=Homo
sapiens GN=RBM33 PE=1 SV=3

sp|Q562R1|ACTBL_HUMAN [2]

3.33E+04

42 kDa

34 kDa

sp|Q99490-2|AGAP2_HUMAN (+3)

2.32E+04

91 kDa

34 kDa

sp|P78368|KC1G2_HUMAN

2.23E+04

47 kDa

34 kDa

sp|P33992|MCM5_HUMAN (+1)

1.62E+04

82 kDa

34 kDa

sp|Q8TBX8-3|PI42C_HUMAN (+1)

1.16E+04

45 kDa

34 kDa

sp|Q15637-2|SF01_HUMAN (+6)

1.09E+04

69 kDa

34 kDa

sp|Q01780-2|EXOSX_HUMAN (+1)

7480

98 kDa

34 kDa

sp|Q92835-2|SHIP1_HUMAN (+3)

5880

133 kDa

34 kDa

sp|Q96EV2|RBM33_HUMAN

3050

130 kDa

34 kDa

Table 13. Proteins identified in band 5.1 from U937 cells
Protein Name
Accession
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Cluster of Protein SET OS=Homo sapiens
GN=SET PE=1 SV=3
(sp|Q01105|SET_HUMAN)
Casein kinase II subunit alpha OS=Homo
sapiens GN=CSNK2A1 PE=1 SV=1
Casein kinase II subunit alpha' OS=Homo
sapiens GN=CSNK2A2 PE=1 SV=1
Isoform 2 of Nucleosome assembly
protein 1-like 1 OS=Homo sapiens
GN=NAP1L1
Cluster of Isoform 2 of Heterogeneous
nuclear ribonucleoprotein R OS=Homo
sapiens GN=HNRNPR (sp|O433902|HNRPR_HUMAN)
Ankyrin-repeat protein B OS=Legionella
pneumophila GN=ankB PE=4 SV=1
Eukaryotic translation initiation factor 2
subunit 1 OS=Homo sapiens GN=EIF2S1
PE=1 SV=3
40S ribosomal protein SA OS=Homo
sapiens GN=RPSA PE=1 SV=4
Isoform 2 of Nucleosome assembly
protein 1-like 4 OS=Homo sapiens
GN=NAP1L4
Isoform 2 of Heterogeneous nuclear
ribonucleoprotein L OS=Homo sapiens
GN=HNRNPL

Norm iBAQ MW

sp|Q01105|SET_HUMAN [2]

2.05E+07

33 kDa

MW on
gel
35 kDa

sp|P68400|CSK21_HUMAN (+3)

6.46E+06

45 kDa

35 kDa

sp|P19784|CSK22_HUMAN

2.75E+06

41 kDa

35 kDa

sp|P55209-2|NP1L1_HUMAN (+13)

1.19E+06

43 kDa

35 kDa

sp|O43390-2|HNRPR_HUMAN [3]

4.83E+05

71 kDa

35 kDa

tr|A0A0A1EKG7|A0A0A1EKG7_LEGPN 4.33E+05

20 kDa

35 kDa

sp|P05198|IF2A_HUMAN

4.02E+05

36 kDa

35 kDa

sp|P08865|RSSA_HUMAN (+3)

3.37E+05

33 kDa

35 kDa

sp|Q99733-2|NP1L4_HUMAN (+5)

3.23E+05

44 kDa

35 kDa

sp|P14866-2|HNRPL_HUMAN (+3)

3.03E+05

51 kDa

35 kDa
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Elongation factor Tu, mitochondrial
OS=Homo sapiens GN=TUFM PE=1
SV=2
LanC-like protein 2 OS=Homo sapiens
GN=LANCL2 PE=1 SV=1
Tyrosine--tRNA ligase, cytoplasmic
OS=Homo sapiens GN=YARS PE=1
SV=4
Isoform 2 of Heterogeneous nuclear
ribonucleoprotein D0 OS=Homo sapiens
GN=HNRNPD
Nucleolin OS=Homo sapiens GN=NCL
PE=1 SV=3
DDB1- and CUL4-associated factor 7
OS=Homo sapiens GN=DCAF7 PE=1
SV=1
Phosphatidylinositol 5-phosphate 4-kinase
type-2 beta OS=Homo sapiens
GN=PIP4K2B PE=1 SV=1
Isoform 2 of Phosphatidylinositol 5phosphate 4-kinase type-2 alpha
OS=Homo sapiens GN=PIP4K2A
Casein kinase I isoform gamma-2
OS=Homo sapiens GN=CSNK1G2 PE=1
SV=1
Obg-like ATPase 1 OS=Homo sapiens
GN=OLA1 PE=1 SV=2
Isoform 2 of Methylmalonatesemialdehyde dehydrogenase [acylating],

sp|P49411|EFTU_HUMAN

2.31E+05

50 kDa

35 kDa

sp|Q9NS86|LANC2_HUMAN

1.73E+05

51 kDa

35 kDa

sp|P54577|SYYC_HUMAN

1.64E+05

59 kDa

35 kDa

sp|Q14103-2|HNRPD_HUMAN (+7)

1.52E+05

36 kDa

35 kDa

sp|P19338|NUCL_HUMAN

1.11E+05

77 kDa

35 kDa

sp|P61962|DCAF7_HUMAN

1.10E+05

39 kDa

35 kDa

sp|P78356|PI42B_HUMAN

1.08E+05

47 kDa

35 kDa

sp|P48426-2|PI42A_HUMAN (+1)

9.98E+04

40 kDa

35 kDa

sp|P78368|KC1G2_HUMAN

9.57E+04

47 kDa

35 kDa

sp|Q9NTK5|OLA1_HUMAN (+1)

8.26E+04

45 kDa

35 kDa

sp|Q02252-2|MMSA_HUMAN (+1)

6.41E+04

56 kDa

35 kDa
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mitochondrial OS=Homo sapiens
GN=ALDH6A1
DNA replication licensing factor MCM5
OS=Homo sapiens GN=MCM5 PE=1
SV=5
Probable asparagine--tRNA ligase,
mitochondrial OS=Homo sapiens
GN=NARS2 PE=1 SV=3
Eukaryotic translation initiation factor 5B
OS=Homo sapiens GN=EIF5B PE=1
SV=4
Isoform 2 of Homer protein homolog 3
OS=Homo sapiens GN=HOMER3
Isoform 2 of Splicing factor 1 OS=Homo
sapiens GN=SF1
Mothers against decapentaplegic
homolog 4 OS=Homo sapiens
GN=SMAD4 PE=1 SV=1
Isoform 3 of Phosphatidylinositol 5phosphate 4-kinase type-2 gamma
OS=Homo sapiens GN=PIP4K2C
X-ray repair cross-complementing protein
6 OS=Homo sapiens GN=XRCC6 PE=1
SV=2
E3 ubiquitin-protein ligase CBL OS=Homo
sapiens GN=CBL PE=1 SV=2

sp|P33992|MCM5_HUMAN (+1)

5.73E+04

82 kDa

35 kDa

sp|Q96I59|SYNM_HUMAN

5.05E+04

54 kDa

35 kDa

sp|O60841|IF2P_HUMAN (+1)

3.92E+04

139 kDa

35 kDa

sp|Q9NSC5-2|HOME3_HUMAN (+3)

2.56E+04

39 kDa

35 kDa

sp|Q15637-2|SF01_HUMAN (+6)

1.73E+04

69 kDa

35 kDa

sp|Q13485|SMAD4_HUMAN (+1)

1.53E+04

60 kDa

35 kDa

sp|Q8TBX8-3|PI42C_HUMAN (+1)

1.48E+04

45 kDa

35 kDa

sp|P12956|XRCC6_HUMAN (+1)

1.10E+04

70 kDa

35 kDa

sp|P22681|CBL_HUMAN (+2)

9750

100 kDa

35 kDa

Table 14. Proteins identified in band 5.2 from U937 cells
Protein Name
Accession
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Cluster of Protein SET OS=Homo sapiens
GN=SET PE=1 SV=3
(sp|Q01105|SET_HUMAN)
Putative RNA-binding protein Luc7-like 2
OS=Homo sapiens GN=LUC7L2 PE=1
SV=2
Elongation factor 1-alpha 1 OS=Homo
sapiens GN=EEF1A1 PE=1 SV=1
sp|TRYP_PIG|
Cluster of Isoform 2 of Nucleosome
assembly protein 1-like 1 OS=Homo
sapiens GN=NAP1L1 (sp|P552092|NP1L1_HUMAN)
sp|K1C9_HUMAN|
Casein kinase II subunit alpha OS=Homo
sapiens GN=CSNK2A1 PE=1 SV=1
Non-POU domain-containing octamerbinding protein OS=Homo sapiens
GN=NONO PE=1 SV=4
Splicing factor 3A subunit 1 OS=Homo
sapiens GN=SF3A1 PE=1 SV=1
Isoform Short of Splicing factor, prolineand glutamine-rich OS=Homo sapiens
GN=SFPQ
Na(+)/H(+) exchange regulatory cofactor
NHE-RF1 OS=Homo sapiens
GN=SLC9A3R1 PE=1 SV=4

Norm iBAQ

MW

sp|Q01105|SET_HUMAN [2]

1.74E+07

33 kDa

MW on
gel
37 kDa

sp|Q9Y383|LC7L2_HUMAN

9.32E+06

47 kDa

37 kDa

sp|P68104|EF1A1_HUMAN (+1)

7.53E+06

50 kDa

37 kDa

sp|TRYP_PIG|
sp|P55209-2|NP1L1_HUMAN [11]

6.08E+06
2.22E+06

24 kDa
43 kDa

37 kDa
37 kDa

sp|K1C9_HUMAN| (+1)
sp|P68400|CSK21_HUMAN (+3)

1.98E+06
1.73E+06

62 kDa
45 kDa

37 kDa
37 kDa

sp|Q15233|NONO_HUMAN

1.09E+06

54 kDa

37 kDa

sp|Q15459|SF3A1_HUMAN

6.26E+05

89 kDa

37 kDa

sp|P23246-2|SFPQ_HUMAN (+1)

5.98E+05

72 kDa

37 kDa

sp|O14745|NHRF1_HUMAN

5.36E+05

39 kDa

37 kDa
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Glutamate dehydrogenase 1,
mitochondrial OS=Homo sapiens
GN=GLUD1 PE=1 SV=2
40S ribosomal protein SA OS=Homo
sapiens GN=RPSA PE=1 SV=4
Isoform 2 of Methylmalonatesemialdehyde dehydrogenase [acylating],
mitochondrial OS=Homo sapiens
GN=ALDH6A1
Chitinase-3-like protein 1 OS=Homo
sapiens GN=CHI3L1 PE=1 SV=2
Isoform 2 of Heterogeneous nuclear
ribonucleoprotein D0 OS=Homo sapiens
GN=HNRNPD
Fructose-bisphosphate aldolase A
OS=Homo sapiens GN=ALDOA PE=1
SV=2
Isoform 2 of Isovaleryl-CoA
dehydrogenase, mitochondrial OS=Homo
sapiens GN=IVD
DNA replication licensing factor MCM5
OS=Homo sapiens GN=MCM5 PE=1
SV=5
Elongation factor Tu, mitochondrial
OS=Homo sapiens GN=TUFM PE=1
SV=2
Isoform 2 of Mitotic checkpoint protein
BUB3 OS=Homo sapiens GN=BUB3
Nucleolin OS=Homo sapiens GN=NCL
PE=1 SV=3

sp|P00367|DHE3_HUMAN

3.60E+05

61 kDa

37 kDa

sp|P08865|RSSA_HUMAN (+2)

2.92E+05

33 kDa

37 kDa

sp|Q02252-2|MMSA_HUMAN (+1)

2.24E+05

56 kDa

37 kDa

sp|P36222|CH3L1_HUMAN

2.12E+05

43 kDa

37 kDa

sp|Q14103-2|HNRPD_HUMAN (+7)

2.02E+05

36 kDa

37 kDa

sp|P04075|ALDOA_HUMAN (+2)

1.65E+05

39 kDa

37 kDa

sp|P26440-2|IVD_HUMAN (+2)

9.23E+04

43 kDa

37 kDa

sp|P33992|MCM5_HUMAN (+1)

9.15E+04

82 kDa

37 kDa

sp|P49411|EFTU_HUMAN

9.06E+04

50 kDa

37 kDa

sp|O43684-2|BUB3_HUMAN (+2)

8.85E+04

37 kDa

37 kDa

sp|P19338|NUCL_HUMAN

8.38E+04

77 kDa

37 kDa

155

NAD-dependent malic enzyme,
mitochondrial OS=Homo sapiens
GN=ME2 PE=1 SV=1
Obg-like ATPase 1 OS=Homo sapiens
GN=OLA1 PE=1 SV=2
Actin, cytoplasmic 1 OS=Homo sapiens
GN=ACTB PE=1 SV=1
Isoform 1 of Growth arrest-specific protein
7 OS=Homo sapiens GN=GAS7
Isoform MBP-1 of Alpha-enolase
OS=Homo sapiens GN=ENO1
LanC-like protein 1 OS=Homo sapiens
GN=LANCL1 PE=1 SV=1
LanC-like protein 2 OS=Homo sapiens
GN=LANCL2 PE=1 SV=1
Isoform 10 of Abl interactor 1 OS=Homo
sapiens GN=ABI1
Isoform 2 of NAD kinase OS=Homo
sapiens GN=NADK
Probable asparagine--tRNA ligase,
mitochondrial OS=Homo sapiens
GN=NARS2 PE=1 SV=3
Isoform 2 of Phosphatidylinositol 5phosphate 4-kinase type-2 alpha
OS=Homo sapiens GN=PIP4K2A
Isoform 2 of Interferon regulatory factor 2binding protein 2 OS=Homo sapiens
GN=IRF2BP2

sp|P23368|MAOM_HUMAN

6.84E+04

65 kDa

37 kDa

sp|Q9NTK5|OLA1_HUMAN (+1)

6.35E+04

45 kDa

37 kDa

sp|P60709|ACTB_HUMAN (+1)

6.01E+04

42 kDa

37 kDa

sp|O60861-1|GAS7_HUMAN (+2)

5.74E+04

47 kDa

37 kDa

sp|P06733-2|ENOA_HUMAN (+1)

5.69E+04

37 kDa

37 kDa

sp|O43813|LANC1_HUMAN (+1)

5.57E+04

45 kDa

37 kDa

sp|Q9NS86|LANC2_HUMAN

5.29E+04

51 kDa

37 kDa

sp|Q8IZP0-10|ABI1_HUMAN (+12)

5.20E+04

43 kDa

37 kDa

sp|O95544-2|NADK_HUMAN (+3)

4.89E+04

63 kDa

37 kDa

sp|Q96I59|SYNM_HUMAN

4.70E+04

54 kDa

37 kDa

sp|P48426-2|PI42A_HUMAN (+1)

4.59E+04

40 kDa

37 kDa

sp|Q7Z5L9-2|I2BP2_HUMAN (+1)

4.18E+04

59 kDa

37 kDa
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U3 small nucleolar RNA-associated
protein 18 homolog OS=Homo sapiens
GN=UTP18 PE=1 SV=3
DNA polymerase beta OS=Homo sapiens
GN=POLB PE=1 SV=3
Tyrosine--tRNA ligase, cytoplasmic
OS=Homo sapiens GN=YARS PE=1
SV=4
Beta-adrenergic receptor kinase 1
OS=Homo sapiens GN=ADRBK1 PE=1
SV=2
Isoform 3 of Bifunctional lysine-specific
demethylase and histidyl-hydroxylase
MINA OS=Homo sapiens GN=MINA
Tyrosyl-DNA phosphodiesterase 1
OS=Homo sapiens GN=TDP1 PE=1
SV=2
Paired amphipathic helix protein Sin3a
OS=Homo sapiens GN=SIN3A PE=1
SV=2
Isoform 2 of Septin-2 OS=Homo sapiens
GN=SEPT2
Phosphatidylinositol 5-phosphate 4kinase type-2 beta OS=Homo sapiens
GN=PIP4K2B PE=1 SV=1

sp|Q9Y5J1|UTP18_HUMAN

3.96E+04

62 kDa

37 kDa

sp|P06746|DPOLB_HUMAN (+2)

3.94E+04

38 kDa

37 kDa

sp|P54577|SYYC_HUMAN (+1)

2.53E+04

59 kDa

37 kDa

sp|P25098|ARBK1_HUMAN

2.48E+04

80 kDa

37 kDa

sp|Q8IUF8-3|MINA_HUMAN (+1)

2.09E+04

24 kDa

37 kDa

sp|Q9NUW8|TYDP1_HUMAN (+2)

1.89E+04

68 kDa

37 kDa

sp|Q96ST3|SIN3A_HUMAN (+1)

1.88E+04

145
kDa

37 kDa

sp|Q15019-2|SEPT2_HUMAN (+3)

9780

45 kDa

37 kDa

sp|P78356|PI42B_HUMAN

7790

47 kDa

37 kDa

Table 15. Proteins identified in band 6 from U937 cells
Protein Name
Accession
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Protein SET OS=Homo sapiens GN=SET
PE=1 SV=3
Isoform 2 of Cleavage and
polyadenylation specificity factor subunit
6 OS=Homo sapiens GN=CPSF6
Isoform 2 of Nucleosome assembly
protein 1-like 1 OS=Homo sapiens
GN=NAP1L1
Cluster of Nucleolin OS=Homo sapiens
GN=NCL PE=1 SV=3
(sp|P19338|NUCL_HUMAN)
Tyrosine--tRNA ligase, cytoplasmic
OS=Homo sapiens GN=YARS PE=1
SV=4
Isoform 2 of Nucleosome assembly
protein 1-like 4 OS=Homo sapiens
GN=NAP1L4
Isoform 2 of Heterogeneous nuclear
ribonucleoprotein L OS=Homo sapiens
GN=HNRNPL
Probable cysteine--tRNA ligase,
mitochondrial OS=Homo sapiens
GN=CARS2 PE=1 SV=1
Lupus La protein OS=Homo sapiens
GN=SSB PE=1 SV=2

Norm iBAQ MW

sp|Q01105|SET_HUMAN

1.42E+07

33 kDa

MW on
gel
43 kDa

sp|Q16630-2|CPSF6_HUMAN (+3)

3.14E+06

63 kDa

43 kDa

sp|P55209-2|NP1L1_HUMAN (+10)

2.99E+06

43 kDa

43 kDa

sp|P19338|NUCL_HUMAN

1.36E+06

77 kDa

43 kDa

sp|P54577|SYYC_HUMAN

1.07E+06

59 kDa

43 kDa

sp|Q99733-2|NP1L4_HUMAN (+3)

9.00E+05

44 kDa

43 kDa

sp|P14866-2|HNRPL_HUMAN (+3)

7.06E+05

51 kDa

43 kDa

sp|Q9HA77|SYCM_HUMAN

3.95E+05

62 kDa

43 kDa

sp|P05455|LA_HUMAN

2.83E+05

47 kDa

43 kDa
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Phenylalanine--tRNA ligase,
mitochondrial OS=Homo sapiens
GN=FARS2 PE=1 SV=1
Probable asparagine--tRNA ligase,
mitochondrial OS=Homo sapiens
GN=NARS2 PE=1 SV=3
Eukaryotic translation initiation factor 5B
OS=Homo sapiens GN=EIF5B PE=1
SV=4
Isoform 2 of Methyltransferase-like
protein 17, mitochondrial OS=Homo
sapiens GN=METTL17
Isoform 3 of Phosphatidylinositol 5phosphate 4-kinase type-2 gamma
OS=Homo sapiens GN=PIP4K2C
E3 ubiquitin-protein ligase CBL
OS=Homo sapiens GN=CBL PE=1 SV=2
Coiled-coil domain-containing protein 6
OS=Homo sapiens GN=CCDC6 PE=1
SV=2
Tyrosyl-DNA phosphodiesterase 1
OS=Homo sapiens GN=TDP1 PE=1
SV=2
Isoform 4 of Squamous cell carcinoma
antigen recognized by T-cells 3
OS=Homo sapiens GN=SART3
Eukaryotic initiation factor 4A-III
OS=Homo sapiens GN=EIF4A3 PE=1
SV=4

sp|O95363|SYFM_HUMAN

2.75E+05

52 kDa

43 kDa

sp|Q96I59|SYNM_HUMAN

2.39E+05

54 kDa

43 kDa

sp|O60841|IF2P_HUMAN (+1)

2.03E+05

139 kDa

43 kDa

sp|Q9H7H0-2|MET17_HUMAN (+3)

1.86E+05

50 kDa

43 kDa

sp|Q8TBX8-3|PI42C_HUMAN (+1)

1.85E+05

45 kDa

43 kDa

sp|P22681|CBL_HUMAN (+2)

1.20E+05

100 kDa

43 kDa

sp|Q16204|CCDC6_HUMAN

1.15E+05

53 kDa

43 kDa

sp|Q9NUW8|TYDP1_HUMAN (+2)

1.03E+05

68 kDa

43 kDa

sp|Q15020-4|SART3_HUMAN (+2)

9.59E+04

106 kDa

43 kDa

sp|P38919|IF4A3_HUMAN

7.59E+04

47 kDa

43 kDa

Beta-adrenergic receptor kinase 1
OS=Homo sapiens GN=ADRBK1 PE=1
SV=2
Nucleolar protein 58 OS=Homo sapiens
GN=NOP58 PE=1 SV=1
Isoform 5 of Protein disulfide-isomerase
A6 OS=Homo sapiens GN=PDIA6
Coronin-1A OS=Homo sapiens
GN=CORO1A PE=1 SV=4
Endoplasmic reticulum resident protein
44 OS=Homo sapiens GN=ERP44 PE=1
SV=1

sp|P25098|ARBK1_HUMAN

7.56E+04

80 kDa

43 kDa

sp|Q9Y2X3|NOP58_HUMAN

7.28E+04

60 kDa

43 kDa

sp|Q15084-5|PDIA6_HUMAN

4.56E+04

53 kDa

43 kDa

sp|P31146|COR1A_HUMAN (+3)

3.44E+04

51 kDa

43 kDa

sp|Q9BS26|ERP44_HUMAN

0

47 kDa

43 kDa

159

Table 16. Proteins identified in band 8 from U937 cells
Protein Name
Accession
X-ray repair cross-complementing
protein 5 OS=Homo sapiens
GN=XRCC5 PE=1 SV=3
Aspartate--tRNA ligase, mitochondrial
OS=Homo sapiens GN=DARS2 PE=1
SV=1
Replication protein A 70 kDa DNAbinding subunit OS=Homo sapiens
GN=RPA1 PE=1 SV=2
Squamous cell carcinoma antigen
recognized by T-cells 3 OS=Homo
sapiens GN=SART3 PE=1 SV=1

MW

sp|P13010|XRCC5_HUMAN

Norm
iBAQ
6.68E+05

83 kDa

MW on
gel
65 kDa

sp|Q6PI48|SYDM_HUMAN

2.54E+05

74 kDa

65 kDa

sp|P27694|RFA1_HUMAN

1.01E+05

68 kDa

65 kDa

sp|Q15020|SART3_HUMAN (+1)

6.94E+04

110 kDa

65 kDa
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Staphylococcal nuclease domaincontaining protein 1 OS=Homo sapiens
GN=SND1 PE=1 SV=1
X-ray repair cross-complementing
protein 6 OS=Homo sapiens
GN=XRCC6 PE=1 SV=2
Bromodomain-containing protein 4
OS=Homo sapiens GN=BRD4 PE=1
SV=2
Stress-70 protein, mitochondrial
OS=Homo sapiens GN=HSPA9 PE=1
SV=2
Asparagine--tRNA ligase, cytoplasmic
OS=Homo sapiens GN=NARS PE=1
SV=1
Ubiquitin-associated protein 2 OS=Homo
sapiens GN=UBAP2 PE=1 SV=1

sp|Q7KZF4|SND1_HUMAN

6.43E+04

102 kDa

65 kDa

sp|P12956|XRCC6_HUMAN (+1)

5.32E+04

70 kDa

65 kDa

sp|O60885|BRD4_HUMAN

3.72E+04

152 kDa

65 kDa

sp|P38646|GRP75_HUMAN

2.37E+04

74 kDa

65 kDa

sp|O43776|SYNC_HUMAN

1.85E+04

63 kDa

65 kDa

sp|Q5T6F2|UBAP2_HUMAN

1.20E+04

117 kDa

65 kDa

APPENDIX 3

Potential AnkB interacting proteins two-step immunoprecipitation

161

Table 17. Potential AnkB interacting proteins identified in region 1 (related to fig. 6)
Protein
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Desmoglein-1
Cluster of Actin, cytoplasmic 1
Isoform 2 of E3 ubiquitin-protein
ligase HUWE1
Alpha-2-macroglobulin
Complement C3
Serum albumin
Polyubiquitin-B
Immunoglobulin heavy constant
alpha
Isoform DSPIa of Desmoplakin
Serotransferrin
Isoform 2 of Fibrinogen alpha chain
Isoform 2 of Glyceraldehyde-3phosphate dehydrogenase
Immunoglobulin kappa constant
Immunoglobulin heavy constant
gamma 1
Isoform 2 of Haptoglobin
Isoform 2 of Gelsolin
Isoform 2 of Immunoglobulin heavy
constant mu
Hemoglobin subunit beta
Apolipoprotein A-I

MW
kDa
114
42
480
163
187
69
26
38

Rep 1
1

Rep 3

Rep 1
2

Control
Rep 2
4

2

2

8
2
12
8
5
1
2

279
77
70
32

3
2

12
36

2
3

38
81
52

1

16
31

AnkB
Rep 2
1
7

2
2
1
1

2

2
3
2
1

Rep 3
3

Table 17 (continued). Potential AnkB interacting proteins identified in region 1 (related to fig. 6)
Protein
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Filaggrin-2
Isoform H14 of Myeloperoxidase
Alpha-enolase
Annexin A1
Isoform Gamma-A of Fibrinogen
gamma chain
Fibrinogen beta chain
Immunoglobulin lambda-like
polypeptide
Cluster of Isoform 2 of Semenogelin1
Isoform 2 of Transketolase
Immunoglobulin heavy constant
gamma 2

MW
kDa
248
74
47
39
49
56
23

Rep 1
1

AnkB
Rep 2

Rep 3

Rep 3

2
1
2
1
1
1

45
69
36

Rep 1

Control
Rep 2

1
2
1

Table 18. Potential AnkB interacting proteins identified in region 2 (related to fig. 6)
Protein
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Isoform 2 of E3 ubiquitin-protein
ligase HUWE1
Ubiquitin-40S ribosomal protein
S27a
Isoform DSPIa of Desmoplakin
Desmoglein-1
Junction plakoglobin
Isoform 1B of Desmocollin-1
Isoform 2 of Glyceraldehyde-3phosphate dehydrogenase
Hornerin
POTE ankyrin domain family
member F

MW
kDa
480

Rep 1
4

AnkB
Rep 2
4

Rep 3
12

18

3

8

3

279
114
82
94
32

3
1

282
121

7
5
6
3
2

Rep 1

Control
Rep 2

Rep 3

1

1

2
1

Table 19. Potential AnkB interacting proteins identified in region 3 (related to fig. 6)
Protein
Isoform 12 of Titin
Isoform 2 of Protein piccolo
Polyubiquitin-B
Isoform 2 of Methylosome protein 50
Desmoglein-1

MW
kDa
3816
531
26
30
114

Rep 1

AnkB
Rep 2

Rep 3

Rep 1
1

Control
Rep 2

1
2
2
1

Rep 3

Table 20. Potential AnkB interacting proteins identified in region 4 (related to fig. 6)
Protein
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Desmoplakin
Desmoglein-1
Ubiquitin-60S ribosomal protein L40
AnkB of L. pneumophila
40S ribosomal protein S3
Junction plakoglobin
Isoform 1B of Desmocollin-1
ATP synthase subunit gamma,
mitochondrial
Isoform 2 of Glyceraldehyde-3phosphate dehydrogenase
Isoform 1 of Plakophilin-1
U1 small nuclear ribonucleoprotein A
Isoform 2 of Annexin A2
Corneodesmosin
Filaggrin-2
Protein-glutamine gammaglutamyltransferase E
Hornerin
Isoform 2 of Extracellular matrix
protein 1
Bleomycin hydrolase
Isoform 3 of Protein KIAA0100

MW
kDa
332
114
15
35
27
82
94
33

Rep 1

AnkB
Rep 2

1
3
4
2

4
6
4

Rep 3
21
10
3
6

Rep 1
2
4
1
1

Control
Rep 2

Rep 3

1
3

11
5
2

32

4

80
31
40
52
248
77

4
3
2
2
1
2

282
46

2
1

53
45

1
1
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1. Structural Mimicry by a Bacterial F Box Effector Hijacks the Host UbiquitinProteasome System.
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2. Divergent evolution of Di-lysine ER retention vs. farnesylation motif
mediated anchoring of the AnkB virulence effector to the Legionellacontaining vacuolar membrane.
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